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ABSTRACT 
The exploration of chemical space in search of molecules that perturb or mimic 
biological systems is essential to understanding human biology. The first part of 
this dissertation (Chapters 1-4) describes efforts to aid in the exploration of 
biologically relevant space through the invention of new π-cyclization 
methodologies. This strategy can be viewed as part of a “top-down” approach to 
investigating biology: the construction of small molecule drugs or probes which 
modify the behavior of the existing system. The second part of this dissertation 
(Chapter 5) describes preliminary efforts to expand life-like chemical space beyond 
the nucleic acids of DNA and RNA. This can be viewed as a “bottom-up” approach 
to biology: the construction of systems which mimic the features of biochemical 
processes.  
In part one, cyclizations of nitrogen tethered 1,6-diynes were developed as a 
means to new heterocyclic scaffolds. A GaX3 promoted halocyclization 
transformed the acyclic diynes into tetrahydropyridine rings with exocyclic vinyl 
halides. In the presence of strong acid, the tetrahydropyridine products were 
further cyclized to tetrahydroindenopyridine scaffolds. These scaffolds were then 
  vii 
diversified through Pd(0)-catalyzed cross-coupling reactions of the vinyl halide, 
and modifications to the tethering amino nitrogen. Subsequently, a Brønsted acid-
catalyzed cyclization was developed, transforming N-sufonyl tethered bis-aryl 1,6-
diynes to dihydroindenopyridines. Using unsymmetric bis-aryl diynes, the regio- 
and chemoselectivity of this Brønsted acid-catalyzed cyclization was investigated, 
and compared to the GaX3 Lewis acid promoted cyclization developed previously. 
The regiochemical preference of the initial cyclization step was found to be 
reversed under the two different conditions. 
In part two, a means to sequence-defined synthetic polymers which emulate 
the information storage and self-replication abilities of nucleic acid-based 
biopolymers was designed. Information was encoded in two dimers as a specific 
sequence of aniline and benzaldehyde subunits, which were linked together by a 
diethynyl benzene backbone. These dimers functioned as a template for the 
synthesis of new dimers with a complementary sequence. Unpolymerized 
ethynylaniline and ethynylbenzaldehyde monomers, associated to a polymer 
template by reversible imine bonds, were polymerized via Sonogashira cross 
coupling with diiodobenzene. Under the same set of conditions, the sequence of 
two parent dimers was transferred to the daughters.  
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CHAPTER I - Introduction 
1.1 Drug-like and Natural Product-like Chemical Space 
 All distinct molecules that could possibly exist can be imagined as inhabiting 
a vast chemical space. Each molecule’s location in this space is determined by its 
unique chemical and structural features, such that molecules with similar 
properties reside near one another. Chemical space is multidimensional and 
immense, reflecting the diversity of molecular properties allowed by nature.  
Considering only small molecules containing 30 or fewer C, N, O, and S atoms, 
the number of unique structures that could be constructed is estimated to be in 
excess of 1060.1 As the largest database of small molecules characterized by 
chemists contains around 108 members,2 only a tiny fraction of this chemical space 
of small molecules (CSSM) has yet been explored. The enormous gap between 
the known and unknown, more than 50 orders of magnitude, suggests that only a 
tiny fraction will ever be explored. Chemists in search of small molecules that 
interact with biological macromolecules must partition the CSSM into biologically 
relevant chemical space, and focus in that area.  
In the vastness of the CSSM, the surest way to explore biologically relevant 
chemical space has been to start near a molecule isolated from a biological source. 
Roughly 60% of currently approved drugs are either directly inspired by natural 
products, or are natural products.3  Assuming that nature has designed these 
molecules for some purpose, it is not surprising that their bioactivity can be coopted 
or augmented for some new function. However, the past two decades have seen 
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a shift in focus; from the isolation, synthesis, and modification of natural products, 
to the screening of large libraries of molecules that are not necessarily inspired by 
nature.4,5  
Modern screening techniques can permit millions of molecules to be assayed 
against a specific protein target with tremendously high throughput. Compounds 
which bind to the target are dubbed “hits,” and serve as a starting point for 
development into structures with improved drug-like properties called “leads.” Lead 
compounds are validated, optimized, and, should their efficacy be shown in 
increasingly expensive PK\PD studies, finally enter rigorous clinical trials. This “hit-
to-lead” strategy of drug design has been widely exploited by pharmaceutical 
companies and academic institutions, and has led to many useful therapeutics.6 
 Despite the impressive scale of these high throughput screen (HTS) 
techniques, success is not guaranteed. From an initial screen of a million 
compounds only a few relevant substructures might be identified for lead 
optimization, and following years of target validation and fine-tuning, a lead 
compound only has a one in ten chance of approval during clinical trials.7 The rate 
at which novel drugs are being approved has been declining in recent decades,8,9 
and the usefulness of HTS in the drug discovery process has become a point of 
contention.10-15 
The success of any HTS screen relies in large part on how accurately the   
researcher defined the chemical space relevant to the target, and how effectively 
that space was sampled. It is now widely recognized that the amount of space 
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covered by a screen is less dependent on the sheer number of molecules 
screened, than on the diversity of structure types represented by the molecules in 
the screen.5 Figure 1.1, adapted from a figure produced by the Tan group in 
2010,16 compares structural similarities between natural products and drugs. The 
two unitless axes represent linear combinations of 20 physicochemical parameters 
intended to broadly quantify the structural features of natural products (triangles), 
drugs (circles), and commercial drug-like libraries (squares). The large circle 
contains >80% of the drugs assessed, and can be taken as an approximation of 
the drug-like chemical space currently targeted by medicinal chemists. Notably, 
many of the drugs outside of this circle are derived from natural products (Valtrex, 
Zocor, Flonase). The large square contains nearly all of the natural products 
assessed and can be taken as an approximation of natural product-like chemical 
space.  
  
4 
Tan concluded from this analysis, that the drug-like space currently being 
probed by medicinal chemists only encompasses a small portion of natural 
product-like space, and is comparatively narrow in the diversity of structures 
surveyed. This assertion has been supported by many other studies,17-18 and has 
Figure 1.1. Comparison of Natural Product-like and Drug-like Chemical Spaces 
Principal component analysis of 20 structural and physicochemical characteristics of 40 top-selling 
drugs (circles), 60 natural products (triangles), and 20 compounds from commercial drug-like 
libraries (squares). The two unitless, orthogonal axes represent 73% of the information in the full 
20-dimensional dataset.  
Figure 1.1. Comparison of Natural Product-like and Drug-like Chemical Spaces 
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driven efforts to develop chemical libraries containing compounds that more fully 
realize the structural complexity and diversity of molecules found in nature.16,20-24 
Traditional drug-like space has been thoroughly scrutinized, and the search for 
bioactive compounds must be expanded to new areas of chemical space. 
However, the majority of chemical space is not necessarily biologically relevant. 
For example, molecules lacking sufficient hydrophilicity to dissolve in aqueous 
environments, or appropriate functional groups to interact with proteins, are not 
likely to be useful in biological systems. So, in order to direct the expanded search 
for bioactive molecules in the enormity of the CSSM, there has been renewed 
interest in natural products as a source of inspiration.16,20-24 
While drug-likeness and natural product-likeness are not attributable to any 
single set of characteristics, one structural feature that is underrepresented in 
many small molecule libraries, but abundant in nature, is a stereochemically rich 
cyclic core. Natural products often possess polycyclic sp3 rich carbon skeletons, 
which give them a defined three-dimensional shape and specific bioactivity. In 
contrast, many of the compounds which populate screening libraries possess flat 
skeletons, and are comprised of mainly sp2 rich aromatic rings.25-29 
Figure 1.2 depicts representative structures of a drug-like molecule, a natural-
product, and a natural product-like molecule. The top structure is the β-adrenergic 
antagonist drug propranolol. Its simple flat structure, an aromatic naphthyl ring and 
acyclic polar chain, is stereotypic of the majority of compounds which populate 
many large screening libraries. While, propranolol has found tremendous success 
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in treating a range of heart conditions,30 the drug-like chemical space around it has 
been thoroughly examined and it unlikely to yield new types of drugs.  
Figure 1.2. Representative Drug-like, Natural Product, and Natural Product-like 
Molecules 
The middle compound is the natural product fumagillin. In contrast to 
propranolol, fumagillin possesses a rigid sp3 rich oxo-spirocyclic core and four 
stereogenic centers. These stereocenters orient the functional group rich side 
chains in space and give fumagillin a unique and complex three-dimensional 
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shape. Chemical space surrounding fumagillin has only recently begun to be 
explored by medicinal chemists.31,32 However, like all natural products, evolution 
has sampled the space around fumagillin and optimized its bioactivity over millions 
of years. Not surprisingly, the unmodified natural product has potent biological 
activity, as an antiparasitic and antibiotic.33 
The bottom compound 1 is a natural product-like molecule synthesized by 
Dakas and coworkers.34 In addition to possessing a sp3 rich carbon skeleton, the 
cyclopentapyranone core of 1 is shared by the iridoid class of terpenoid natural 
products. However, unlike the natural product, 1 has not benefited from years of 
evolutionary refinement in biological systems. As a single point in chemical space, 
1 is unlikely have optimal biological properties.  Decoupling the 
cyclopentapyranone core from its ester appendages, and regarding the core as a 
scaffold to orient any number of different functional groups in space, the area 
around this cyclic structure can be explored more broadly.35 Dakas and coworkers 
performed several modifications to this scaffold in their successful efforts to 
develop compounds with neurotropic properties (Scheme 
1.1). In ESC-derived motor neurons treated with epoxide 
derivative 1a (inset), mean neurite length was increased 
1.5-fold, and neuron count more than 2-fold. 
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Scheme 1.1. Diversification Scaffold 1 
Conditions: a) OsO4, NMO, THF/H2O, rt; b) DibalH, -78 ⁰C; c) pTSA, (CH2OH)2; d) mCPBA, rt. 
The necessity to expand the search for bioactive molecules beyond drug-like 
chemical space is now well established, and efforts to build the natural product-
like scaffolds needed to explore this space are underway.16,20-24 However, the 
added complexity of these natural product-like structures poses non-trivial 
synthetic challenges.  
Traditional target oriented synthesis (TOS) approaches to complex molecules 
entail a sequence of steps to produce a single structure. For compounds of high 
import, such natural products or established drugs, TOS provides a means to 
efficiently access the target. However, as HTS techniques attempt to broadly 
explore an area of chemical space, they require many hundreds of compounds. A 
TOS approach to even a small library of complex molecules is likely to be too 
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intensive, with each molecule in the library the product of an independent multistep 
synthesis.  
Several approaches have been developed to efficiently access diverse 
populations of complex cyclic scaffolds.36-38 One strategy which has received 
considerable attention is diversity oriented synthesis (DOS), which will be 
discussed briefly in the following section. 
1.1.1 Diversity Oriented Synthesis (DOS) 
In DOS a divergent synthetic pathway is designed to access a range of different 
structures. The goal of DOS is to efficiently construct as diverse a population of 
complex molecules as possible via a common synthetic pathway. One of the 
primary aims of DOS is to expand the diversity of structure types in small molecule 
libraries to include structural features common to natural products, namely: sp3 rich 
scaffolds with diverse three-dimensional shapes.  
This strategy to complex molecule synthesis was pioneered by the Schreiber 
group in the early 2000’s.39 An early example is the collection of 1,3-dioxanes 
depicted in Scheme 1.2. 40  γ,δ-Epoxy alcohols 2, attached through silyl ether 
linkages to polystyrene beads, were diversified through epoxide opening with thiol 
or amine nucleophiles to give diols 3. Benzaldehydes, protected as the dimethyl 
acetals, and substituted with an Fmoc protected amine, were condensed with the 
diol to produce dioxane rings 4. Following removal of the Fmoc protecting group, 
the amine could be functionalized as an amide or sulfonamide by treatment with 
various acid chlorides or sulfonyl chlorides to give 5.  Finally, fluoride cleavage of 
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the silyl ether released the fully diversified scaffold 6 from the solid support. 
Utilizing a split pool synthesis strategy, a library of 1800 dioxanes, corresponding 
to 3 R1 diversifications, 30 R2 diversifications, 2 benzaldehydes, and 10 R3 
diversifications was realized. This synthetic strategy was later elaborated to a  
7,200 membered dioxane library. 41  A 
chemical genetic screen of this set of small 
molecules lead to the discovery of ‘‘tubacin,’’ 
(inset) which inhibits α-tubulin deacetylation 
in mammalian cells through inhibition of 
histone deacetylase 6 (HDAC6).42  
The 1,3-dioxane core was chosen for these libraries because it is a rigid 
stereochemically defined skeleton. The diversity achieved in this example stems 
from the multitude of functional groups which could be attached to this core. Later 
developments in DOS strive, not only to provide easily diversifiable scaffolds, but 
to access a diversity of skeletal frameworks from a single synthetic pathway.   
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Scheme 1.2. DOS of 1,3-Dioxanes 
Scheme 1.3 shows a recent example of a DOS strategy employed for the 
construction of terpinoid-like scaffolds by Winssinger and coworkers.43  In this 
work, enynene 7, synthesized in six steps from hepta-1,5-dien-4-ol, functioned as 
a common intermediate for the formation of six structurally diverse scaffolds 8 - 13. 
Treatment of 7 with Grubbs catalyst produced decalin 8. The cyclization product 
presumably a directing effect of the free hydroxy group initiating the metathesis 
cascade on the adjacent alkene. Accordingly, a two-step procedure wherein the 
directing hydroxyl was first protected as a TBDPS ether, afforded alternative [5.3.0] 
framework 9 with the same catalyst.  Using a similar strategy, cyclization of 7 via 
AuCl catalysis gave pyran 10, while the TBDPS protected variant gave tetracyclic 
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scaffold 11 under the same conditions. Under alternative conditions, with 
[AuPPh3]OTf catalysis, 7 was transformed into [5.3.0]oxobicyclic product 12 in 
excellent yields. And finally, under PtCl2 catalysis, cyclization product 13 was 
obtained in quantitative yield.  
Scheme 1.3. DOS of Cyclic Scaffolds from Enynene 2 
Condtions: a) Grubbs II cat., toluene, 100 ⁰C, 12 h, 81%; b) i) TBDPS-Cl, base, ii) Grubbs II cat., 
toluene, 100 ⁰C, 12 h, quant; c) AuCl, CH2Cl2,23 ⁰C, 20 min, 50%; d) i) TBDPS-Cl, base, ii) AuCl, 
CH2Cl2,23 ⁰C, 20 min, quant; e) [AuPPh3]OTf, CH2Cl2, 23 ⁰C, 20 min, 87%. OTf = triflate f) PtCl2, 
toluene, 50 ⁰C, 2 h, quant. 
Comparing the set of structures produced by Winssinger and coworkers 
(Scheme 1.3), to the structures produce by Schreiber and coworkers (Scheme 
1.2), and the structures of Dakas and coworkers (Scheme 1.1) illustrates the 
difference between DOS and scaffold diversification. Dakas’ structures all possess 
a bicyclic lactone framework, and so a similar three-dimensional shape. The 
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modifications made to this core component serve to explore the local chemical 
space around this particular structure type. In the library constructed by Schreiber, 
modifications are also made to a single framework, 1,3-dioxanes, however the 
synthesis was designed to maximize the diversity of auxiliary groups that could be 
oriented around this scaffold. The chemical space accessed is therefore much 
broader, but still localized around the 1,3-dioxane framework. Winssinger’s 
structures possess dramatically different frameworks, and so very different three-
dimensional shapes. 
Notably, the success of the DOS depicted in Scheme 1.3 was contingent upon 
the diversity of cyclizations available to the enyene substrate 7. The selection of 
the appropriate starting material was critical, and the scaffold diversity accessible 
was directly related to the diversity of cyclizations amenable to that substrate. 
Thus, the development of new cyclization strategies is essential to increasing the 
diversity of accessible structure types. 
1.2 Heterocycles from Alkynes 
Of the chemically distinct molecules discovered in nature, up to 90% contain 
either a carbocyclic or a heterocyclic subunit. Figure 1.3, adapted from Waldmann 
and coworkers ,44 depicts some of most common heterocyclic substructures which 
appear in natural products. The development of efficient cyclization chemistry to 
access these and related structures has long motivated chemists, and constitutes 
one of the major areas of research in organic chemistry.45 One focus of the Snyder 
group has been the construction of complex heterocycles by investigating the 
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cyclization chemistry of systems with multiple π-bonds, namely: Diels-Alder and 
inverse electron demand Diels-Alder [4+2] cycloadditions,46-48 and alkyne-
mediated, metal-catalyzed [n+2+2] cycloadditions (vide infra, Section 1.2.2). The 
chemistry developed in the following chapters of this thesis, stems directly from a 
persistent interest in the utility of alkynes as precursors to heterocycles. 
 Figure 1.3. Common Heterocyclic Substructures Found in Natural Products 
 
1.2.1 Alkyne Cyclization Reactions 
The π-bonds of alkynes are largely responsible for the rich chemistry of these 
functional groups, possessing a sufficiently low LUMO that they commonly function 
as electron acceptors in addition reactions, radical reactions, and sigmatropic 
reactions. The HOMO of alkynes is also sufficiently high to engage with 
electrophiles, such as Brønsted and Lewis acids. 
By coordination to an appropriate π-Lewis acid the LUMO of this functional 
group can be further lowered and the alkyne is susceptible to an even greater 
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range of chemical transformations. Metal-catalyzed reactions of alkynes have 
found widespread use for the construction of cyclic structures (Scheme 1.4). 
Participation of alkynes in π-cyclization through metal catalysis is a well-
established, synthetically valuable process; from the initial reports of Ni(0)-
catalyzed cyclotrimerization of acetylene to benzene in the 1950s (eq 1),49 to Co(I)-
catalyzed [2+2+2] alkyne trimerizations in the 1970s (eq 2),50 to Pd(II)-catalyzed 
cyclizations in the 1980s (eq 3).51  
Scheme 1.4. Cycles from Alkynes 
When one alkyne is tethered through a heteroatom to another π-system, such 
as a nitrile, alkene, or second alkyne, it forms a tethered bis π-system. Reactions 
which form a carbon-carbon bond between these tethered π-systems have proven 
a versatile means to polycyclic heterocycles.52 In the context of designing complex 
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natural product-like scaffolds, N-tethered 1,6-enynes and -diynes have been 
shown to be versatile acyclic precursors to a range of complex natural product-like 
scaffolds. 
Scheme 1.5, shows the construction of an alkaloid-like library undertaken by 
the Tan group.53 From common starting materials they were able to construct 
many different heterocyclic scaffolds by varying the cyclization chemistry 
employed. Reacting diyne 14 (Scheme 1.5, right) with Grubs I catalyst and 
propargyl alcohol gave isoindoline alcohol scaffolds 15 and 16, Ru(I) catalyst and 
benzyl isocyanate gave pyrrolopyridones 17 and 18, Ru(I) catalyst and 
cyanoformate gave pyrrolopyridines 19, and Ni(0) catalyst and ethyl 
cyclopropylidene acetate gave cycloheptapyrrolidines 20 and 21. The ability to 
transform a common precursor into a range of diverse structures in this way is far 
more efficient than targeting each of these scaffolds individually.  
  
17 
Scheme 1.5. Library of Diverse Alkaloids from 1,6-Enynes and Diynes  
Condtions: a) Co2(CO)8; b) Rh(COD)2BF4, H2, (R)-BINAP; c) Rh(COD)2BF4, H2, (S)-BINAP; d) i) m-
CPBA, ii) Rh(Mes)(COD)Cl, AgOTf, butadiene; e) Grubbs II; f) i) m-CPBA, ii) Grubbs II, iii) N-phenyl 
maleimide; g) i) m-CPBA, ii) Grubbs II, iii) DMAD, iv) DDQ; h) Grubbs I, propargyl alchol; i) 
RuCp*(COD)Cl, BnNCO; j) Rh(COD)2BF4, rac-BINAP, NCCO2Et; k) i) Ni(COD)2, PPh3, ethyl 
cyclopropylidene acetate, ii) cyclopentyl-MgCl, Me(MeO)NH2Cl. 
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The diversity of scaffolds that were constructed in this library (Scheme 1.5) is 
directly related to the diversity of cyclizations amenable to 1,6-diyne and -enyne 
starting materials. While Tan and coworkers realized an impressive variety of 
scaffolds, all of the members of the library contain a 5-membered pyrrolidine ring. 
If, for example, 6-membered piperidine rings could have been included, the 
diversity of the library would have been substantially increased. However, as will 
be discussed in greater detail in the following chapter (Section 2.1.2), reactions 
which produce 6-membered piperidine rings from tethered 1,6-enynes and -diynes 
are rare. The development of reactions which access new cyclic frameworks is 
thus directly related to ease with which chemical space can be explored.  
1.2.2 Prior Work in the Snyder Group 
Naphthyridines are interesting targets for library development, as related 
compounds have been shown to have promising bioactivity.54-56 Despite being 
relatively simple structures, efficient methods for their construction are uncommon. 
Using an inverse electron demand Diels-Alder (IEDDA) approach, the Snyder 
group developed an efficient route to 1,2,3,4-tetrahydro-1,5-naphthyridines 22 
from pyrrole-tethered triazines 21 (Scheme 1.6, top).57 Utilizing the amino nitrogen 
as a handle, these structures could be diversified through acylation, urea 
formation, Buchwald-Hartwig amination, Petasis–Mannich reactions, and epoxide 
opening (Scheme 1.6, middle). The ring opening of enantiospecific (+)-
epichlorohydrin by 22, followed by reformation of the epoxide, gave epoxidated 
scaffold 23 (Scheme 1.6, bottom).58 Utilizing the epoxide of 23 as a diversification 
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site, the Snyder group was able to construct a small library of complex 
naphthyridines 24 from a diverse set of amine nucleophiles (Scheme 1.6, bottom). 
Scheme 1.6. IEEDA approach to a 1,5-Naphthyridine Library 
Despite the diversity of modifications that could be made to these scaffolds, the 
IEDDA approach to their construction limited the skeletal framework to 1,2,3,4-
tetrahydro-1,5-naphthyridines. To access tetrahydronaphthyridine scaffolds with 
alternative nitrogen positions a different strategy was required. Scheme 1.7 depicts 
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the Co(I)-catalyzed [2+2+2] cyclotrimerization of N-tethered alkynylnitriles 25 to 
1,6-naphthyridine scaffolds 26.59 While Co(I)-catalyzed cyclizations of two alkynes 
and a nitrile had been established as reliable means to pyridines prior to this 
work,60-66 the nitrogen tether of 25 allowed for creation of the bicyclic 
naphthyridines in a single step. By changing the tether length n,m, alternative 
scaffolds with 5- and 7-membered rings could be constructed. Furthermore, 
dialkynylnitriles 27 could by cyclized intramolecular to produced tricyclic scaffold 
28 (Scheme 1.2, bottom). A library derived from diversification of the amino 
nitrogen of these 5,6,7,8-tetrahydro-1,6-naphthyridine scaffolds  has been shown 
to have antituberculosis activity.67  
Scheme 1.7. Co(I)-catalyzed Cyclotrimerization of N-tethered Alkynylnitriles 
As an extension of this work, intramolecular [2+2+2] trimerizations were 
developed with tethered 1,6-diynes 29, containing an appended enone. 68 
Cycloadditions between tethered diynes and enones had been reported 
previously,69,70 however not as intramolecular reactions. Under Rh(I) catalysis 
tricyclic scaffolds 30 were produced (Scheme 1.8), the intramolecular nature of the 
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reaction forming an oxygen or nitrogen heterocycle, a carbocycle, and a benzene 
ring in a single step. This chemistry was used as the key bond forming reaction in 
the synthesis of the natural product, alcyopterosin I, which was accessed from O-
tethered 1,7-diynyl ether 31, following cyclization and asymmetric reduction of 
ketone 32 (Scheme 1.8, bottom). 
Scheme 1.8. Rh(I)-catalyzed Cyclotrimerization of Tethered 1,6-Diynyl Enones 
This Rh(I)-catalyzed cyclization was further developed using disubstituted 
enones 33, such that the formation of a quaternary carbon on the central ring 
prevented aromatization of the tetrasubstituted cyclohexadiene products 34 
(Scheme 1.9, top).71 This cyclization could also be accomplished intermolecularly 
with diyne 35 and methyl methacrylate, to give cyclohexadienes 36 (Scheme 1.9, 
bottom). Dienes 34 and 36 were found to be effective Diels-Alder partners with a 
range of heterodienophiles, and unique scaffolds could be constructed from 
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cycloaddition products of singlet oxygen, acyl nitroso compounds, and 
triazolediones (not shown). Nitroso dienophiles proved especially useful and 
following cycloaddition could be reduced to the corresponding amino alcohols 37 
and 38 (Scheme, 1.9).  
Scheme 1.9. Rh(I)-catalyzed Cyclization and Diels-Alder Diversification 
Following this report, 1,7-diynes were investigated. While they were not 
amenable to the Rh(I) conditions, in the presence of pTSA, water, and InI3 (20 
mol%), 1,7-diynyl ethers 39 were found to undergo hydrative cyclization/skeletal 
rearrangement to tetrahydrofurans 40 (Scheme 1.10).72 A mechanism to explain 
the substantial reorganization of the carbon framework was proposed wherein 
homopropargylic alkyne 39 is initially activated through In(III) coordination to the 
ether oxygen and alkyl substituted alkyne A. This activation promotes 7-endo-dig 
cyclization to carbocation B. Subsequent trapping of B by water and 
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protodemetalation of the vinyl indium generates enol C, which can undergo 
elimination to generate acyclic cross-conjugated dienone D. Protonation of D 
yields tertiary carbocation E, and then ring closure gives the THF products 40.  
Scheme 1.10. InI3-catalyzed Hydrative Cyclization of 1,7-Diynyl Ethers 
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During this study it was noted that treatment of O-tethered 1,6-diynyl ether 41 
with stoichiometric InBr3 in the presence of H2O and pTSA gave presumed 
halocyclization product 42 (Scheme 1.11). Attempts to isolate and characterize 42 
were unsuccessful, however the presumed vinyl bromide could be functionalized 
through Pd(0)-catalyzed Suzuki cross-coupling to give the expected bisarene 43, 
which was isolated in 36% yield.  Subsequently, it was discovered utilizing 
stoichiometric InI3 or GaI3, and omitting the unnecessary pTSA and H2O, vinyl 
iodide 44 could be isolated in low 30% yield (Scheme 1.11, bottom). This initial 
observation served as the starting point for the chemistry developed in the 
subsequent chapters of this thesis. 
Scheme 1.11. Halocyclization of 1,6-Diynyl Ether 12 
1.3. Conclusion  
Only a small portion of chemical space is likely to contain molecules which 
interact with biological systems in useful ways. Given the vastness of chemical 
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space and the relative sparseness that will ever be explored, it is vital to focus on 
areas that are most likely to contain biologically relevant structures. The drug-like 
chemical space that has received the majority of attention in the past two decades, 
is too narrowly defined and potentially not the most likely to contain useful bioactive 
small molecules. Natural product-like chemical space is potentially more 
biologically relevant and a richer source of small molecule drugs and biochemical 
probes. 
Given the increased complexity of natural product-like scaffolds, new methods, 
such as DOS and natural product remodeling, are being developed to efficiently 
explore natural product-like chemical space. Essential to these strategies is the 
ability to transform acyclic precursors into cyclic structures in a regio- and 
stereocontrolled manner. The Snyder group has had success using tethered bis 
π-systems as acyclic precursors to heterocyclic scaffolds (Scheme 1.12). The 
primary focus of this thesis describes efforts to further develop and understand the 
cyclizations of bisalkynes to access uncommon heterocyclic frameworks. 
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 Scheme 1.12. Snyder Group Bis π-system Cyclizations 
Condtions: a) CpCo(CO)2; b) i) RuCl(PPh3)3, ii) DDQ; c) Rh(COD)2BF4, (rac)-BINAP; d) InI3, 
pTSA∙H2O, H2O; e) i) GaI3, ii) TfOH; f) TfOH. 
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CHAPTER II - Gallium Promoted Halocyclization Reactions of 1,6-diynes 
2.1 Introduction 
2.1.1 Initial Observation and Impetus 
As described in Chapter 1, it was observed that 1,6-diyne 1a cyclized to vinyl iodide 
2a in modest yield (30%) on treatment with GaI3 (Scheme 2.1).72 Three features 
of this reaction motivated our efforts to explore this chemistry. First, cyclizations of 
1,6-diynes typically give 5-membered rings with two exocyclic alkenes; the s-trans 
diene of 2a with one internal and one external alkene is much less common 
(Section 2.1.2). Second, gallium’s utility as a π-Lewis acid has only recently 
generated interest and its applications to organic transformations are vastly 
underdeveloped (Section 2.1.3). Third, vinyl iodides are potentially excellent 
handles for further diversification, and 2a should be easily functionalized through 
Pd(0)-catalyzed cross-coupling reactions.73 Taken together, we envisioned this 
reaction could be developed as a means to unique and easily diversifiable 
heterocyclic frameworks potentially relevant to drug-like chemical space. 
Scheme 2.1. GaI3 Promoted Halocyclization of a 1,6-Diynyl Ether 
2.1.2 Previous Studies on the Cycloisomerization Reactions of 1,6-Diynes 
As described in Chapter 1, chemists have long been motivated to develop 
methods for the formation of cyclic ring systems as they are relevant substructures 
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in many drugs and natural products. Metal-catalyzed cyclizations of tethered 1,n-
diynes,74,75 -allenynes,76-80 and especially -enynes,52 have been widely exploited 
for this purpose, functioning as readily accessible acyclic precursors to many novel 
carbo- and heterocyclic small molecules. The discussion in this section will be 
limited to the cyclizations of 1,6-diynes in support of the claim that the s-trans diene 
of 2a is rarely observed in the cyclization chemistry of these substrates. 
The most well studied carbocyclization reactions of 1,6-diynes are those 
which involve the cyclization of multiple π-bonds; most commonly [2+2+2] and 
[2+2+1] cycloadditions (Scheme 2.2, eq 1 and 2).50,81-84 In [2+2+2] cyclizations, the 
two π systems of the diyne react with an additional π system, such as an alkene, 
alkyne, or nitrile. The starting diyne is typically cyclized to a 5-membered ring and 
an s-cis diene, or 6-membered aryl ring (Scheme 2.2, eq 1). In [2+2+1] cyclizations 
the π bonds of the diyne are cyclized with a two electron chelotrope such as carbon 
monoxide, the result being a 5-membered ring and insertion of the chelotrope 
between C1 and C7 of the 1,6-diyne (Scheme 2.2, eq 2). These are powerful 
methodologies but, given they exclusively form 5-membered rings from the parent 
diyne, they are less relevant to this discussion than additive cycloisomerization 
reactions which have a range of cyclization possibilities (Scheme 2.2, eq 3 - 5).  
Additive cycloisomerizations of 1,6-diynes can be grouped based on the 
skeletal framework of the products formed. 85  Exo/exo cyclizations give 5-
membered rings and external s-cis dienes (eq 3). The two possible endo/exo 
cyclizations differ in the location of nucleophilic addition, internal (eq 4) or external 
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(eq 5), but both give 6-membered rings and s-trans dienes. Although virtually 
unobserved, endo/endo cyclizations would give 7-membered rings with an internal 
s-cis 1,3-diene (eq 6). 
Scheme 2.2. 1,6-Diyne Cyclizations 
2.1.2.1 Exo/Exo Cyclizations of 1,6-Diynes (Scheme 2.2, eq 3) 
 The first catalytic cycloisomerization of a 1,6-diyne was reported by Trost 
and coworkers as a reductive cyclization with a Pd(II) catalyst and triethylsilane as 
a stoichiometric reductant (Scheme 2.3). 86  They proposed that cis-
hydropalladation of the alkyne 4 gave vinyl palladium intermediate 5, which 
underwent cyclization to the 5-membered ring of vinyl palladium 6. Reductive 
elimination of 6 gave s-cis 1,3-diene 7 in moderate to excellent yields. 
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Scheme 2.3. Pd-catalyzed Reductive Cyclization of 1,6-Diynes 
Since this initial report, methods have been developed for the addition of a 
range of nucleophiles to metal π-complexes, including: water,87-89 alcohols, 90 
carboxylic acids,90 silanes,91-96 arenes, 97  aldehydes, 98 , 99  hydroxylamines, 100 
phosphines,101 metaloalkanes,102 and others.103-106 The mechanisms reported for 
these cyclizations often parallel that shown in Scheme 2.3; cis-addition of the metal 
and nucleophile across the alkyne to give a vinyl metal intermediate, then 
cyclization to give the exo/exo carbon skeleton.89,91-94,99 However, metalocycles 
are frequently reported as key intermediates in these diverse reaction 
pathways.87,88,90,96-98,101-103,105,106 The various ways the metals, substrates, and 
ligand environments impact these transformations remains an active area of 
research and, is too expansive to be included here. Remarkably, given the breadth 
of conditions employed for the transformations, all of these reactions favor exo/exo 
cyclization to give s-cis products according to Scheme 2.2, eq 3.  
Notably, the Pd(II)-catalyzed reductive cycloisomerization of 1,6-diynes has 
been used by Trost and coworkers as a key carbon-carbon bond forming step in 
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the construction of the natural product (+)-streptazolin (Scheme 2.4). 107  The 
reductive cyclization of diyne 8 with 2.5 mol% Pd2(dba)3⋅CHCl3, in the presence of 
formic acid and Et3SiH gave the desired s-cis diene 9 in 64% yield, which was 
readily elaborated to (+)-streptazolin in two steps.   
Scheme 2.4. Pd-catalyzed Reductive Cyclization of 1,6-Diynes, Route to (+)-
Streptazolin 
2.1.2.2 Exo/Endo Internal Cyclizations of 1,6-Diynes 
Relatively few exo/endo internal cycloisomerizations (above) have been 
reported. The exo/endo cyclization 1,6-heptadiyne was first described by the 
Yamamoto group.108 They observed 1,6-heptadiyne cyclized to a vinyl silane 10 in 
the presence of stoichiometric hydrosilane and catalytic AlCl3, an observation that 
has been confirmed in several later reports109,110 (Scheme 2.5, eq 1). As reported 
by the Shiro group, electrophilic activation of diynes with PhIO and BF3 prompted 
cycloisomerization of 1,6-heptadiyne to give  vinyliodonium 11; the chloride 
apparently having originated from the solvent, DCE (Scheme 2.5, eq 2). 111 
Recently, the Ingleson group has reported that BCl3 was able to function as both 
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a Lewis acid and a chloride source, prompting a chlorocyclization of 1,6-
heptadiyne. The resulting vinyl boronate could be stabilized and isolated as the 
pinacol ester to give a s-trans diene 12 (Scheme 2.5, eq 3).112 It is worth noting 
that these reactions each appeared as single observations; the scope of these 
cyclizations was not investigated beyond this single 1,6-heptadiyne substrate. 
Scheme 2.5. Exo/endo Cycloisomerizations of 1,6-Heptadyne 
Another isolated example of an endo/exo cyclization appears in a report 
exploring Au(I)-catalyzed cyclizations of diynes by Ohno and coworkers.113 They 
found that cyclization of aniline substituted 1,6-diyne 13 gave s-trans indole 
product 14 as mixture of stereoisomers (Scheme 2.6, eq 1). Surprisingly, they 
reported that related phenyl substituted substrate 15 gave the 7-membered ring 
16 as the sole product (Scheme 2.6, eq 2). To the best of our knowledge, this is 
only report of a 1,6-diyne producing the endo/endo cyclization product (Scheme 
2.2, eq 6). The authors did not speculate on the reason for this change in 
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cyclization preference. For related 1,5-diyne cyclizations they proposed a tandem 
cyclization wherein the ortho-substituted aniline-yne 17 initially underwent Au(I)-
catalyzed indolization to indole-yne 18. This indole-yne, they proposed, underwent 
in situ Au(I)-catalyzed cyclization to the terminal product, naphthyl indole 19 
(Scheme 2.6, eq 3). 
Scheme 2.6. Gold-Catalyzed Cascade Cyclizations of Diynes 
Using a Rh(I) catalyst the Zhang group developed a domino 
heterocyclization and [(3+2)+2] carbocyclization of enone substituted 1,6-diynes 
20 with exogenous alkynes to produce 5,6,7-tricycles 21 (Scheme 2.7, top).114 
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Their proposed mechanism leading to the observed products involves a Rh(I) 
promoted oxocyloaddition to metalocycle 22 followed by alkyne insertion and 
reductive elimination. They have developed this chemistry extensively and are able 
to trap the proposed rhodacycle intermediate with a range of species including: 
carbon dioxide115 and indole,116 both of which give s-trans products (Scheme 2.7, 
bottom).  
Scheme 2.7. Domino Heterocyclization and [(3+2)+2] Carbocyclization 
In addition, Au(I) has also been shown to catalyze the hydrative cyclization 
of 1,6-diynes which, following tautomerization gave enones or ketones (Scheme 
2.8). Zhang and coworkers reported exo/endo cyclization of doubly terminal 
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bisalkynes 23 to enones 24 in the presence of Au(I) and methanol (Scheme 2.8, 
eq 1).117,118 The carbon skeleton of the cyclization product was found to be highly 
substrate dependent, bisphenyl-substituted diyne 25 gave exclusively exo/exo 
product 26 (Scheme 2.8, eq 2). This observation was corroborated in a report from 
the Fiksdahl group, who observed that substitution at either alkyne could change 
the selectivity of the reaction from endo/exo to exo/exo (Scheme 2.8, eq 3).89 
Scheme 2.8. Au(I)-catalyzed Cycloisomerizations of 1,6-Diynes 
  
36 
2.1.2.3 Exo/Endo External Cyclizations of 1,6-Diynes  
Like the endo/exo interval cycloisomerizations according to eq 4 (Scheme 
2.2), only a few endo/exo external cycloisomerizations (above) have been 
reported.  Rigid, conjugated 1,6-diynes such as 27 are known to undergo domino 
reactions in the presence of I2 to extensively conjugated polycycles such as 28 
(Scheme 2.9, eq 1).119-122 Bisthiolphenyl-1,6-diyne 29 has also been shown to 
undergo a tandem cycloisomerization/Freidel-Crafts reaction in the presence of 
IPy2BF4 and HBF4 to give tricycle 30 (Scheme 2.9, eq 2).123 These reactions are 
particularly noteworthy because in addition to cyclizing to s-trans dienes, they are 
halocyclizations, producing vinyl iodides as products. Both reactions are likely 
prompted by electrophilic activation of an alkyne, which initiates cycloisomerization 
and intramolecular addition of the appended phenyl ring to a vinyl carbocation.  
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Scheme 2.9. Iodine and Ionium Electrophilic Cyclizations of 1,6-Diynes 
Like the electrophilic cyclizations above, the majority of metal-catalyzed 
endo/exo external cycloisomerizations according to Scheme 2.2, eq 5 have 
internal nucleophiles. Scheme 2.10 depicts three Au(I)-catalyzed reactions where 
1,6-diynes were cyclized to polycyclic s-trans dienes though the action of an 
internal nucleophile. Liu and coworkers reported bis-aryl diyne 31 cyclized to 
tricycle 32 when treated with 2 mol % of AuCl(PPh3)/AgSbF6 (Scheme 2.10, eq 
1).124 Zhang and coworkers reported cyclopropanol substituted bis-aryl diyne 33 
underwent a tandem cyclization/ring expansion to vinylidenyl-cyclobutanone 34 
when treated with 8 mol% of AuCl(PPh3)/AgOTf (Scheme 2.10, eq 2).125 Eycken 
and coworkers reported N-propynylbutynamide 35 cyclized to s-trans bicycle 36 
when treated 5 mol% AuCl(PPh3)/AgSbF6. The products presumably the result of  
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Au(I) mediated Csp3–H functionalization of the tert-butyl substituent (Scheme 2.10, 
eq 3). 126  Although the mechanisms proposed for these reactions vary 
substantially, the overall transformations are similar. 
Scheme 2.10. Au (I)-catalyzed Tandem Cyclizations of 1,6-Diynes 
To the best of our knowledge, aside from the GaX3 halocyclizations 
developed in this thesis, only two endo/exo external cycloisomerizations of 1,6-
diynes with the intermolecular addition of a nucleophile have been reported. Using 
a Ru(II) catalyst, Lee and co-workers reported the carboxylative cyclization of 1,6-
diyne 37 to vinyl ester 38 (Scheme 2.11).127 They proposed that cyclization occurs 
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through metal-vinylidene 39, followed by addition of the carboxylate nucleophile, 
and protodemetalation. 
Scheme 2.11. Ru-Catalyzed Carboxylative Cyclization 1,6-Diynes 
Yu and coworkers have reported the tandem cyclization of bis-aryl-diyne 40 
to polycyclic vinyl chloride 41 (Scheme 2.12).128 They proposed oxocarbonium 
cation 42 generated from diethyl benzaldehyde acetyl and FeCl3 acted as 
electrophilic promotor of cyclization, generating vinyl carbocation 43.  For R=H, 
this vinyl cation was trapped by chloride to give intermediate 44, which underwent 
in situ cyclization to 45. For R=EDG the vinyl carbocation intermediate was trapped 
by the internal arene, and following rearomatization, gave product 46. This is 
particularly notable because it mirrors our mechanistic proposal for the Ga(III)-
catalyzed cyclization of 1,6-diynes, wherein a common vinyl cation intermediate 
can be trapped by either an external halide nucleophile or an internal arene (vida 
infra, sec. 2.5) 
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Scheme 2.12. Tandem Cyclization of Diynes with Benzaldehyde Acetals 
2.1.3 Gallium as a π-Lewis Acid and Halide Source 
 The utility of gallium as a catalyst in organic methodologies has seen a 
surge of interest in the last decade.129-131 Gallium is not a transition metal, it is 
abundant, cheap, and environmentally benign. As a Lewis acid, it does not occupy 
an obvious catalytic niche; functioning as both hard σ-acceptor and as a soft π-
acceptor. As the former, methods have been developed for the Ga-catalyzed 
nucleophilic addition to epoxides 132  and 1,4-addition to α,β-unsaturated 
carbonyls, 133  Nazarov reactions, 134  allylation of imines, 135  and sulfidation of 
alkynes. 136  As a π-Lewis acid, methods have been developed for allylation, 
alkenylation, ethynylation, coupling, cycloaddition, insertion, and glycosylation, of 
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a range of substrates.129-131 This section focuses on methodologies most relevant 
to the halocyclization chemistry developed in our work, namely, halide addition 
reactions in involving Ga(III) and cycloisomerizations involving Ga(III). 
2.1.3.1 Gallium as a Halide Source 
 To the best of our knowledge, aside from our gallium promoted 
halocyclization, only three accounts wherein gallium trihalide functions to both 
promote a reaction and as a halide source have been reported. As described by 
the Li group, the GaCl3-catalyzed coupling of an akynylbenzene 47 with an 
aldehyde 48 gave α-β unsaturated ketone 49 as the major product with 
chloroindene 50 as the minor product (Scheme 2.13). 
Scheme 2.13. GaCl3-Catalyzed Coupling of Ethnylbenzenes with Aldehydes 
The Yadav group has reported the GaCl3 promoted construction of 1,3,5-
triaryl-1,5-dihalo-1,4-pentadienes 53 from arylaldehydes 51 and ethnylbenzene 52 
(Scheme 2.14, top).137 While the Yadav group didn’t speculate on a mechanism, 
Kabalka and coworkers have observed this same transformation with BCl3 as a 
promotor (Scheme 2.14).138 For the BCl3 mediated reaction, they proposed initial 
syn-addition of BCl3 to ethynylbenzene gave vinyl boronate 54. Coupling of this 
intermediate with an arylaldehyde gave dichloroboronate ether 55, which on 
dissociation gave benzylilc/allylic cation 56. Trapping of this cation by another 
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ethynylbenzene lead to vinyl cation 57, and finally capture of the vinyl cation by 
chloride furnished 1,3,5-triaryl-1,5-dihalo-1,4-pentadiene 53 (Scheme 2.14). This 
mechanism is potentially applicable to the Ga(III) mediated reactions as well and 
offers an explanation for the minor product 50 observed by Lu and coworkers 
(Scheme 2.13); trapping of the proposed vinyl cation 57 by the internal phenyl ring 
would be expected to give the observed chloroindene after rearomatization.  
Scheme 2.14. GaCl3 or BCl3 Mediated Alkyne Aldehyde Coupling of 
Ethnylbenzene with Arylaldehydes 
 Recently, the Zhan group has reported the InX3 promoted halocyclization of 
N‑propargylic sulfonylhydrazones 58 (Scheme 2.15).139 While they found indium 
gave superior yields, they noted GaI3 was able to furnish the desired 5,6-
dihydropyrazolo[5,1‑a]isoquinoline 59 in 50% yield. This transformation is of 
particular relevance to the halocyclization reaction developed herein, because it 
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utilizes GaX3 as both a π-Lewis acid and as a halide source to furnish an exocyclic 
vinyl halide as the terminal product. The authors proposed π-coordination of InX3 
prompted cyclization from the adjacent hydrazone to give pyrazolium cation 60. 
Trapping of this carbocation by the remaining alkyne generated exocyclic vinyl 
carbocation 61. Trapping of 61 by iodide gave 59 after protodemetalation and 
detosylation/aromatization.  
Scheme 2.15. Halocyclization of N‑Propargylic Sulfonylhydrazones 
2.1.3.2 Gallium-Catalyzed Cycloisomerization Reactions 
Unlike the few reports of halocyclizations that have been disclosed, gallium 
trihalide’s ability to function as a π-Lewis acid and activate alkynes and alkenes 
has received considerable attention in the recent literature. Cycloisomerizations of 
enynes, allenynes, arylynes, and others have been developed.129-131 In many 
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cases, these Ga(III)-catalyzed methods have proved superior or complementary 
to the transition metal based Au(I) methods, which have dominated the literature 
in the past decade.140  
Scheme 2.16 depicts the GaCl3-catalyzed cycloisomerization of arenynes 
62 to bicycles 63, as reported by Murai and coworkers.141 While this transformation 
is known to be catalyzed by other transition metals such as Ru(II) and Pt(II), the 
authors note this Ga(III) based approach was tolerant of a full range of electronic 
states of the arene from electron rich (R = OMe) to mildly electron poor (R = Cl).142 
The comparable transition metal-catalyzed approaches require electron rich 
aromatics.  
Scheme 2.16. GaCl3-Catalyzed Cycloisomerization of Arylynes 
This reaction was further developed by the Gandon group into a tandem 
cycloisomerization/Friedel-Crafts reaction where, following the initial 
cycloisomerization of 62, the products could be arylated with electron rich 
aromatics to produce products such as 64 in excellent yield (Scheme 2.17).143 
Subsequently, the same group developed a catalytic system utilizing NHC ligated 
Ga(III) complexes and Ag(I) salts to generate LGaCl2+ cations. Using the 1,3-
bis(2,6-diisopropylphenyl)imidazol-2-ylidene (IPr)  ligand, they were able to 
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catalyze the same transformations with much lower catalyst loadings, and 64 could 
be isolated quantitatively with only 1 mol% catalyst. (Scheme 2.17).131,144 This 
report marks one of the first successful ligand systems for gallium based 
cycloisomerization. The observation that the active species in these 
transformations is likely the cationic species has also been proposed for related 
In(III)-catalyzed cycloisomerizations145.  
 Scheme 2.17. GaCl3-Catalyzed Tandem Cycloisomerization/Friedel-Crafts 
Alkylation of Arylynes 
Notably, a GaCl3-catalyzed cycloisomerization has been used as a key 
carbon-carbon bond forming step in the construction of (+)-salviasperanol146 and 
related icetexones, 147  as well as natural product cores of the hetidines and 
hetisines.148 Scheme 2.18 depicts the key cycloisomerization step employed by 
the Sarpong group in their synthesis of (+)-salviasperanol. Enyne 65 underwent 
cycloisomerization with 20 mol% GaCl3 to diene 66 nearly quantitatively, which 
was further elaborate to the natural product in three steps. 
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Scheme 2.18. GaCl3-Catalyzed Cycloisomerization in the Synthesis of (+)-
Salviasperanol 
2.2 Gallium Promoted Halocyclization Reactions of 1,6-diynes – Our work 
2.2.1 Scope of the Halocyclization Reaction 
Our initial efforts to explore this Ga(III) promoted halocyclization of 1,6-
diynes were made difficult by the instability of the cyclic ether product 2a, which 
slowly decomposed to a complex mixture during the reaction and chromatography. 
Gallium (III) is known to promote ring opening polymerization (ROP) reactions of 
cyclic ethers.149 The identity of the tether is known to strongly effect the outcome 
of related cyclization of bis π-systems.127 Diynes with various tethers were 
screened in an effort find products that would be less susceptible to decomposition 
(Table 2.1).  
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Table 2.1. Varying the Diyne Tether 
 
entry diyne A time (h) prod. (NMR yielda, yieldb) 
1 1a O 0.5 2a (71%, 30%) 
2 1b NTs 0.2 2b (91%, 88%) 
3 1c NNs 1.0 2c (93%, 90%) 
4 1d C(CO2Et)2 0.1c 2d (40%, 0%) 
5 1e C 0.1c 2e (30%, 0%) 
6 1f NOPh 24d No reaction 
 aQuantitative NMR yield. bIsolated yield. cRun at 0 °C. dRun at 60 °C 
 
N-Tosylate and N-nosylate tethered 1,6-diynes 1b and 1c were converted 
to products 2b and 2c in near quantitative yields (Table 2.1, entries 2 and 3). 
Notably, like etherate 1a, these products were found to be unstable to 
chromatography. However, unlike etherate 1a, the crude material was nearly pure, 
and final purification could be accomplished by quick filtering through a silica gel 
plug, minimizing decomposition. The production of a nitrogen containing 
heterocycle had the added benefit of making these molecules more drug-like, and, 
in the case of the easily removable nosylate, provided a  handle for further 
diversification (vida infra, Section 2.2.7). The (Z) stereochemistry of the exocyclic 
alkene 2b was confirmed by an NOE between the methyl group 
and the adjacent phenyl protons (inset). Malonate 1d (Table 2.1, 
entry 4) and hydrocarbon 1e (Table 2.1, entry 5) gave very fast 
conversion to products at 0 °C. Despite forming complex mixtures, 
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the NMR of the crude material supported formation of the expected vinyl iodide 2d 
and 2e as the major products. These proved even more sensitive to decomposition 
than the etherate 2a and could not be isolated. In contrast, amide tethered diyne 
1f gave no reaction even at elevated temperature (Table 2.1, entry 6). This lack of 
reactivity is potentially due to amide coordination of the gallium promotor. The 
scope of the reaction was then investigated with a range of N-tosyl tethered diynes 
(Table 2.2). 
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Table 2.2. Halocyclization Scope 
 
entry diyne R1 R2 time (h) prod. (NMR yielda, yieldb) 
1 1g Me p-OMe 0.1 2g (93%, 88%) 
2 1h Me 3,5-Me 0.2 2h (94%, 93%) 
3 1i Me m-OMe 0.8 2i (94%, 87%) 
4 1j Me p-Cl 0.8 2j (92%, 78%) 
5 1k Me p-CO2Me 9c 2k (88%, 36%) 
6 1l Me p-CF3 2 2l (88%, 61%) 
7 1m Me p-NO2 3c 2m (83%, 45%) 
8 1n Et H 0.8 2n (80%, 53%) 
9 1o H H 24 N/A (0%) 
10 1p Ph H 0.2 2p (41%, 41%) 
11 1q CH2-SiMe3 H 2d 
 
     
 
aQuantitative NMR yield. bIsolated yield. cRun at 60 °C. dRun with 10 mol % 
GaCl3. 
 
Varying the electronic state of the arene R2 was found to have an effect on 
both the yield and the rate of the reaction. Electron-rich substrates (Table 2.2, 
entries 1 and 2) gave near immediate conversion to product, while electron 
withdrawing groups slowed the reaction considerably (Table 2.2, entries 3−7). In 
the case of benzoate 1k and nitrobenzene 1m, mild heating to 60 ⁰C was effective 
in decreasing the reaction time. The isolated yields dropped considerably for 
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electron poor substrates. Like the etherate 1a, the disparity between the excellent 
NMR yields observed for the crude materials and the isolated yields is likely 
reflective of the method of purification. Products requiring a rigorous silica column 
gave significantly diminished yields. Nonetheless, the nearly pure crude materials 
could be used in subsequent reactions after removal of Ga(III) via basic extraction, 
without silica-gel purification and the associated loss of material (vide infra, Section 
2.2.7). Thus, the NMR yields better reflect the functional yields for further 
chemistry. Notably, the reaction was tolerant of the full range of electron states 
from the strongly activated p-methoxy substituted to the strongly deactivated p-
nitro substituted. 
Varying R1 to an alternative ethyl alkyl group 1n gave similar results (Table 
2.2, entry 8). Terminal alkynes 1o gave a mixture of several intractable products. 
(Table 2.2, entry 9). Trimethylsilyl-substituted alkyne 1q gave only the desilylated 
allene 67 on treatment with catalyst. Under the original reaction conditions, this 
allene-yne did not cyclize with prolonged reaction times.150 Bis-aryl diyne 1p gave 
41% of the expected diyne as the minor product of a mixture with 46% tricycle 68 
as the major product. Given the prevalence of tandem cycloisomerizations 
involving internal arene nucleophiles as trapping agents, this is not surprising (see 
above, Schemes 2.9, 2.10, and 2.12).  The yield of 68 could be increase to 82% 
with 10 mol% GaCl3 (Scheme 2.19). This product mixture provided key insights 
into the reaction mechanism (vide infra, sec. 2.5.), and was the initial observation 
leading to the chemistry developed in Chapter 3.  
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Scheme 2.19. Bisphenyldiyne Cycloisomerization 
2.2.2 Mechanistic Considerations  
In an effort to expand the scope of the reaction and validate Ga(III) as the 
active species, a range of alternative reagents were screened (Table 2.3). With 
GaBr3 and GaCl3 the corresponding vinyl bromide 69 and vinyl chloride 70 
products were obtained in 95% and 55% yields, respectively (Table 2.3, entries 2 
and 3). These reactions required longer reaction times in comparison to the iodide, 
and in the case of GaCl3, mild heating was necessary. In contrast, GaF3 gave no 
reaction (Table 2.3, entry 1). As expected from earlier work, In(III) halides were 
also competent promoters, giving similar yields, however requiring longer reaction 
times than the corresponding Ga(III) halides (Table 2.3, entries 5-7). The In(I) salt 
InBr gave no reaction (Table 2.3, entry 8), and AlBr3 gave decomposition products 
even at lowered temperatures (Table 2.3, entry 9). Two control reactions with I2 
and HI (48% aq), gave only slow conversion to complex mixtures with no apparent 
halocyclization (Table 2.3, entries 10 and 11). 
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Table 2.3. Alternative Catalyst Trials 
 
entry cat. equiv time (h) prod. (yield)a 
1 GaF3 1.0 36 NR 
2 GaCl3 1.0 1 70 (55%)b 
3 GaBr3 1.0 0.5 69 (95%) 
4 GaI3 1.0 0.2 2b (88%) 
5 InCl3 1.0 12 70 (72%)c 
6 InBr3 1.0 36 69 (80%) 
7 InI3 1.0 3 2b (93%) 
8 InBr 1.0 24 NR 
9 AlBr3d 1.0 24 Complex mixture 
10 I2 1.0 24 Complex mixture 
11 HI (48% aq) 1.0 24 Complex mixture 
aIsolated yield. bRun at 50 °C. cRun at 84 °C. d0 °C 
 
  Figure 2.1 depicts two plausible mechanisms, M1 and M2, for the formation 
of halocycle products 2, 69, and 70. Both mechanisms presume the catalytically 
active species to be the GaX2+ cation, formed by halide exchange between two 
neutral GaX3.151 In M1, initial activation of the arylalkyne (A1) prompts addition of 
iodide and generation of vinyl gallium intermediate B1, hypothetical anti- 
cyclization produces s-trans vinyl gallate C1, and finally protodemetalation affords 
the halocyclization product (2, 69, or 70). This mechanism is reminiscent of those 
often invoked for Pd, Pt, Pd, and Au-catalyzed nucleophilic cycloisomerization 
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reactions, save the cyclization step (B1 → C1) typically gives syn addition in these 
chemistries.  
In M2, Ga(III) activates the R1 substituted alkyne, producing A2, which then 
undergoes a 6-endo-dig cycloisomerization to generate vinyl carbeneium B2. 
Trapping of B2 by iodide gives C2, then protodemetallation affords the 
halocyclization product (2, 69, or 70). Similar mechanisms have been reported for 
Fe(III)129 and halonium123,124 promoted cyclizations. Alternative mechanisms 
wherein oxidative cyclization forms metalocycles, like those reported for Ru, Rh, 
Co, Ir, catalysts50,84 seem unlikely, both because Ga(III) is already in its highest 
oxidation state, and because these mechanisms give exclusively exo/exo 
cyclization products.  
Figure 2.1. Two Possible Halocyclization Mechanisms 
  
54 
Mechanism M1 is attractive because the anti-addition of iodide (A1 → B1) 
potentially offers an explanation for the exclusive alkene stereochemistry observed 
in these reactions. However, M1 is less able to explain the formation of side 
product 68, when R1 = Ph. The relevant intermediate would be a 9-membered 
macrocyclic vinyl gallate, B1’ (inset). The M2 pathway can explain both the 
formation of 2p and 68, as B2 is a plausible intermediate for the formation of both. 
When R1 = Ph the intramolecular capture of the vinyl carbocation by the internal 
arene should compete effectively with the intermolecular capture by the halide. 
This tandem cycloisomerization/Friedel-Crafts mechanism can also explain the 
increase in Friedel-Crafts product 68 when switching from GaI3 to GaCl3 (Scheme 
2.19). Compared to iodide, the less nucleophilic chloride is less able to compete 
for carbocation B2. For M2, the stereochemistry of the halocyclization products is 
perhaps a steric effect, R1 blocks the halide approach from that side. Mechanism 
M2 also explains the slower rate observed for electron poor arenes 
(Table 2.2), as these substrates would be less able to stabilize the 
high energy vinyl cation B2. M1 could also explain this result, as 
alkynes substituted with electron deficient arenes would be less π-
basic. 
Relevance of the proposed vinyl gallate C (Figure 2.1, C1 and C2) was 
supported by D2O studies (Scheme 2.20). When 1b was subjected to the reaction 
in DCE solvent had been saturated with D2O, then quenched with D2O, a 48% 
incorporation of deuterium at the proposed site of protodemetalation was 
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observed. That a higher percentage of deuterium incorporation wasn’t observed is 
likely the result of GaX3’s extremely hygroscopic nature 152   and competing 
demetalation by water present with the catalyst.   
Scheme 2.20. Deuterium Incorporation  
2.2.3 Alternative Nucleophiles 
Based on the proposed mechanism it was reasoned the vinyl cation 
intermediate B2 could be trapped by externally added nucleophiles, potentially 
removing the need for stoichiometric Ga(III) and increasing the overall utility of the 
reaction. Table 2.4, shows a subset of the conditions attempted to this end with 
substoichiometric Ga(III) catalyst. Added HBr or Br2,resulted in intractable mixtures 
(Table 2.4, entries 1-3). While some of the desired vinyl bromide was detected, so 
were many side products. Trials with hard nucleophiles, KBr, TBA-Br, NaCN, and 
TBA-CN were found to render the catalyst inactive and the reactions returned 
starting materials (Table 2.4, entries 1-4). Likely, these nucleophiles coordinate the 
gallium, disfavoring the formation of the presumed catalytically active GaX2+. 
In the presence of soft nucleophiles, the catalyst remained active. When 
diyne 1b was treated with 1 equiv Et3SiCl and 30 mol% GaBr3, a 2:8 mixture of 
vinyl Cl and vinyl Br halocyclization products 70 and 69 were formed, respectively 
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(Table 2.4, entry 9). That more brominated product was produced than the 0.3 
equivalents of catalyst added suggested that the chlorosilane was able to replace 
the ligands of the catalyst, turning it over. The ratio of chloro- to bromo-product 
(70:69) could be increase to 3:7 (Cl:Br) using 3 equiv Et3SiCl (Table 2.4, entry 10). 
Matching the halosilane to the GaX3 catalyst produced only a single halide product, 
and vinyl bromide and vinyl iodide, 70 and 2b, could be isolated in 76% and 56% 
yields respectively using 20 mol% GaX3 and 1 eq Me3SiX (Table 2.4, entries 11 
and 12).  
Given the decreased yield, more difficult purification, comparable cost of the 
gallium salts relative to the halosilanes, and a turnover number of only 3, 
stoichiometric gallium trihalides were used in subsequent studies. Substrates 
containing electron rich aromatics were also found to be incompatible with the 
catalytic conditions, giving alterative cleavage products (data not show).  
In combination with the least nucleophilic gallium trihalide, GaCl3, other soft 
nucleophiles, including anisole, toluene, N-Me-pyrole, furan, TES-CN, TES-H, 
allyl-silane, proved less amenable (Table 2.4, entries 13-19). Each gave low 
conversions to complex mixtures of products contaminated with the undesired vinyl 
chloride halocyclization product 69. For anisole and toluene, the corresponding 
addition products could be detected by UPLC, however the complexity of the 
reaction prevented their characterization. 
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Table 2.4. Alternative Nucleophiles 
 
 
entry MX3 Additive Nu- (equiv) time (h) prod. (yield)a 
1 GaBr3 HBr aq Br 1.0 16 Complex mixture 
2 GaBr3 HBr/AcOH Br 1.0 16 Complex mixture 
3 GaBr3 Br2 Br 1.0 16 Complex mixture 
4 GaBr3 KBr Br 1.0 24 NR 
5 GaBr3 TBA-Br Br 1.0 12 NR 
6 GaBr3 NaCN CN 1.0 3 NR 
7 GaBr3 TBA-CN CN 1.0 24 NR 
8 GaBr3 NaBr Br 1.0 36 NR 
9 GaBr3 Et3SiCl Cl 1.0 1 70:69 Cl:Br (2:8)b 
10 GaBr3 Et3SiCl Cl 3.0 1 70:69 Cl:Br (3:7)b 
11 GaBr3 Me3SiBr Br 1.0 0.5 69 76%c 
12 GaI3 Me3SiI I 1.0 0.2 2b 56% 
13 GaCl3 Et3SiCN CN 2.0 16 Complex mixture 
14 GaCl3 Et3SiH H 2.0 16 Complex mixture 
15 GaCl3   2.0 16 Complex mixture 
16 GaCl3 Toluene Toluene 2.0 16 Complex mixture 
17 GaCl3 Anisole Anisole 2.0 16 Complex mixture 
18 GaCl3 Furan Furan 2.0 16 Complex mixture 
19 GaCl3 
N-Me-
Pyrole 
N-Me-
Pyrole 
2.0 16 Complex mixture 
aIsolated yield. bNMR ratio. cRun at 50 °C 
Anisole gave the most tractable mixture, but efforts to optimize the yield by 
varying the ratio of catalyst to anisole proved difficult. With high loadings of GaCl3 
catalyst (50-100 mol%) anisole was unable to compete with the chloride 
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nucleophile; anisole incorporation diminished and vinyl chloride was produced as 
the major product. The formation of chlorinated product paralleled the amount of 
catalyst; with 5 mol% catalyst the reaction ceased once 5% of the vinyl chloride 70 
was formed. Using a large amount of both catalyst and anisole gave complex 
mixtures, with UPLC-MS consistent with multiple anisole additions. Analyzing the 
relative ratios of UPLC-MS peaks corresponding to the starting material, vinyl 
chloride, and anisole addition product, optimal conditions were found with 3 equiv 
anisole and three separate additions of 10 mol% GaCl3 (Scheme 2.21). However, 
on isolation none of the expected vinyl anisole product 71 was obtained and 
instead the two tricyclic products 72 and 73 were isolated in 12% and 3% yields, 
respectively, along with vinyl chloride 70, and cycloisomerization product 74. 
Scheme 2.21. GaCl3-Catalyzed Cycloisomerization Anisole Addition 
While synthetically this reaction is likely of little use, it offers an alternative 
explanation for the generally high catalyst loadings (10-30%) employed for GaX3-
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catalyzed reactions. The reason typically cited for these high catalyst loadings is 
that, due to its extremely hygroscopic nature, significant amounts of GaX3 catalyst 
are rendered inactive do to hydration and hydrolysis by adventitious water.143,144 
From these results, we can speculate that small amounts of halide addition 
products might be responsible for the slow depletion of catalyst in other GaX3-
catalyzed reactions.  
2.2.4 Halide Free Catalyst System 
Given the inability to effectively outcompete the gallium derived halide 
nucleophiles with added nucleophiles, and difficulties maintaining an active 
catalyst as the halocyclizations depleted the active catalyst, we attempted to 
develop halide free reaction conditions. Two strategies were employed to this end: 
(1) utilizing Ga(OTf)3 as a catalyst, and (2) generation of a ligated L-GaCl3 from 
which L-GaCl2+ could be formed by activation with AgSbF6. The tandem 
cycloisomerization/arylation reaction of diyne 1b utilizing anisole as an added 
nucleophile was chosen as a model system, expecting either monocyclized s-trans 
diene 71, or polycyclized indenopyridene 73 as products. Table 2.5 shows a subset 
of the conditions attempted to accomplish a tandem cycloisomerization/arylation 
reaction.  
Attempts to make a GaCl2+ or InCl2+ directly by addition of a silver salt to 
the trihalide gave no reaction (Table 2.5, entries 1 and 7). Attempts to stabilize the 
gallium with various ligands including bipy, 153  5-NO2-phen, 154  Ph2-PyBOX, 155 
tetra-glyme, and the NHC ligand IPr,131,144 were also unsuccessful (Table 2.5, 
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entries 2-6). Bipy, Ph2-PyBOX, and tetraglyme ligands gave no reaction (Table 2.5, 
entries 2-4). While, 5-NO2-phen and IPr ligands maintained some activity, only 
slow conversions to complex mixtures were observed (Table 2.5, entries 5 and 6). 
The UPLC-MS analysis of these mixtures indicated products consistent with 
anisole addition, but these could not be isolated in sufficient quantities for 
characterization. In addition, 5-NO2-phen was also attempted as a ligand for InCl3, 
however no reaction was observed (Table 2.5, entry 7). 
  
61 
Table 2.5. Tandem Cycloisomerization/Arylation Reaction, Catalyst-Ligand 
Screen 
 
entry MX3 Ligand yield (%) 
1 GaCl3 None NR 
2 GaCl3 Bipy NR 
3 GaCl3 Ph2-PyBOX NR 
4 GaCl3 Tetraglyme NR 
5 GaCl3 IPr <5% 
6 GaCl3 5-NO2-Phen <5% 
7 InCl3 None NR 
8 InCl3 5-NO2-Phen NR 
9 (PPh3)AuCl None <5% 
10 Ga(OTf)3a None NR 
11 Ga(OTf)3a Triglyme NR 
12 Ga(OTf)3 a 5-NO2-Phen NR 
13 Ga(OTf)3 a THF NR 
14 Ga(OTf)3a HIFP 
Alternative product  
(see Scheme 2.22) 
a Run without the addition of AgSbF6 
    
Furthermore, Ga(OTf)3 was found to be unreactive under all conditions 
attempted. This is likely due to its insolubility in non-coordinating organic solvents, 
and the unlikelihood that unstabilized Ga(OTf)3 would form the presumed 
catalytically active Ga(OTf)2+ cation. With the addition of 5-NO2-phen ligand or 
triglyme, the catalyst remained inactive (Table 2.5, entries 11 and 12). Likewise, 
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attempts to bring the Ga(OTf)3 into solution without complete solvation by adding 
small amounts of HIFP or THF also proved ineffective (Table 2.5, entries 13 and 
14). However, under the Ga(OTf)3/HIFP conditions 1b was converted to 
cycloisomerization product 74 in low yield (Scheme 2.22). It was later determined 
this reaction is likely independent of Ga(OTf)3 and could be catalyzed by a 
Brønsted acid alone, and 1b was converted to 74 when treated with 20 mol% TfOH 
in TFA in comparable yield (22% vs 20%) (Scheme 2.22).  
Scheme 2.22. Cycloisomerization of Aryl/Alkyl Diyne 1h 
2.2.5 Tandem Halocyclization/Friedel-Craft Cycloisomerization 
In the course of studies into the effects of exogenously added nucleophiles, 
we also screened the effects of added proton sources (data not shown). While no 
significant enhancement of the halocyclization reaction was observed, diyne 1b 
was cleanly converted to tricyclic indenopyridine scaffold 75b in the presence of 
GaI3 with TFA (Scheme 2.23).  
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Scheme 2.23. Tandem Halocyclization Friedel-Craft Cycloisomerization 
Product 75b was imagined to be the result of a Friedel-Crafts type 
alkylation, derived from initially formed 2b. Protonation of the endo alkene of 
product 2b produced allylic/benzylic cation 76, with subsequent trapping of the 
cation by the aromatic ring affording intermediate 77, which on deprotonation gave 
the observed product 75b (Scheme 2.24). 
Scheme 2.24. Plausible Mechanism for the formation of Indeneopyridenes 
Surprisingly, no reaction was observed on treatment of isolated 2b with TFA 
in the absence GaI3 (Table 2.6, entry 2), but in the presence of GaI3 and TFA full 
conversion from to 2b to 75b was observed (Table 2.6, entry 3). It was presumed, 
the mixture of GaI3, a Lewis acid, and TFA, a Brønsted acid, functioned to create 
a more acidic environment than just TFA alone, either by liberation of HI from GaI3 
through ligand exchange or by Lewis acid activation of TFA. Consistent with this 
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hypothesis, halocycle 2b underwent full conversion to indeneopyridene 75b in the 
absence of GaI3 on treatment with 20 mol% of TfOH (Table 2.6, entry 4). 
 
entry Cond. time (h) conversion 
1 GaI3 (1 equiv) 16 <10% 
2 TFA (1 equiv) 16 0% 
3 GaI3 (1 equiv) and TFA (1 equiv)  0.2 >99% 
4 TfOH (0.2 equiv) 0.2 >99% 
aNMR conversion.  
 
The applicability of this chemistry to a range of N-Ts and N-Ns diynes was 
then assessed. Two methods were employed to this end, a one pot procedure 
wherein TFA was added to the halocyclization reaction once TLC had confirmed 
full conversion to halocycle 2, and a two-step procedure wherein after the 
halocyclization was complete, gallium was removed via basic extraction and the 
crude material subjected to 20 mol% TfOH in DCE (Table 2.7).  
Table 2.6. Acid-Catalyzed Conversion of Halocycle to Indenopyridine 
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Table 2.7. Tandem Halocyclization/Friedel-Craft Cycloisomerization Scope 
 
entry diyne A R1 R2 prod.a (% yield)b (% yield)c 
1 1a O Me H N/A 0 0 
2 1b NTs Me H 75b 91 - 
3 1n NTs Et H 75n 66 73 
4 1g NTs Me p-OMe 75g 0 58 
5 1h NTs Me 3,5-Me 75h 91 - 
6 1i NTs Me m-OMe 75i 29 52 
7 1j NTs Me p-Cl 75j 97 - 
8 1k NTs Me p-CO2Me 75k 20 33 
9 1l NTs Me p-CF3 75l 25 48 
10 1m NTs Me p-NO2 N/A 0 0 
11 1c Ns Me H 75c - 95 
12 1r Ns Me p-CO2Me 75r - 56 
13 1s Ns Me p-CF3 75s - 52 
aIsolated yield. bOne-pot procedure with TFA. cTwo step procedure with TfOH. 
 
In all cases where both the one-pot and two-step procedure were 
compared, the two-step procedure fared significantly better (Table 2.7, entries 3, 
4, 6, 8, and 9), most dramatically for p-methoxyphenyl substituted diyne 1g, which 
failed to give any product in the one-pot procedure and a moderate 58% with the 
two step protocol (Table 2.7, entry 4). The rate of reaction was found to be 
dependent on the electron state of the arene. Although slow, even strongly 
deactivated aromatic groups underwent cyclization, except for the most 
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deactivated p-NO2-phenyl 1m, which failed to react (Table 2.7, entry 10). Nosylate 
tethered 1,6-diynes gave nearly identical results as the tosylates (Table 2.7, entry 
11-13). 
2.2.6 Asymmetric Tandem Halocyclization/Friedel-Craft Cycloisomerization 
The ability to construct molecules in a stereospecific manner is of 
fundamental importance to reaction development and drug discovery.156 Since 
compounds 75 possess a quaternary stereocenter at R1, we were motivated to 
develop a method to access indenopyridenes 75 in a stereo-controlled fashion.  
Constructing a chiral environment around the Ga(III) metal center seemed 
unlikely to succeed, as previous results indicated Ga(III) does not play a direct role 
in the conversion of the achiral halocycle 2 to chiral indenopyridene 75 (see above, 
Table 2.6).  Instead, we envisioned chiral Brønsted acids157 could be used (Table 
2.8). On their own, chiral binap-phosophoric acids were unable to catalyze the 
conversion of the halocycle products 2 to indeninopyridenes 75 (Table 2.8, entries 
1-3). This result is unsurprising given the significant disparity in acidity between 
the phosphoric acids (pKaDMSO ≈ 3.5)158 and catalytically active TfOH (pKaDMSO ≈ -
14).159   
Based on the observation that a mixture of TFA and GaI3 was able to 
promote the conversion of 2 to 75 (see above, Table 2.6, entry 3), mixtures of the 
chiral phosphoric acids and the GaI3 Lewis acid were screened. 160  2,4,6-
Triisopropylphenyl, and 3,5-ditrifluoromethylphenyl substituted binaphthyl 
phosphoric acids failed to react (Table 2.8, entries 5 and 6). The mixture of  (R)- 
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binaphthyl phosphoric acid and 20 mol% GaI3 gave full conversion to 75 in 16 h 
(Table 2.8, entry 4). Likewise, following conversion of 1,6-diyne 1c to 2c with 100 
mol% GaI3, addition of (R)-binaphthyl phosphoric acid gave full conversion to 
indenopyridene 75c. Unfortunately, this Lewis acid assisted chiral Brønsted acid 
transformation gave no measurable enantioenrichment as determined by chiral 
NMR.  
Table 2.8. Asymmetric Friedel-Crafts Cycloisomerization 
 
entry catalyst R Conversion (%) %eea 
1 None H 0 NA 
2 None 2,4,6-triisopropylphenyl 0  NA 
3 None 3,5-ditrifluoromethylphenyl 0 NA 
4 GaI3 (20 mol%) H >99 0 
5 GaI3 (20 mol%) 2,4,6-triisopropylphenyl <5 NA  
6 GaI3 (20 mol%) 3,5-ditrifluoromethylphenyl <5 NA 
7 GaI3 (100 mol%)b H >99 0 
a %ee was determined via chiral resolution NMR of the denosylated free amine 
with 1 eq mandelic acid  bOne-pot procedure from diyne 1c, phosphoric acid was 
added after conversion to 2c. 
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Notably, denosylated scaffold 76c was extremely amenable to NMR-based 
chirality distinction. The addition of 1 equivalent of mandelic acid fully resolved the 
methylenes adjacent to the free amine, with Δ δ 87 Hz and 146 Hz, respectively. 
(Figure 2.2). 
Figure 2.2. Chiral Resolution of Enantiomeric Mixture of 76c with Madelic Acid   
2.2.7 Diversification of Indenopyridine Scaffold 
Having developed a concise route to indenopyridines 75, the applicability of 
these molecules as scaffolds for the development of a library of drug-like small 
molecule was explored. Several related indenopyridines have been reported with 
potentially useful biological activities, including insecticidal, 161 , 162 
antihistaminic,163,164 antifungals,165,166 antidepressants,167,168 integrin inhibitors,169 
 
87 Hz 146 Hz 
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herbicides, 170  opioids, 171  contraceptives, 172 , 173  and antiarrhythmics. 174  (Figure 
2.3). Of particular note is the drug phenindamine, an antihistamine and 
anticholinergic sold over the counter to treat the symptoms of the allergies and 
common cold until 2004. 
Figure 2.3. Bioactive Indenopyridines 
Scheme 2.25 depicts the synthesis of an indenopyridine singleton 80, which 
was accessed in 8 steps from propargyl amine with an overall yield of 32%.  
Following nosylation of propargyl amine, R1 was installed via SN2 displacement 
with appropriately substituted 1-bromoalkyne. For R1 = Me, 1-bromo-2-butane 
bisalkyne gave 78 in quantitative yield. A Pd(0)/Cu(I)-catalyzed Sonogashira 
cross-coupling was then used to install R2. For R2 = CF3, 4-trifluoromethyl-1-
iodobenzene was used and aryl/alkyldiyne 1s was isolated in 71% yield. 
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Cyclization via the two-step GaI3 promoted halocyclization and acid-catalyzed 
Friedel-crafts alkylation chemistry developed herein, lead to vinyl 
iodoindenopyridine 75s in 52% isolated yield. Denosylation with thiophenol gave 
free amine 76s nearly quantatively.175 Stirring 76s with isocyanatocyclohexane 
gave the corresponding urea 79, installing R3.  Lastly, R4 was installed via Pd(0) 
cross-coupling. Suzuki cross-coupling with (4-methoxyphenyl)boronic acid gave 
the fully decorated singleton 80. The route to 80 was simple, high yielding, and 
only required a single protection and deprotection step of the nosylate. The two 
key diversification steps, installing R3 and R4, are the final two steps of the 
synthesis making modifications at these sites from a stock of cyclized precursor 
(76s in this example) maximally efficient.  
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Scheme 2.25. Synthesis of an Indenopyridine from Propargyl Amine 
Figure 2.4 shows a small library of 15 molecules constructed following the 
synthesis outlined in Scheme 2.25. Substituent R1 was maintained as Me for all 
substrates, except 89 where R1 = Et.  Substituent R2 was successfully varied as H 
(Figure 2.4, 86-88, and 92-94), 4-CF3 (Figure 2.4, 80-83), 4-CO2Me (Figure 2.4, 
84, 85, and 91), and 4-Cl (Figure 2.4, 90). Substrates bearing an N-Ts protecting 
group could not be deprotected for further diversification, so R3 remained the 
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sulfonamide for these entries (Figure 2.4, 88-94). Substrates with N-Ns were easily 
deprotected and the nitrogen alkylated (Figure 2.4, 87), acylated (Figure 2.4, 81-
85), converted to the HCl salt (Figure 2.4, 82 and 86), or functionalized as a urea 
by reaction with isocyanate (Figure 2.4, 80 and 81). Suzuki cross-coupling73 of the 
vinyl iodides with boronic acids afforded various aromatic substitutions at R4 
(Figure 2.4, 80-87, 89, 91, 93 and 94), and Sonogashira cross-coupling176 gave 
various alkynes (Figure 2.4, 88, 90, 92). Buchwald-Hartwig aminations177 and Cu 
catalyzed amidations178 failed to react, perhaps due to the steric encumbrance of 
the tri-substituted vinyl iodide.  
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Figure 2.4. Diversification of Indenopyridines 
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2.3 Conclusion  
We have developed a concise high yielding route to readily diversifiable 
indenopyridine scaffolds utilizing a GaX3 promoted halocyclization/Friedel-Crafts 
sequence. The halocyclization is accomplished by treatment of an appropriately 
functionalized 1,6-diyne with stoichiometric GaX3 in DCE. The reaction requires an 
N-nosylate or N-tosylate tethered 1,6-dyine, for maximal yield, and substitution 
with an alkyne and an arene; terminal alkynes and bisalkyl diynes give complex 
mixtures, and bis-aryl diynes give alternative products. Attempts to generalize the 
reaction to non-halide nucleophiles were unsuccessful, however bromide, and 
iodide could be incorporated under catalytic conditions with 20 mol% GaX3 and the 
appropriate stoichiometric halosilane.  
Friedel-Crafts cyclization of the halocycle products is best preformed via a 
two-step procedure, treating with the crude halocycle with 20 mol% TfOH in DCE. 
All the substrates compatible with halocyclization gave fair to excellent yields of 
the Friedel-crafts product, save the very electron deficient nitroarene, which failed 
to react. Efforts to render this cyclization enantioselective were also unsuccessful. 
The vinyl iodides from both the halocyclization and tandem 
halocyclization/Friedel-Crafts reaction proved amenable to Pd(0)-catalyzed cross-
coupling. As well, nosylate proved an easily removable protecting group allowing 
for functionalization of the indenopyridine nitrogen, enabling the synthesis of a 
small library of 15 compounds. 
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Chapter III - Gallium Trihalide vs Triflic Acid-Catalyzed Cycloisomerization 
Reactions of 1,6-Diynes 
3.1 Introduction 
3.1.1 Initial Observation and Impetus 
As introduced in Chapter 2, the halocyclization of bis-aryl 1,6-diyne 1p gave 
a mixture of vinyl halide 2p and 6,5,6-tricyclic product 68. Given the prevalence of 
polycyclizations of 1,6-diynes, wherein cycloisomerization occurs with the 
intervention of an internal nucleophile (See Chapter 2, Schemes 2.6, 2.9, 2.10, 
2.12), the production of 68 is not particularly remarkable, and the transformation 
of 1p to 68 has been previously observed under Au(I) catalysis (vide infra, Section 
3.1.3).124 
Scheme 3.1. Chemoselectivity of GaX3 Promoted Cyclization of 1,6-Diynes 
However, diyne 1p is a symmetric bis-aryl 1,6-diyne. Unsymmetrical bis-
aryl 1,6-diynes, those substituted with two different arenes, have received little 
attention. Considering the mechanism proposed in Chapter 2 (Figure 2.1) and 
elaborated below (Figure 3.1), these unsymmetrical substrates possess an 
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interesting electronic dichotomy. If the more electron rich, and presumably more 
π-basic alkyne recruits the π-Lewis acid (95), the less electron rich alkyne would 
function as the nucleophile in the cycloisomerization step (96). The vinyl 
carbocation generated would be less capable of resonance stabilization (97) 
compared to the alternative regioisomer 100, however the more electron rich arene 
would be poised as the nucleophile to participate in the Friedel-Crafts reaction. 
Conversely, if the less π-basic alkyne recruits the Lewis acid (98), the more 
electron rich alkyne would function as the nucleophile (99) for cyclization, and the 
more stable vinyl carbocation 100 would be generated. However, the unactivated 
arene would then participate as the nucleophile in the Friedel-Crafts step.  
Given these alternative regiochemical outcomes, unsymmetrical bis-aryl 
diynes proved ideal substrates to explore the chemo- and regioselectivity of these 
reactions. The impact of substituents on these diyne substrates gave important 
insight into the mechanism of these cyclizations.  
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Figure 3.1. Regioselectivity of Ga(III)-Catalyzed Cycloisomerization of 1,6-diynes 
3.1.2 Previous Studies on Tandem Cycloisomerization/Friedel-Crafts 
reactions. 
Metal-catalyzed cycloisomerizations terminated by intra- or intermolecular 
Friedel-Crafts arylations have been reported for many catalysts and substrates.179 
In particular, Au(I)-catalyzed cyclizations of dimethyl 1,6-enynes 101 have been 
extensively studied.145,180-195 In contrast to the 6-endo cyclization which afford the 
6,5,6-tricyclic skeleton of 68, these cyclizations typically give 5,6,6-tricycles 102, 
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the product of a 5-exo-process (Scheme 3.2). The  alternative 6,5,6-tricycles 103 
appear as a minor product in a few reports.183 
Scheme 3.2. Carbon Skeletons from 1,6-Enynes 
Furthermore, the cyclization pathway and carbon skeleton of the product is 
often observed to be highly substrate dependent. The Echavarren group has 
reported utilizing a tris(2,6-di-tert-butylphenyl)phosphite ligated Au(I) catalyst for 
the cycloisomerization of malonate tethered 1,6-enynes 104 to produce a range of 
polycyclic scaffolds 105 in moderate to excellent yields (Scheme 3.3, eq 1, A = 
C(CO2Et)2).183 However, etherate and bis-sulfone tethered enynes failed to react, 
and N-tosyl tethered enyne 106 gave cyclopropane 107 as the major product 
(Scheme 3.3, eq 2). As well, they reported that p-methoxy substituted arenes 
produced the aforementioned 6,5,6-carbon skeleton in significant yields, and 
enyne 108 gave a 4:1 mixture of the 5,6,6-exo-product 109 to 6,5,6-endo-product 
110 (scheme 3.3, eq 3). 
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Scheme 3.3. Au(I)-Catalyzed Cyclizations of 1,6-Enynes 
Notably, Dake and coworkers have reported under Au(I) catalysis, 
enamides 111 favored cyclization to the 6,5,6-tricyclic product 112 over the 5,6,6-
product 113, from 8:1 up to 20:1 (Scheme 3.4).196  Yields for this process ranged 
from 21% to 98%.  
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 Scheme 3.4. Au(I)-Catalyzed Cyclizations of Enamides to 5,6,5-Tricycles 
Corey and coworkers have recently reported an impressive extension of an 
InI3 based cycloisomerization they developed.145 Utilizing InI2+, generated from 10 
mol% InI3 and 10 mol% AgBARF, they were able to catalyze the cycloisomerization 
of sulfone tethered 1,6-enyne 114 to 5,6,6-tricycle 115 in excellent yields (Scheme 
3.5, top). Under the same conditions they are able to cyclize several aryl-polyene-
ynes, such as 116, which cyclized stereospecifically to polycycle 117 in 86% yield 
(Scheme 3.5, bottom). Both these reactions were proposed to occur through a 
carbocation cascade, initiated at the alkyne and terminated by the arene (Scheme 
3.5).  
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Scheme 3.5. InI2+-catalyzed Polycyclization Reactions 
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3.1.3 Cyclizations of Bis-aryl 1,6-Diynes 
In contrast to the enynes described above, which are predictably initiated at 
the alkyne, bis-aryl diynes have the potential to be initiated at either alkyne and 
give mixtures of products (Figure 3.1). The cyclization of bis-aryl 1,6-diyne 118 
was initially reported by Shibata and coworkers, under thermal and Au(I) conditions 
(Scheme 3.6).197 Regrettably, their initial report misassigned the structures of the 
cyclization products as [4+2] cycloadducts 119. A later report124 on this Au(I)-
catalyzed cycloisomerization by the Liu group corrected the structures as 6,5,6-
tricycles 120, which were furnished in 61-93% yield. Notably, for A = NTs, the major 
product is the same as that depicted in Scheme 3.1, and 68 was isolated in 61% 
yield. 
Scheme 3.6. Au(I)-Catalyzed Cycloisomerization of Symmetric Bis-aryl 1,6-
diynes 
Liu and coworkers also investigated two unsymmetric bis-aryl diynes 121 
and 122 with their Au(I) catalyst (Scheme 3.7). For 121, they observe a 1:1 mixture 
of the two regioisomeric products, 123 and 124, which were each isolated in 37% 
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yield. For 122, they report a preference for product 125, which was isolated in 47% 
yield, compared to its regioisomer 126 which was only isolated in 13% yield. 
However, they assess the regiochemical preference based only on the isolated 
yields, thus it is possible this difference is reflective of the products ease of 
purification and not any inherent selectivity. 
Scheme 3.7. Au(I)-Catalyzed Cyclization of Unsymmetric Bis-aryl 1,6-diynes 
The mechanism they proposed for the transformation of 121 begins with 
Au(I) activation of the more electron rich phenyl substituted alkyne 127 (Figure 3.2, 
top). Subsequent arylation by the electronically activated methoxy substituted aryl 
ring gives vinyl Au(I) macrocycle 128.  Protonation of this macrocycle generates 
vinyl cation 129, which cyclizes to doubly benzylic cation 130. Elimination of Au(I) 
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affords the observed product. However, they note that a mechanism involving Au(I) 
activation of the less electron rich alkyne 131, and cycloisomerization before 
arylation, to vinyl cation 132, is also consistent with their results (Figure 3.2, 
bottom). Given similarities to the mechanisms often reported for related enyne 
cyclizations (see above, Section 3.1.2), and the ability of a vinyl cation such as 
intermediate 132, to explain both the halocyclization product 2p and tricyclic 
product 68, a mechanism similar to the latter seems more consistent with our 
Ga(III)-catalyzed reactions. 
Figure 3.2. Mechanistic Proposals for Au(I)-Catalyzed Cycloisomerization of Bis-
aryl 1,6-Diynes 
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3.2 Ga(III) and H+ Catalyzed Cycloisomerizations of Unsymmetrical bis-aryl 
diynes. 
3.2.1 Mechanistic Proposal 
In the reaction of an unsymmetric bis-aryl diyne with a GaX3 catalyst, four 
possible products were expected, corresponding to two possible regioselectivities 
and two possible chemoselectivities. Figure 3.3 depicts these pathways:  initial π-
coordination of GaX2+ to either alkyne prompts a 6-exo-dig cyclization to generate 
either of two regioisomeric vinyl carbocations (Figure 1, AB and CD).  Internal 
trapping of those cations by the neighboring arene, followed by rearomatization 
and protodegallation, affords the two Friedel-Crafts (FC) products a and c, 
whereas, trapping by an external halide affords the halocyclization (HC) products 
b and d. 
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Figure 3.3. Ga(III) Promoted Cyclization Pathways for Unsymmetric Bis-aryl 1,6-
Diynes 
3.2.2 Optimization  
 Initial efforts to maximize the FC pathway focused on removal of the 
nucleophilic halide counterion, anticipating that this would prevent the competing 
halocyclization and afford solely the FC products, a and c. However, no reaction 
with Ga(OTf)3 under a range of conditions was observed (Table 3.1, entry 1, other 
aprotic solvents, ACN, THF, DMF, not shown). It was presumed that generating 
the Ga(OTf)2+ cation is difficult in the absence of stabilizing ligands. As previous 
efforts to generate catalytically active Ga(OTf)3●L complexes were unsuccessful 
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(Chapter 2, Section 2.2.4), an alternative strategy using polar protic solvents to 
solubilize and stabilize the catalyst was attempted.  
In the  presence of Ga(OTf)3 and non-nucleophilic protic solvents such as 
hexafluoroisopropanol (HFIP) or TFA, diyne 1p was converted to tricycle 68 in 25% 
and 55% yields respectively (Table 3.1, entries 2 and 3). Low conversion was 
observed with less acidic AcOH as the solvent (Table 3.1, entry 4). The possibility 
that the combination of Ga(OTf)3 and protic solvent was simply acting as a source 
of triflic acid was then explored. A control experiment using triflic acid in place of 
Ga(OTf)3 revealed the Brønsted acid to be similarly reactive and the desired 
product was obtained with an improved yield (80%) (Table 1, entry 5). Optimal 
conditions using triflic acid as the initiator benefited from the use of TFA as the 
solvent. Switching to AcOH or DCE gave slow conversion to complex mixtures with 
significantly diminished yields (Table 3.1, entries 6 and 7), while THF was not 
compatible with the triflic acid catalyst (Table 1, entry 8). Trifluoroacetic acid alone 
was unable to catalyze the reaction (Table 1, entry 9). 
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Table 3.1. Optimization of FC Cyclization Pathway 
 
entry catalyst (mol%) solvent conversion to 68 (%)a 
1 Ga(OTf)3 (100) DCE 0 
2 Ga(OTf)3 (100) HFIP 25 
3 Ga(OTf)3 (20) TFA 55 
4 Ga(OTf)3 (20) AcOH <5 
5 TfOH (20) TFA 80b 
6 TfOH (20) DCE 45 
7 TfOH (20) AcOH 35 
8 TfOH (20) THF 0 
9 none TFA 0 
aAssessed from NMR integrations of crude reaction mixtures bIsolated yield 
 
This Brønsted acid-catalyzed 
reaction can potentially be understood 
in a similar way to the Ga(III) promoted 
reaction (Figure 3.3), with protonation of 
the alkyne initiating the chemistry in lieu 
of Lewis acid coordination (Figure 3.4). 
For an unsymmetrical diyne, a potential 
mixture of the two FC products, a and c, 
was therefore anticipated.  
Figure 3.4.  
Bronsted Acid Catalyzed Cyclization  
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3.2.3 Lewis Acid vs Brønsted Acid Cyclization 
Using these halide-free Brønsted acid conditions (TfOH/TFA), the 
regioselectivity of the reaction with unsymmetric bis-aryl diynes was assessed and 
compared to GaI3 catalysis (Table 2). As expected, a mixture of two regioisomers 
arising from protonation of either alkyne was produced (Table 3.2, a and c). For 
strongly activated p-methoxy substituted arene 133, an intractable mixture was 
formed (Table 3.2, entry 1). For 3,5-dimethylphenyl substituted diyne 134, a 1:15 
mixture of products (138a:138c) was obtained (Table 3.2, entry 2). The major 
product 138c was isolated in 80% yield. This regiochemical outcome indicates the 
more electron rich dimethylphenyl substituted alkyne had been preferentially 
protonated to initiate the first cyclization, and subsequently, this same electron rich 
aryl ring had served as the Friedel-Crafts nucleophile. Notably, for this 
electronically activated substrate, TfOH was not 
required and the reaction progressed in TFA 
alone. For m-methoxyphenyl substituted diyne 
135, a 7:3 mixture of products (139a:139c) was 
produced (Table 3.2, entry 3). Strikingly, the 
major product 139a, isolated in 52% yield, 
indicates the unactivated phenyl acted as the 
Friedel-Crafts nucleophile over the electronically 
activated m-methoxyphenyl (Figure 3.5). 
Considering the m-methoxyphenyl substituent 
Figure 3.5. 
H+ Catalyzed Cyclization of 135 
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would presumably decrease the basicity of the appended alkyne (σmeta = 0.115),198 
the primary factor controlling the regioselectivity of this Brønsted acid-catalyzed 
cyclization is likely the initial site of protonation (Figure 3.5). Arenes substituted 
with the electron withdrawing groups p-CO2Me 136 and p-CF3 137 supported this 
conclusion, giving single detectable regioisomers 140a and 141a which could be 
isolated in 63% and 90% yield respectively (Table 3.2, entries 4 and 5). In both 
cases, initial protonation would be expected to occur on the more electron-rich 
phenyl substituted alkynes, leading to the observed products.  
Table 3.2. Brønsted and Lewis Acid-Catalyzed Cyclization of Bis-aryl 1,6-Diynes 
 
   Brønsted Acid Conditionsa GaI3 Conditionsb 
entry diyne R 
r.r. 
(a:c)c 
major prod. (% 
yield)d 
r.r. (a:b:c:d)c 
(a+b:c+d) 
major prod. 
(% yield)d 
1 133 p-OMe 0:0 NA (0) 
0:0:0:0 
NA 
NA (0) 
2 134 3,5-Me 1:15 138c (80)e 
15:34:51:0 
49:51 
139c (45) 
3 135 m-OMe 7:3f 139a (52) 
25:18:57f:0 
41:57 
139c’ (29) 
4 136 p-CO2Me 20>1g 140a (63) 
30:0:14:56 
40:60 
140d (48) 
5 137 p-CF3 20>1g 141a (90) 
26:0:0:74 
26:74 
141d (55) 
a0.2 equiv. TfOH in 0.1 M TFA b1 equiv GaI3 in 0.2 M DCE cProduct ratios determined from NMR 
integrations of crude reaction mixtures dIsolated yields eRun in 0.1 M TFA without added TfOH fMixture of 
two isomers: C6-methoxy 139c’, and C8-methoxy 139c’’, 2:1 139c’:139c’’. gMinor regioisomers were not 
detected at the limit of the NMR. 
The regio- and chemoselectivity of these substrates under Ga(III) promoted 
cyclization conditions was then assessed (Table 3.2). On treatment with GaI3, 
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mixtures of up to 4 products are possible: two halocyclization products (b and d), 
arising from iodine trapping of the proposed vinyl cation intermediates (Figure 3.3, 
AB and CD), and two FC products (a and c), arising from arene trapping of the 
same intermediates. Summing the yields of the two products presumed to arise 
from each vinyl cation (a+b:c+d) gave a measure of the regioselectivity (r.r) of the 
initial cyclization step (Table 3.2). Like the Brønsted acid-catalyzed reaction, p-
methoxyphenyl substituted diyne 133 gave a complex mixture on treatment with 
GaI3 (Table 3.2, entry 1). 3,5-Dimethylphenyl substituted diyne 134 gave a mixture 
of three products with no apparent regioselectivity in the initial cyclization step 
(49:51). The two observed products 138a and 138b presumed to arise from 
carbocation AB (Figure 3.3) comprised 49% of the mixture, while the single 
observed product 138c presumed to arise from intermediate CD comprised 51% 
of the mixture. It is understandable that HC product 138d was not detected, as the 
intramolecular trapping of vinyl cation CD via the FC pathway is likely to be fast for 
electronically activated 3,5-dimethylphenyl nucleophile in comparison to the 
intramolecular iodine trap. For m-methoxyphenyl substituted diyne 135 a slight 
regiochemical preference (41:57) for products presumed to arise from the CD 
cation were found to predominate (Table 3.2, entry 3). Surprisingly, this selectivity 
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is the reverse of the observations with TfOH 
promoted catalysis, which gave a 7:3 
selectivity favoring the other regioisomeric 
pathway. This result can be explained if this 
Ga(III) process favors the formation of the 
presumed more stable vinyl carbocation 
(Figure 3.6). As electron withdrawal on one 
of the alkynes increased, this disparity 
became more acute. Arenes substituted with 
the electron withdrawing groups p-CO2Me 
136 and p-CF3 137 gave predominately HC 
products 140d (48%) and 141d (55%), with 
the product distributions indicating 
cyclization favored the CD cation 40:60 and 
26:74, respectively (Table 3.2, entries 4 and 5). Trapping of the CD cation by the 
internal arene was presumably slowed by the electron withdrawing substituents, 
favoring halocyclization over FC closure (56:14 for R = CO2Me, and 74:0 for R = 
CF3). 
3.2.4 Effect of the Ga(III) Halide 
 As expected from the observation that GaCl3 gave higher yields of the FC 
cyclization product for symmetric diyne 1p (Scheme 3.1), changing the Ga(III) 
counterion significantly affected the chemoselectivity (FC:HC) of the products for 
Figure 3.6. 
Ga(III) Catalyzed Cyclization of 135 
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unsymmetric diyne 136 (Table 3.3), though little apparent change in overall 
regioselectivity (AB:CD) was observed (Table 3.3, column 4). While GaF3 was 
unable to promote the reaction even at elevated temperatures (Table 3.3, entry 1), 
in all other cases, the regioselectivity was found to be between 38:62 (Table 3.3, 
entry 2) and 30:70 (Table 3.3, entry 4), indicating the preferred reaction pathway 
proceeded through vinyl cation intermediate AB. In the halide series Cl - Br - I, the 
ratio of HC product 140d to FC product 140c increased as the halide became more 
nucleophilic (Table 3.2, entries 2-4). For GaCl3, the FC product 140c was favored 
over the HC product 140d’ by 2:1 (Table 3, entry 2), whereas, this selectivity was 
reversed for GaI3 and the HC product 140d was favored over the FC product 140c 
4:1 (Table 3.3, entry 4). This is consistent with the proposed mechanism: as the 
nucleophilicity of the halide increases, its ability to compete with the p-CO2Me 
substituted phenyl nucleophile in trapping the intermediate vinyl carbocation CD 
also increases, resulting in more halocyclization product d relative to c. In contrast, 
none of the halides were able to compete with the more nucleophilic phenyl, so 
vinyl halide 140b was not observed in significant quantities and the amount of 140a 
was essentially unchanged with the different gallium trihalides.  
Low concentration of halide was expected to further disfavor 
halocyclization. Thus, it was rationalized that the amount of 140d’ could be further 
reduced, and the amount of 140c maximized, by maintaining a low [Cl-] through 
the slow addition of GaCl3 to a more dilute solution of diyne. This proved marginally 
successful, when a solution of GaCl3 was added to diyne 136 over a period of 48 
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h the apparent ratio of 140c:140d’ was increased (4:1) relative to a single 
stoichiometric addition (2:1), and 140c could be isolated in 41% yield (Table 3.3, 
entry 5). Notably, 60 mol% of GaCl3 was required for the full conversion of diyne 
136. This marks a significant increase from the 10 mol% successfully employed 
for diyne 1p (Scheme 3.1). The electron withdrawal of the p-CO2Me substituent of 
136 both slowed the reaction relative to 1p and favored the formation of HC product 
140d’ by decreasing the nucleophilicity of the arene. Since vinyl chloride product 
140d’ is a stoichiometric reaction with GaCl3, the formation of 140d’ slowly 
depletes the catalyst. Therefore, more catalyst was required for full conversion of 
the starting materials. 
A higher concentration of halide was expected to favor halocyclization. 
Thus, it was reasoned that the amount of 140c could be minimized with maximum 
140d production using super-stoichiometric GaI3. However, treating diyne 136 with 
1.5 equivalents of GaI3 gave mixed results (Table 3.3, entry 6). While 140d was 
increased relative to 140c (64:4) as expected, several new side-products were 
observed in significant quantities including a small amount of product consistent 
with 140b. The HC product 140d was only isolated in 30% yield. 
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Table 3.3. Cyclization of Diyne 136 with GaX3 
 
entry GaX3 (a:b:c:d)a r.r. (a+b:c+d) FC:HC (c:d) prod. (% yield)b 
1c GaF3 0:0:0:0 NA NA NA 
2 GaCl3 38:0:42:20 38:62 42:20 140c (35) 
3 GaBr3 31:0:40:29 31:69 40:29 140c (29) 
4 GaI3 30:0:14:56 30:70 14:56 140d (48) 
5d GaCl3 35:0:50:15 35:65 50:15 140c (41) 
6e GaI3 24:8:4:64 32:68 4:64 140d (30) 
aProduct ratios determined from NMR integrations of crude reaction mixtures bIsolated yields c80 °C, 48 h 
d0.6 equiv. GaCl3 added over 48 h as 0.5 M solution in hexanes to a 0.05 M solution of diyne in DCE e1.5 
equiv GaI3, 0.4 M DCE 
 
The change in chemoselectivity seen  for 136 was observed with 
electronically activated substrates as well. Treatment of dimethyl phenyl 
substituted diyne 134, with stoichiometric GaI3 gave a 15:34:51:0 mixture of 
products 138a:138b:138c:138d (Scheme 3.8). This ratio indicates the 
regioselectivity of the initial cyclization step was 49:51 (AB:CD). Treatment of 134 
with only 10 mol% of the less nucleophilic GaBr3 gave exactly the same ratio of 
products presumed to arise from each regioisomeric cation (49:51, AB:CD). 
However, the chemoselectivity was significantly altered, with GaI3 favoring the HC 
product 138b over the FC product 138a (34:15), and GaBr3 favoring the FC product 
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138a over the HC product 138b (39:10). Under GaBr3 conditions product 138a 
could be isolated in 28% yield. 
Scheme 3.8. Ga(III)-Catalyzed Cyclization of 134  
3.2.5 Halocyclization Free Comparison of Regioselectivities 
In order to more directly compare the 
regiochemical outcomes of these cyclization 
conditions without the added complexity of the 
halocylization products, diyne 142 was prepared 
and subjected to both GaI3-catalyzed cyclization 
and Brønsted acid-catalyzed cyclization. Electron 
donation from the m-methoxy (σpara = -0.268) and methyl substituents (σpara = -0.170) 
on the arenes of 142 were expected to activate both rings as nucleophiles such 
that the FC cyclization pathway would dominate over the HC pathway regardless 
of the regioselectivity of the initial cyclization (Figure 3.7). However, the alkynes of 
142 possess an electronic difference. Donation from the methyl groups should 
increase the electron density the adjacent alkyne (σmeta = -0.069), while the m-
Figure 3.7. Diyne 142. 
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methoxy substituted arene should decrease the electron density in the other alkyne 
(σmeta = 0.115).198 Based on the regiochemical outcomes of substrates in Table 2, 
the Brønsted acid conditions were expected to favor protonation of the more basic 
3,5-dimethylphenyl substituted alkyne and give 143 as the major product, via 
intermediate B (Scheme 3.9, left). Conversely, the Ga(III) conditions were 
expected to favor the formation of the more stable carbocation C to give 144 and 
145 as the major products (Scheme 3.9, right). 
Under TFA conditions, NMR of the crude reaction mixture indicated product 
143 was favored 96:4 over products 144 and 145, and 143 could be isolated in 
75% yield (Scheme 3.9, left). As anticipated, under GaI3 conditions no 
halocyclization products were observe, and the NMR indicated 144 and 145 were 
favored 6:4 over 143. A mixture of the two FC products (2:1, 144:145) was isolated 
in 60% yield (Scheme 3.9, right).  Thus, the two different methods for catalyzing 
the diyne cyclizations, Ga(III) Lewis acid and strong Brønsted acid, resulted 
predictably in two different regioselectivities. 
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Scheme 3.9. GaI3 and TFA-Catalyzed Cyclization of 142 
3.2.6 Expanding the Substrate Scope 
Cyclizations of bis-aryl diynes with alternative tethers were largely 
unsuccessful under both TfOH/TFA and GaI3 conditions (Figure 3.8). Amines and 
anilines 146, 147, and 148 returned only starting material, while N-Boc diyne 149 
gave Boc deprotected, amine-tethered diyne as the sole product. Etherate 151 
gave decomposition products. Hydrocarbon 150 and malonate 152 gave small 
amounts of material consistent with the expected product, but as minor 
components of complex mixtures and were unisolable.  
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Figure 3.8. Incompatible Substrates 
On treatment with GaBr3, o-CO2Et substituted diyne 153 gave 
isochromenone 154 in 24% yield.  Similar transformations of ortho-ester 
substituted ethynylbenzenes have been observed under a range of catalysts 
including:  Au(I),199  Fe(III),200  Hg(II),201  Br2,202  HI,203  and TfOH.204  Regrettably, 
once formed isochromenone-yne 154 did not undergo further cyclization. 
Scheme 3.10. Alternative Cyclization of 153 to Isochromenone 154 
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In order to assess the potential of this reaction to catalyze intermolecular 
cyclizations, diphenyl acetylene was treated with 10 mol% GaBr3, resulting in a 
complex mixture. Surprisingly, the major product isolated from this reaction was 
the bright blue dimerization product 1,2,3-triphenylazulene, which was obtained in 
25% yield (Scheme 3.10). A speculative mechanism for this transformation can be 
proposed wherein diphenylacetylene is activated by the Ga(III) Lewis acid, leading 
to addition of a second diphenylacetylene, generating vinyl cation A. This cation is 
then trapped by the a phenyl arene to give spirocyclic cation B. Rearrangement of 
this cation to cyclopropyl cation C, followed by ring expansion affords the observed  
1,2,3-triphenylazulene product. Notably, this transformation has been observed 
with diphenylacetylene under AlCl3,205 Hg(II)/TfOH,206  and SO2/SbF6 catalysis.207 
Scheme 3.11. Dimerization of Diphenyl Acetylene to Triphenylazulene 
Finally, the applicability of the Brønsted acid-catalyzed cyclization to 
aryl/alkyl diynes was investigated. As reported in Chapter 2, aryl/alkyl diynes 
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undergo halocyclization in the presence of GaI3 to give exclusively vinyl iodides 2 
(Scheme 3.12, left). The presumed intermediate of this reaction D, does not 
possess an arene nucleophile capable of intermolecularly tapping the cation. 
Success of the FC cyclization therefore requires the generation of the opposite 
regioisomer, carbocation E (Scheme 3.12, right). However, vinyl cation E is 
presumably higher in energy than the alternative cation C, which can be stabilized 
through resonance to the phenyl ring.  
Scheme 3.12. Cyclization of Aryl/Alkyl Diyne 1b 
Under the TfOH/TFA conditions, 1b was converted to 155 in only 20% 
isolated yield with complete consumption of the starting material. Although 
uncharacterized, the mass balance of this reaction was consistent with the 
formation of highly conjugated polymers; broad complex NMR peaks and 
spairingly soluble bright yellow solids.  These polymers can potentially be 
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explained by the formation of unproductive carbocation D. As no obvious 
intramolecular pathway exists for this intermediate, intermolecular trapping of vinyl 
cation D by the aromatic rings of products and starting material of the ongoing 
reaction is likely to generate polymers.  Consistent with this explanation, more 
concentrated reaction conditions (1M) gave diminished yields (13%) and more 
dilute reaction conditions (0.05M) increased the yield to 41% (Scheme 3.9). Two 
attempts were made to intercept the presumed unproductive cation D with 
externally added nucleophiles: TBAI and anisole. Unfortunately, these reactions 
lead to complex mixtures (data not shown). 
3.2.7 Diversification of the FC and HC Products 
With access to a range of 6,5,6-tricycles via the FC cycloisomerization 
pathway, and vinyl halides via the HC halocyclization pathway, the applicability of 
these molecules to further diversification was then accessed. Bis-aryl vinyl iodides 
2p and 140d were subjected to the Friedel-Crafts cyclization reaction developed 
in Section 2.2.5. Surprisingly, when vinyl iodide 2p was treated with TfOH, 
deiodinated product 68 was isolated in excellent yield and none of the expected 
product was observed. On treatment with TfOH diyne 140d was found to give 
some deiodinated product 140c, however the major product was found to be the 
expected 6,5,6-ticyclic vinyl iodide 156, which was isolated in 44% yield. The crude 
NMR indicated a 3:1 preference for 156 over 140c. 
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Scheme 3.13. Friedel-Crafts Cyclization of Vinyl Halides 
This result can potentially be understood as a competition between the two 
arenes for presumed intermediate 157, generated by protonation of the vinyl iodide 
starting material (Figure 3.9). When R = EWG, such as p-CO2Me, the more 
nucleophilic unsubstituted phenyl arene traps the cation leading to the expected 
6,5,6-ticyclic vinyl iodide (Figure 3.9, right). When R = H, the other arene functions 
as the nucleophile leading to presumed intermediate 158. Considering the likely 
stability of doubly benzylic and allylic carbocation 159 generated on iodide 
departure, it can be speculated 158 is susceptible to a 1,4-E1 elimination like 
process which would afford deiodinated product 68.  
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Figure 3.9. Formation of Deiodinated Products 
In an effort to remove the N-tosyl group under reducing conditions,208 it was 
serendipitously found 68 undergoes effective 1,4-reduction when treated with 
SmI2/water/piperidine to give 160, without removing the tosyl (Scheme 3.14, top). 
Likely, SET from the SmI2 generated radical anion 161, which was quenched in 
situ by water, and following another SET and quenching gave the observed 
product 160. Attempts to intercept this proposed intermediate with electrophilic 
methyliodide where unsuccessful (Scheme 3.14, bottom).  
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Scheme 3.14. SmI2 Reduction of 68 
Scaffold 68 was found amenable to dihydroxylation with K2OsO2(OH)4, 
and afforded compound 162 in 27% yield (Scheme 3.13). Although the yield for 
this reaction was low, dihydroxide 162 was the sole observed product of the 
reaction. The remainder of the mass balance being starting material, which was 
recovered quantitatively. 
Scheme 3.13. Dihydroxylation of 68 
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3.3 Conclusion  
In conclusion, a versatile method to access both halocyclization (HC) and 
cycloisomerization Friedel-Crafts (FC) products from unsymmetric bis-aryl 1,6-
diyne starting materials has been developed. Employing TfOH/TFA conditions, a 
strong preference for a single cyclization product arising from protonation of the 
more basic alkyne was observed. With GaX3 conditions, a modest preference for 
products arising from Lewis acid coordination to the less basic alkyne was 
observed. Dilute GaCl3 favored the Friedel-Crafts cyclization product, and 
stoichiometric or super stoichiometric GaI3 favored the halocyclization product.  
These reactions have been shown to work efficiently with the N-nosyl 
derivative 142, which may enable deprotection for further diversification of the 
amino nitrogen. The Friedel-Crafts scaffolds were able to be functionalized through 
K2OsO2(OH)4-catalyzed dihydroxylation, and serendipitously it was discovered 
they undergo 1,4-reduction when treated with SmI2. As well, the bis-aryl 
halocyclization products have been shown potentially amenable to acid-catalyzed 
cyclization to iodoindenopyridines, potentially expanding the chemistry developed 
in Chapter 2.2.7 to include scaffolds with angular aromatic rings. Angular aromatic 
groups have only rarely been observed in these tetrahydroindenopyridine ring 
systems. 
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Chapter IV - Experimental Procedures and Data for Chapters 2 and 3 
4.1 General Methods 
The 1H NMR and 13C NMR spectra were recorded at 117.42 kG (1H 500 MHz, 13C 
125 MHz), or 93.94 kG (1H 400 MHz, 13C 100 MHz) at ambient temperature as 
noted. Hydrogen chemical shifts are expressed in parts per million (ppm) relative 
to the residual protio solvent resonance: CDCl3 δ 7.26, benzene-d6 δ 7.16, 
acetone-d6 δ 2.05. For 13C spectra, the centerline of the solvent signal was used 
as internal reference: CDCl3 δ 77.00. Unless otherwise noted, each carbon 
resonance represents a single carbon (relative intensity). All exchangeable OH 
and NH hydrogen resonances were confirmed by D2O exchange. High resolution 
mass spectrometric data were obtained on a QToF (hybrid quadrupolar/time-of-
flight) API US system by electrospray (ESI) in the positive ion mode. Mass 
correction was done by an external reference using a lockspray accessory. Mobile 
phases were water and acetonitrile (1:9) with 0.1% formic acid. With a flow rate of 
0.2 mL/min. The MS settings were: capillary voltage 3kV, cone voltage 35, source 
temperature 120 °C and desolvation temperature 350 °C unless otherwise noted. 
Flash chromatography was performed on silica gel-60 (43-60 μm). A silica gel plug 
refers to a short pad of silica gel through which crude materials are quickly eluted 
in a single fraction using a mobile phase that gives the desired compound at an Rf 
near 1.0. Commercially available anhydrous solvents were used as indicated.  
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General Procedure A: Sonogashira 
Couplings of Terminal Alkynes.  
An oven dried screw cap vial, equipped with a stir bar, was purged with Ar 
atmosphere, then charged with Pd(PPh3)2Cl2 or Pd(PPh3)4 (3-5 mol%) and CuI (6-
10 mol%). The terminal alkyne was added to the flask and dissolved in the 
specified solvent. TEA was added, if not the solvent, and finally the aryl halide was 
added (1.2 eq). The solution was sparged with Ar for 15 min, then sealed with a 
teflon cap. After stirring for the specified time and temperature, the reaction mixture 
was diluted with CH2Cl2 (10 mL/0.1 mmol alkyne) and poured into 1 N HCl (20 
mL/0.1 mmol alkyne). The organic layer was separated and the aqueous layer 
extracted with CH2Cl2 (2 X 10 mL/0.1 mmol alkyne). The combined organic layers 
were, dried over Na2SO4, filtered, and then the solvent removed in vacuo. The 
crude product was purified via silica gel flash chromatography. 
General Procedure B: SN2 Alkylation of N-
Tosyl- and N-Nosylpropargylamines with 
Alkynyl Bromides.  
An oven dried round bottom flask, equipped with 
a stir bar and reflux condenser, was placed under Ar and charged with K2CO3 (4 
eq). N-Tosylpropargylamine or N-nosylpropargylamine was added to the flask and 
dissolved in acetonitrile (0.2 M). Alkynyl bromide (1-2 eq) was added with stirring, 
then the solution was brought to reflux for the specified time. After cooling to rt, the 
reaction mixture was diluted with CH2Cl2 (10 mL/0.1 mmol amine) and poured into 
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1 N HCl (20 mL/0.1 mmol amine). The aqueous layer was extracted with CH2Cl2 
(2 X 10 mL/0.1 mmol amine), then the organic layers were combined, dried over 
Na2SO4, filtered, and the solvent removed in vacuo. The crude product was purified 
via silica gel flash chromatography. 
 General Procedure C: Ga(III) Trihalide 
Promoted Cyclizations of Diynes to Vinyl 
Halides.  
An oven dried thick-walled tube was equipped 
with a stir bar was placed under an argon atmosphere. A single portion of GaX3 
was added directly to the tube, avoiding prolonged exposure to air, and the tube 
was then capped with a septum. In a separate vessel, diyne (1 eq) was dissolved 
in anhydrous DCE to give a 0.2 M solution. This solution was added to the tube 
containing the GaX3 via syringe, and the reaction was allowed to stir at rt for the 
indicated time. Once complete, as determined by TLC, the reaction was diluted 
with CH2Cl2 (10 mL/0.1 mmol diyne) and poured into 1 M NaOH (20 mL/0.1 mmol 
diyne). The aqueous layer was extracted with CH2Cl2 (2 X 10 mL/0.1 mmol diyne), 
then the combined organic layers were dried over Na2SO4, filtered, and the solvent 
removed in vacuo. The crude product was used directly, or after eluting through a 
short plug of silica gel, as indicated. If not used immediately, the vinyl halides could 
be stored in a freezer at 0 °C under argon. Protection from prolonged exposure to 
light and acid was essential to the longevity of the compounds. 
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General Procedure D: Single 
Pot Preparation of Tricyclic 
Vinyl Iodides. 
Bisalkynes were treated with 
GaI3 according to General Procedure C. Once conversion to the vinyl iodide was 
complete, as determined by TLC, TFA (1 eq) was added to the reaction mixture 
via syringe. The solution was brought to 50 oC, and stirred for the indicated time. 
After cooling to rt, the reaction was diluted with CH2Cl2 (10 mL/0.1 mmol diyne) 
and poured into 1 M NaOH (20 mL/0.1 mmol diyne). The aqueous layer was 
extracted with CH2Cl2 (2 X 10 mL/0.1 mmol diyne), then the combined organic 
layers were dried over Na2SO4, filtered, and the solvent removed in vacuo. The 
crude product was purified via silica gel flash chromatography. The products were 
stored at 0 °C, and protected from light. However, no significant decomposition 
was observed on the benchtop under ambient conditions over several weeks. 
General Procedure E: Two Step Preparation 
of Tricyclic Vinyl Iodides.  
Cyclohexyl vinyl iodides were prepared 
according to General Procedure C. Immediately 
following work up, the crude isolates were dissolved in anhydrous DCE to give a 
0.2 M solution, transferred to a thick-walled test tube, and placed under an argon 
atmosphere. Triflic acid (TfOH, 1 eq) was added and the reaction mixture stirred 
for the indicated time at the indicated temperature. When the reaction was 
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complete as determined by TLC, the mixture was diluted with CH2Cl2 (10 mL/0.1 
mmol diyne) and poured into 1 M NaOH (20 mL/0.1 mmol diyne). The aqueous 
layer was extracted with CH2Cl2 (2 X 10 mL / 0.1 mmol diyne), then the combined 
organic layers were dried over Na2SO4, filtered, and the solvent removed in vacuo. 
The crude product was purified via silica gel flash chromatography. The products 
were stored at 0 °C, and protected from light. However, no significant 
decomposition was observed on the bench top under ambient conditions over 
several weeks. 
General Procedure F: Denosylation of 
Tricyclic Vinyl Iodides.175 An oven dried 
round bottom flask, equipped with a stir 
bar and reflux condenser, was charged 
with K2CO3 (4 eq). Nosylate was added to the flask and dissolved in acetonitrile 
(0.1 M). Thiophenol (2.4 eq) was added and the reaction stirred at 60 °C for 0.5 h. 
After cooling to rt, the reaction mixture was diluted with CH2Cl2 (10 mL/0.1 mmol 
amine) and poured into water (20 mL/0.1 mmol amine). The aqueous layer was 
extracted with CH2Cl2 (2 X 10 mL/0.1 mmol amine), then the organic layers were 
combined, dried over Na2SO4, filtered, and the solvent removed in vacuo. The 
crude product was purified via silica gel flash chromatography. 
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General Procedure G: Triflic Acid-catalyzed 
Friedel-Crafts Cycloisomerization of 1,6-Diynes.  
The diyne was added to a screw cap vial equipped 
with a stir bar and dissolved in TFA (0.1 M). Triflic 
acid was added (0.2 equiv), the vial was sealed and stirred at rt for the time 
indicated. The reaction was diluted with CH2Cl2 (2 mL) and the organic layer 
washed with water (10 mL/0.1 mmol diyne), followed by 0.5 M NaOH (20 mL/0.1 
mmol diyne). The organic layer was dried over Na2SO4, filtered, and the solvent 
removed in vacuo. The crude product was purified via silica gel flash 
chromatography. 
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4.2 Supplemental Compounds 
 Supplemental compounds are those synthesized in route to the compounds 
described in Chapters 2 and 3, but that do not appear in the text, they have been 
assigned compound numbers sequentially beginning with roman numeral I. 
4-Methyl-N-(3-phenylprop-2-yn-1-yl)benzenesulfonamide (I). 
Prepared according to General Procedure A: N-tosyl propargylamine76 
(630 mg, 3.0 mmol) was reacted with iodobenzene (400 uL, 3.6 mmol), 
in the presence of Pd(PPh3)2Cl2 (60 mg, 0.09 mmol), CuI (33 mg, 0.17 mmol), and 
TEA (0.84 mL, 6.0 mmol), in DMF (3 mL, 1.0 M), for 1.5 hr at rt. Purification via 
flash chromatography gave I (pet ether:EtOAc, 1:1, Rf 0.75, 675 mg, 82%) as a 
light orange solid. The identity of I was confirmed by comparison to reported 1H 
NMR data.209 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 
8.4 Hz, 2H), 7.27 – 7.18 (overlap, 3H), 7.13 (m, 2H), 4.58 (br t, J = 6.2 Hz, NH), 
4.08 (d, J = 6.2 Hz, 2H), 2.36 (s, 3H). 
Methyl 4-(3-(4-Methylphenylsulfonamido)prop-1-yn-1-yl)benzoate 
(II).  
Prepared according to General Procedure A: N-tosyl propargylamine 
(209 mg, 1.0 mmol) was reacted with methyl 4-iodobenzoate (314 mg, 
1.2 mmol), in the presence of Pd(PPh3)2Cl2 (35 mg, 0.05 mmol), CuI 
(19 mg, 0.1 mmol), in TEA (2 mL), for 2 hr at rt. Purification via flash 
chromatography gave II (1% MeOH in CH2Cl2, Rf 0.5, 290 mg, 84%) as an orange 
solid. The identity of II was confirmed by comparison to reported 1H-NMR data.210 
  
114 
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 8.3 Hz, 2H), 
7.27 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.3 Hz, 2H), 4.85 (br t, J = 6.2 Hz, NH), 4.09 
(d, J = 6.2 Hz, 2H), 3.91 (s, 3H), 2.35 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.6, 
144.0, 137.1, 131.7 (2C), 130.0, 129.9 (2C), 129.5 (2C), 127.7 (2C), 126.9, 86.5, 
84.1, 52.5, 33.9, 21.7. 
4-Methyl-N-(3-(4-nitrophenyl)prop-2-yn-1-yl)benzenesulfonamide 
(III).211  
Prepared according to General Procedure A: N-tosyl propargylamine 
(209 mg, 1.0 mmol) was reacted with 1-iodo-4-nitrobenzene (298 mg, 
1.2 mmol), in the presence of Pd(PPh3)2Cl2 (35 mg, 0.05 mmol), CuI (19 
mg, 0.1 mmol), in TEA (2 mL), for 1.5 hr. Purification via flash chromatography 
gave III (pet ether:EtOAc, 3:2, Rf 0.7, 274 mg, 82%) as an orange solid. 1H NMR 
(500 MHz, CDCl3) δ 8.11 (d, J = 8.7 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 
8.7 Hz, 2H), 7.27 (d, J = 8.3 Hz, 2H), 4.91 (br t, J = 6.2 Hz, NH), 4.12 (d, J = 6.2 
Hz, 2H), 2.36 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 147.4, 144.1, 137.0, 132.5 
(2C), 130.0 (2C), 129.1, 127.7 (2C), 123.6 (2C), 89.0, 83.0, 33.8, 21.7; HRMS 
compound failed to ionize under various conditions. 
N-(3-(3-Methoxyphenyl)prop-2-yn-1-yl)-4-
nitrobenzenesulfonamide (IV).  
Prepared according to General Procedure A: N-nosyl 
propargylamine (145 mg, 0.60 mmol) was reacted with 1-iodo-3-
methoxybenzene (108 uL, 0.9 mmol), in the presence of Pd(PPh3)4 (35 mg, 0.03 
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mmol), CuI (11 mg, 0.06 mmol), and TEA (420uL), in DMF (1.2 mL)  at for 1.5 hr 
at 60 ⁰C. Purification via flash chromatography gave IV (4% MeOH in CHCl3, Rf 
0.6, 207 mg, 90%) as an orange oil.1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.9 
Hz, 2H), 8.10 (d, J = 8.9 Hz, 2H), 7.11 (dd, J = 8.3, 7.6 Hz, 1H), 6.81 (ddd, J = 8.3, 
2.7, 0.9 Hz, 1H), 6.62 (ddd, J = 7.6, 1.5, 0.9 Hz, 1H), 6.55 (dd, J = 2.7, 1.5 Hz, 1H), 
5.82 (br, NH), 4.14 (d, J = 5.8 Hz, 2H), 3.73 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
159.2, 149.9, 146.2, 129.4, 128.7 (2C), 124.1 (2C), 123.7, 122.5, 116.8, 114.8, 
85.1, 82.6, 55.2, 33.7. 
N-(But-2-yn-1-yl)-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide 
(V).  
Prepared according to General Procedure B: N-tosyl propargylamine 
(0.50 g, 2.39 mmol) was refluxed with 1-bromobut-2-yne (0.32 g, 2.39 mmol) in 
acetonitrile (12 mL, 0.2 M) over K2CO3 (1.32 g, 9.56 mmol) for 16 hr. Purification 
via flash chromatography gave V (pet ether:EtOAc, 9:1, Rf 0.55, 0.57 g, 91%) as 
a white solid. The identity of V was confirmed by comparison to reported 1H-NMR 
data.212 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 
2H), 4.14 (dt, J = 2.5, 0.8 Hz, 2H), 4.10 (qt, J = 2.4, 0.8 Hz, 2H), 2.42 (s, 3H), 2.13 
(t, J = 2.5 Hz, 1H), 1.65 (t, J = 2.4 Hz, 1H). 
N-(But-2-yn-1-yl)-4-nitro-N-(prop-2-yn-1-yl)benzenesulfonamide 
(VI, 78).  
Prepared according to General Procedure B: N-nosyl propargylamine (1 
g, 4.17 mmol) was refluxed with 1-bromobut-2-yne (0.55 mL, 6.20 mmol) in 
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acetonitrile (20 mL, 0.2 M) over K2CO3 (2.90 g, 21 mmol) for 16 hr. Purification via 
flash chromatography gave VI (pet ether:EtOAc, 4:1, Rf 0.4, 1.04 g, 85%) as a light 
orange solid. 1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 9.1 Hz, 2H), 8.02 (d, J = 
9.1 Hz, 2H), 4.18 (d, J = 2.5 Hz, 2H), 4.13 (q, J = 2.4 Hz, 2H), 2.16 (t, J = 2.5 Hz, 
1H), 1.64 (t, J = 2.4 Hz, 3H). 
N-(3-(3-Methoxyphenyl)prop-2-yn-1-yl)-4-nitro-N-(prop-2-yn-
1-yl)benzenesulfonamide (VII).  
Prepared according to General Procedure B: IV (162 mg, 0.47 
mmol) was refluxed with propargyl bromide (348 uL, 2.4 mmol) in 
acetonitrile (2.3 mL, 0.2 M) over K2CO3 (325 mg, 2.4 mmol) for 16 hr. Purification 
via flash chromatography gave VII (pet ether:EtOAc, 4:1, Rf 0.50, 180 mg, 99%) 
as an orange solid. 1H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 8.9 Hz, 2H), 8.07 (d, 
J = 8.9 Hz, 2H), 7.16 (dd, J = 8.5, 7.6 Hz, 1H), 6.85 (ddd, J = 8.5, 2.7, 1.1 Hz, 1H), 
6.74 (ddd, J = 7.6, 1.5, 1.1 Hz, 1H), 6.68 (dd, J = 2.7, 1.5 Hz, 1H), 4.45 (s, 2H), 
4.27 (d, J = 2.4 Hz, 2H), 3.76 (s, 3H), 2.23 (t, J = 2.4 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 159.3, 150.2, 144.3, 129.4, 129.1 (2C), 124.1 (2C), 123.9, 122.5, 116.8, 
115.0, 86.4, 80.5, 75.8, 74.7, 55.2, 37.6, 36.9. 
4.3 Chapter II Compounds 
(3-(But-2-yn-1-yloxy)prop-1-yn-1-yl)benzene (1a).  
An oven dried round bottom flask was charged with NaH (25 mg as 60% 
in mineral oil, 0.6 mmol), then purged with argon. Anhydrous THF (2.5 
mL) was then added and the suspension cooled to 0 °C. 3-Phenylprop-2-yn-1-ol 
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(60 uL, 0.5 mmol) was added dropwise while stirring. Stirring was continued at 0 
°C for 30 min, followed by the addition of 1-bromobut-2-yne (53 uL, 0.6 mmol). The 
solution was stirred at 0 °C another 30 min, then allowed to warm to rt. After 1 h, 
the reaction was quenched by the addition of water (100 uL), and the mixture 
poured into a separatory funnel containing brine (50 mL). The organic layer was 
separated, and the aqueous layer extracted with CH2Cl2 (2 X 15 mL). The 
combined organic layers were dried over Na2SO4, filtered, and the solvent 
removed in vacuo. Purification via filtration though a silica plug gave 1a (CHCl3, Rf 
0.95, 92 mg, 99%) as a colorless oil. The identity of 1a was confirmed by 
comparison to reported 1H-NMR data.213 1H NMR (500 MHz, CDCl3) 7.45 (m, 2H), 
7.33 – 7.27 (overlap, 3H), 4.46 (s, 2H), 4.27 (q, J = 2.3 Hz, 2H), 1.87 (t, J = 2.3 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 131.9 (2C), 128.6, 128.4 (2C), 122.7, 86.7, 
84.7, 83.3, 74.6, 57.4, 57.3, 3.8. 
N-(But-2-yn-1-yl)-4-methyl-N-(3-phenylprop-2-yn-1-
yl)benzenesulfonamide (1b).  
Prepared according to General Procedure B: tosyl amine I (630 mg, 2.2 
mmol) was refluxed with 1-bromobut-2-yne (270 uL, 3.1 mmol) in acetonitrile (11 
mL, 0.2 M) over K2CO3 (1.2 g, 8.8 mmol), for 4 h. Purification via flash 
chromatography gave 1b (pet ether:EtOAc, 9:1, Rf 0.65, 707 mg, 95%) as a 
colorless oil which solidified to a white solid on standing. The identity of 1b was 
confirmed by comparison to reported 1H-NMR data.87 1H NMR (400 MHz, CDCl3) 
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δ 7.75 (d, J = 8.3 Hz, 2H), 7.35 – 7.20 (overlap, 5H), 7.17 (dd, J = 8.1, 1.6 Hz, 2H), 
4.38 (s, 2H), 4.13 (q, J = 2.4 Hz, 2H), 2.36 (s, 3H), 1.69 (t, J = 2.4 Hz, 3H).  
N-(But-2-yn-1-yl)-4-nitro-N-(3-phenylprop-2-yn-1-
yl)benzenesulfonamide (1c).  
Prepared according to General Procedure A: diyne VI (1.6 g, 5.5 mmol) 
was reacted with iodobenzene (1.5 mL, 13.7 mmol), in the presence of Pd(PPh3)4 
(300 mg, 0.26 mmol), CuI (26 mg, 0.14 mmol), and TEA (27.5 mL, 5 mmol), in 
DMF (20 mL, 0.3 M), for 3 h. Purification via flash chromatography gave 1c (pet 
ether:EtOAc, 7:3, Rf  0.45, 77 mg, 27%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ  8.28 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.30 (t, J = 7.4 Hz, 1H), 
7.24 (dd, J = 7.4, 6.9 Hz, 2H), 7.15 (d, J = 6.9 Hz, 2H), 4.43 (s, 2H), 4.20 (q, J = 
2.4 Hz, 2H), 1.68 (t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 150.0, 144.5, 
131.4 (2C), 129.2 (2C), 128.9, 128.3 (2C), 123.9 (2C), 121.6, 86.2, 82.6, 81.0, 
71.1, 37., 37.4, 3.4. 
Diethyl 2-(but-2-yn-1-yl)-2-(3-phenylprop-2-yn-1-yl)malonate 
(1d).  
Diethyl malonate (0.50 g, 3.12 mmol) was added to an oven dried 
flask, then purged with argon and sealed with a septum. A solution of NaOEt in 
ethanol (1.17 mL of a 21 wt% solution, 3.12 mmol, 1 eq) was then added, followed 
by 1-bromobut-2-yne (0.28 mL, 3.12 mmol). The solution was stirred at rt for 30 
minutes, then another equivalent of NaOEt was added (1.17 mL, 3.12 mmol) 
followed by (3-bromoprop-1-yn-1-yl)benzene (0.609 mg, 3.12 mmol). The solution 
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was allowed to stir for another 30 minutes, then quenched with H2O (10 mL), 
diluted with CH2Cl2 (20 mL) and poured into 1 N HCl (20 mL). The organic layer 
was separated, dried over Na2SO4, filtered and concentrated in vacuo. Purification 
via flash chromatography gave 1d (1:9 pet. ether:EtOAc, Rf 0.50, 533 mg, 52%) 
as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.35 (m, 2H), 7.28 – 7.23 (overlap 
3H), 4.225 (q, J = 7.1 Hz, 2H), 4.223 (q, J = 7.1 Hz, 2H), 3.17 (s, 2H), 2.97 (q, J = 
2.5 Hz, 2H), 1.75 (t, J = 2.5 Hz, 3H), 1.25 (t, J = 7.1 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δ 169.2 (2C), 131.8 (2C), 128.3 (2C), 128.1, 123.4, 84.4, 83.6, 79.2, 73.3, 
61.9 (2C), 57.2, 23.6, 23.2, 14.2 (2C), 3.6. 
Octa-1,6-diyn-1-ylbenzene (1e).  
Hepta-1,6-diyn-1-ylbenzene (92 mg, 0.55 mmol) was added to an oven 
dry round bottom flask equipped with  a stirbar, sealed with a septum, 
and placed under N2 atmosphere. Freshly distilled anhydrous THF (1 mL) was 
added to the fask via syringe and the resulting solution cooled to -78 ⁰C. A solution 
of n-butyl lithium in hexanes was then added (0.41 mL, 1.6 M). The solution was 
stirred at -78 ⁰C for 5 minutes then methyl iodide (51 uL, 0.82 mmol) was added 
dropwise. The reaction was warmed to 0 ⁰C and stired for 1 h, then warmed to rt. 
After 0.5 h, the reaction was cooled to -78 ⁰C quenched by the addition of methanol 
(5 drops) and then water (50 uL). The mixture was poured into a separatory funnel 
containing brine (20 mL) and diethyl ether (20 mL). The organic layer was 
separated, dried over Na2SO4, filtered, and the solvent removed in vacuo. 
Purification via flash chromatography  (2.5% EtOAC in cyclohexanes, Rf 0.8, 95 
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mg, 95%) gave 1e as a colorless oil. 1H NMR (500 MHz, CDCl3) δ  7.41 – 7.35 (m, 
2H), 7.30 – 7.23 (overlap, 3H), 2.51 (t, J = 7.1 Hz, 2H), 2.30 (tq, J = 7.1, 2.5 Hz, 
2H), 1.78 (t, J = 2.5 Hz, 3H), 1.77 (tt, J = 7.1, 7.1 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 131.5 (2C), 128.1 (2C), 127.5, 123.9, 89.4, 81.0, 78.2, 76.1, 28.2, 18.6, 
18.0, 3.4. 
N-(But-2-yn-1-yl)-N-(3-phenylprop-2-yn-1-yl)benzamide (1f).  
An oven dry round bottom flask equipped with  a stirbar was charged 
with NaH (40 mg 60%, 0.75 mmol)  sealed with a septum, and placed 
under N2 atmosphere. Freshly distilled anhydrous THF (0.5 mL) was 
added to the fask via syringe and the resulting solution cooled to -0 ⁰C. N-(3-
Phenylprop-2-yn-1-yl)benzamide (117 mg, 0.5 mmol) dissolved in anhydrous THF 
(0.5 mL) was then added. After stirring at 0 ⁰C for 0.5 h a solution of 1-bromobut-
2-yne (61 uL, 0.75 mmol) dissolved in anhydrous THF (1.0 mL) was then added. 
The reaction was allowed to warm to rt. After 1.5 h, the reaction was quenched by 
the addition of water (0.1 mL). The mixture was poured into a separatory funnel 
containing 1 N HCl (20 mL) and CH2Cl2 (20 mL). The organic layer was separated, 
dried over Na2SO4, filtered, and the solvent removed in vacuo. Purification via flash 
chromatography  (4:1 pet. Ether:EtOAc, Rf 0.4, 50 mg, 35%) gave 1f as a colorless 
oil. 1H NMR shows indefinite rotamers. 
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N-(But-2-yn-1-yl)-N-(3-(4-methoxyphenyl)prop-2-yn-1-yl)-4-
methylbenzenesulfonamide (1g).  
Prepared according to General Procedure A: diyne V (200 mg, 0.77 
mmol) was reacted with 1-iodo-4-methoxybenzene (217 mg, 0.93 
mmol), in the presence of Pd(PPh3)2Cl2 (16 mg, 0.02), CuI (9 mg, 0.05), and TEA 
(0.2 mL, 1.5 mmol), in DMF (0.77 mL, 1.0 M), for 3 h. Purification via flash 
chromatography gave 1g (pet ether:EtOAc, 7:3, Rf  0.65, 77 mg, 27%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 
2H), 7.12 (d, J = 8.7 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 4.36 (s, 2H), 4.13 (q, J = 2.3 
Hz, 2H), 3.79 (s, 3H), 2.37 (s, 3H), 1.68 (t, J = 2.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 159.9, 143.7, 135.8, 133.3 (2C), 129.6 (2C), 128.2 (2C), 114.6, 114.0 
(2C), 85.7, 82.0, 80.4, 71.9, 55.5, 37.4, 37.1, 21.7, 3.7; HRMS (ESI) m/z 390.1144 
([M+Na]+, 100%), calc’d for C21H21NO3S 390.1140 
N-(But-2-yn-1-yl)-N-(3-(3,5-dimethylphenyl)prop-2-yn-1-yl)-4-
methylbenzenesulfonamide (1h).  
Prepared according to General Procedure A: diyne V (116 mg, 
0.44 mmol) was reacted with 1-iodo-3,5-dimethylbenzene (75 uL, 
0.53 mmol), in the presence of Pd(PPh3)2Cl2 (9 mg, 0.013 mmol) and CuI (5 mg, 
0.03 mmol) in TEA (1 mL, 0.4 M) for 16 hr. Purification via flash chromatography 
gave 1h (pet ether:EtOAc, 9:1, Rf 0.65, 147 mg, 91%) as a colorless oil. 1H NMR 
(500 MHz, CDCl3) δ 7.76 (d, J = 8.2 Hz, 2H), 7.28 (br d, J = 8.2 Hz, 2H), 6.92 (br 
s, 1H), 6.80 (br s, 2H), 4.38 (s, 2H), 4.13 (q, J = 2.3 Hz, 2H), 2.37 (s, 3H), 2.25 (s, 
  
122 
6H), 1.69 (t, J = 2.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 143.7, 137.9 (2C), 
135.7, 130.5, 129.6 (2C), 129.5 (2C), 128.1 (2C), 122.1, 86.2, 82.0, 81.0, 71.9, 
37.3, 37.1, 21.7, 21.2 (2C), 3.7; HRMS (ESI) m/z 366.1547 ([M+H]+, 100%), calc’d 
for C22H23NO2S 366.1528. 
N-(But-2-yn-1-yl)-N-(3-(3-methoxyphenyl)prop-2-yn-1-yl)-4-
methylbenzenesulfonamide (1i).  
Prepared according to General Procedure A: diyne V (105 mg, 
0.40 mmol) was reacted with 1-iodo-3-methoxybenzene (57 uL, 
0.48 mmol), in the presence of Pd(PPh3)2Cl2 (8 mg, 0.012 mmol) and CuI (5 mg, 
0.024 mmol), in TEA (1 mL, 0.4 M), for 2 hr. Purification via flash chromatography 
gave 1i (pet ether:EtOAc, 9:1, Rf 0.45, 140 mg, 95%) as a light orange solid. 1H 
NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 1H), 7.26 (d, J = 8.3 Hz, 2H), 7.16 
(dd, J = 8.4, 7.6  Hz, 1H), 6.84 (ddd, J = 8.4, 2.6, 1.2 Hz, 1H), 6.76 (ddd, J = 7.6, 
1.4, 1.2 Hz, 1H), 6.71 (dd, J = 2.6, 1.4 Hz, 1H), 4.38 (s, 2H), 4.13 (q, J = 2.4 Hz, 
2H), 3.77 (s, 3H), 2.36 (s, 3H), 1.68 (t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 159.3, 143.9, 135.6, 129.6 (2C), 129.4, 128.1 (2C), 124.3, 123.4, 117.0, 114.8, 
85.7, 82.1, 81.7, 71.8, 55.4, 37.26, 37.21, 21.6, 3.6; HRMS (ESI) m/z 368.1333 
([M+H]+, 100%), calc’d for C21H21NO3S 368.1320. 
N-(But-2-yn-1-yl)-N-(3-(4-chlorophenyl)prop-2-yn-1-yl)-4-
methylbenzenesulfonamide (1j).  
Prepared according to General Procedure A: diyne V (150 mg, 0.57 
mmol) was reacted with 1-chloro-4-iodobenzene (165 mg, 0.69 mmol), in 
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the presence of Pd(PPh3)2Cl2 (12 mg, 0.02 mmol) and CuI (7 mg, 0.03 mmol) in 
TEA (1.5 mL, 0.4 M) for 3 hr. Purification via flash chromatography gave 1j (CHCl3, 
Rf 0.85, 214 mg, 99%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J 
= 8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 7.22 (d, J = 8.7 Hz, 2H), 7.10 (d, J = 8.7 
Hz, 2H), 4.36 (s, 2H), 4.12 (q, J = 2.4 Hz, 2H), 2.36 (s, 3H), 1.67 (t, J = 2.4 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 143.8, 135.7, 134.7, 133.0 (2C), 129.6 (2C), 
128.7 (2C), 128.2 (2C), 120.9, 84.6, 83.0, 82.2, 71.7, 37.27, 37.22, 21.6, 3.6; 
HRMS (ESI) m/z 372.0818 ([M+H]+, 100%), calc’d for C20H1835ClNO2S 372.0825. 
Methyl 4-(3-(N-(But-2-yn-1-yl)-4-methylphenylsulfonamido)prop-
1-yn-1-yl)benzoate (1k).   
Prepared according to General Procedure B: tosyl amine II (75 mg, 
0.22 mmol) was refluxed with 1-bromobut-2-yne (40.35 mg, 0.306 
mmol) over K2CO3 (121 mg, 0.874 mmol) in acetonitrile (1.1 mL, 0.2M) for 0.5 h. 
Purification via flash chromatography gave 1k (pet ether:EtOAc, 4:1, Rf 0.60, 85 
mg, 98%) as a light yellow oil that solidified to an off-white solid upon standing. 1H 
NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.3 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.26 
(d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H), 4.40 (s, 2H), 4.13 (q, J = 2.4 Hz, 2H), 
3.91 (s, 3H), 2.35 (s, 3H), 1.69 (t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
166.6, 143.9, 135.6, 131.7 (2C), 130.0, 129.7 (2C), 129.5 (2C), 128.2 (2C), 127.1, 
85.1, 85.0, 82.3, 71.7, 52.5, 37.4, 37.3, 21.7, 3.7; HRMS (ESI) m/z 396.1295 
([M+H]+, 100%), calc’d for C22H21NO4S 396.1270. 
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N-(But-2-yn-1-yl)-4-methyl-N-(3-(4-(trifluoromethyl)phenyl)prop-2-
yn-1-yl)benzenesulfonamide (1l).  
Prepared according to General Procedure A: diyne V (50 mg, 0.19 mmol) 
was reacted with 1-iodo-4-(trifluoromethyl)benzene (60 mg, 0.22 mmol), 
in the presence of Pd(PPh3)2Cl2 (4 mg, 0.006 mmol) and CuI (2 mg, 0.01 mmol) in 
TEA (0.4 mL, 0.4 M) for 1 hr. Purification via flash chromatography gave 1l (pet 
ether:EtOAc 4:1, Rf 0.85, 65 mg, 84%) as an orange solid. 1H NMR (500 MHz, 
CDCl3) δ 7.75 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 
7.26 (d, J = 8.2 Hz, 2H), 4.39 (s, 2H), 4.13 (q, J = 2.4 Hz, 2H), 2.35 (s, 3H), 1.68 
(t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 143.9, 135.6, 132.0 (2C), 130.4 
(q, 2JC-F = 32.7 Hz), 129.6 (2C), 128.2 (2C), 126.2 (q, 5JC-F  = 1.3 Hz), 125.2 (q, 3JC-
F = 3.9 Hz, 2C), 123.9 (q, 1JC-F = 272.2 Hz) 84.7, 84.4, 82.3, 71.6, 37.3, 37.2, 21.6, 
3.7; HRMS (ESI) m/z 406.1090 ([M+H]+, 100%), calc’d for C20H18F3NO2S 
406.1089. 
N-(But-2-yn-1-yl)-4-methyl-N-(3-(4-nitrophenyl)prop-2-yn-1-
yl)benzenesulfonamide (1m).   
Prepared according to General Procedure B: tosyl amine III (165 mg, 0.5 
mmol) was refluxed with 1-bromobut-2-yne (60 uL, 0.7 mmol) over 
K2CO3 (276 mg, 2 mmol) in acetonitrile (2.5 mL, 0.2M) for 1 h. Purification via flash 
chromatography gave 1m (pet ether:EtOAc, 4:1, Rf 0.50, 141 mg, 74%) as an 
orange solid. 1H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 8.8 Hz, 2H), 7.74 (d, J = 
8.2 Hz, 2H), 7.32 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 4.40 (s, 2H), 4.13 
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(q, J = 2.4 Hz, 2H), 2.36 (s, 3H), 1.67 (t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 147.2, 144.0, 135.5, 132.5 (2C), 129.6 (2C), 129.2, 128.1 (2C), 123.5 
(2C), 87.4, 83.8, 82.4, 71.4, 37.4, 37.1, 21.6, 3.6; HRMS (ESI) m/z 383.1075 
([M+H]+, 100%), calc’d for C20H18N2O4S 383.1066. 
4-Methyl-N-(pent-2-yn-1-yl)-N-(3-phenylprop-2-yn-1-
yl)benzenesulfonamide (1n).  
Prepared according to General Procedure B: tosyl amine I (100 mg, 0.35 
mmol) was refluxed with 1-bromopent-2-yne (77 mg, 0.53 mmol) over K2CO3 (194 
mg, 1.4 mmol) in acetonitrile (1.75 mL, 0.2M) for 2 h. Purification via flash 
chromatography gave 1n (pet ether:EtOAc, 9:1, Rf 0.65, 107 mg, 87%) as an off-
white solid. 1H NMR (500 MHz, CDCl3)  δ 7.75 (d, J = 8.3 Hz, 2H), 7.36 – 7.20 
(overlap, 5H), 7.11 (br d, J = 8.1 Hz 2H), 4.39 (s, 2H), 4.17 (t, J = 2.2 Hz, 2H), 2.34 
(s, 3H), 2.05 (qt, J = 7.5, 2.2 Hz, 2H), 1.00 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, 
CDCl3)  δ 143.8, 135.6, 131.7 (2C), 129.6 (2C), 128.6, 128.3 (2C), 128.1 (2C), 
122.4, 87.9, 85.7, 81.9, 71.9, 37.20, 37.19, 21.6, 13.7, 12.4; HRMS (ESI) m/z 
352.1366 ([M+H]+, 100%), calc’d for C21H21NO2S 352.1371. 
4-Methyl-N-(3-phenylprop-2-yn-1-yl)-N-(prop-2-yn-1-
yl)benzenesulfonamide (1o).  
Prepared according to General Procedure B: N-tosyl propargylamine 
(0.49 g, 2.39 mmol) was refluxed with (3-bromoprop-1-yn-1-yl)benzene (0.93 g, 
4.78 mmol) in acetonitrile (12 mL, 0.2 M) over K2CO3 (1.32 g, 9.55 mmol) for 16 hr. 
Purification via flash chromatography gave 1o (pet ether:EtOAc, 9:1, Rf 0.55, 0.78 
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g, 99%) as a white solid. The identity of 10 was confirmed by comparison to 
reported 1H-NMR spectral data.214 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.3 
Hz, 2H), 7.37 – 7.19 (overlap, 5H), 7.15 (dd, J = 7.8, 1.7 Hz, 2H), 4.41 (s, 2H), 4.19 
(d, J = 2.5 Hz, 2H), 2.33 (s, 3H), 2.22 (t, J = 2.5 Hz, 1H); 13C NMR (100 MHz, 
CDCl3)  δ 144.0, 135.1, 131.6 (2C), 129.7 (2C), 128.6, 128.2 (2C), 127.9 (2C), 
122.1, 86.0, 81.3, 76.5, 74.2, 37.2, 36.6, 21.5. 
4-Methyl-N,N-bis(3-phenylprop-2-yn-1-yl)benzenesulfonamide (1p). 
Tosyl amine (500 mg, 2.9 mmol) and K2CO3 (2 g, 14.5 mmol) were added 
to a round bottom flask, and suspended in acetonitrile (25 mL, 0.1 M). 
The solution was brought to reflux with vigorous stirring, then (3-bromoprop-1-yn-
1-yl)benzene (1.71 g, 8.8 mmol) was added dropwise. After refluxing 1 hr, the 
reaction was allowed to cool to rt, filtered, then concentrated to a brown solid. 
Purification via flash chromatography gave 1p (pet ether:EtOAc, 9:1, Rf  0.6, 735 
mg, 63%) as an off-white solid. The identity of 1p was confirmed by comparison to 
reported 1H-NMR spectral data.124 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.2 
Hz, 2H), 7.27 – 7.07 (overlap, 12H), 4.37 (s, 4H), 2.23 (s, 3H). 
4-Methyl-N-(3-phenylprop-2-yn-1-yl)-N-(4-(trimethylsilyl)but-
2-yn-1-yl)benzenesulfonamide (1q).  
Prepared according to General Procedure B, with modifications as 
noted: tosyl amine I (47 mg, 0.16 mmol) was reacted with (4-bromobut-2-yn-1-
yl)trimethylsilane 215  (34 mg, 0.16 mmol) over K2CO3 (68 mg, 0.49 mmol) in 
acetonitrile (1 mL, 0.15 M) for 4 days at rt. Purification via flash chromatography 
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gave 1q (pet ether:EtOAc, 20:1, Rf 0.3, 35 mg, 52%) as a colorless oil. 1H NMR 
(500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.33 – 7.24 (overlap, 5H), 7.17 (dd, 
J = 8.1, 1.6 Hz, 2H), 4.39 (s, 2H), 4.18 (t, J = 2.5 Hz, 2H), 2.35 (s, 3H), 1.37 (t, J = 
2.5 Hz, 2H), 0.06 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 143.8, 135.6, 131.8 (2C), 
129.7 (2C), 128.6, 128.3 (2C), 128.1 (2C), 122.5, 85.7, 84.7, 81.8, 71.1, 37.5, 37.0, 
21.7, 7.3, -1.8 (3C); HRMS (ESI) m/z 410.1618 ([M+H]+, 100%), calc’d for 
C23H27NO2SSi 410.1610. 
Methyl 4-(3-((N-(but-2-yn-1-yl)-4-nitrophenyl)sulfonamido)prop-
1-yn-1-yl)benzoate (1r).  
Prepared according to General Procedure A: diyne IV (100 mg, 0.34 
mmol) was reacted with methyl 4-iodobenzoate (108 mg, 0.41 
mmol), in the presence of Pd(PPh3)4 (20 mg, 0.017 mmol), CuI (7 
mg, 0.034 mmol), and TEA (0.24 mL, 3.3 mmol) in toluene (1.4 mL, 0.25 M) for 4 
h. Purification via flash chromatography gave 1r (pet ether:EtOAc 4:1, Rf 0.35, 
110mg, 76%) as an orange solid. 1H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 8.8 Hz, 
2H), 8.08 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 8.1 Hz, sH), 7.25 (d, J = 8.1 Hz, 2H), 
4.43 (s, 2H), 4.21 (q, J = 2.6 Hz, 2H), 3.92 (s, 3H), 1.66 (t, J = 2.6 Hz, 3H). 
N-(But-2-yn-1-yl)-4-nitro-N-(3-(4-(trifluoromethyl)phenyl)prop-2-
yn-1-yl)benzenesulfonamide (1s).  
Prepared according to General Procedure A: diyne VI (250 mg, 0.59 
mmol) was reacted with 1-iodo-4-(trifluoromethyl)benzene (227 mg, 
0.83 mmol), in the presence of PdCl2(PPh3)2 (30 mg, 0.04 mmol), CuI 
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(16 mg, 0.08 mmol), and TEA (0.24 mL, 3.3 mmol) in toluene (4 mL, 0.15 M) for 4 
h. Purification via flash chromatography gave 1s (pet ether:EtOAc 4:1, Rf 0.35, 
265mg, 71%) as an orange solid.  1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 8.8 
Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 
4.43 (s, 2H), 4.22 (q, J = 2.4 Hz, 2H), 1.66 (t, J = 2.4 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 150.2, 144.4, 131.8 (2C), 130.6 (q, 2JC-F = 32.8 Hz) 129.2 (2C), 125.5, 
(5JC-F  = 1.3 Hz), 125.3 (q, 3JC-F = 3.9 Hz, 2C), 124.0 (2C), 123.6 (q, 1JC-F = 272.2 
Hz), 84.6, 83.7, 82.9, 70.9, 37.4, 37.3, 3.4. 
(Z)-3-(Iodo(phenyl)methylene)-4-methyl-3,6-dihydro-2H-pyran 
(2a).  
Prepared according to General Procedure C: diyne 1a (10 mg, 0.053 
mmol) was reacted with GaI3 (24 mg, 0.053, 1.0 eq) in DCE (0.26 mL) for 30 min. 
After work-up, 1H NMR showed the crude isolate to be 70% 2a. Purification via 
flash chromatography gave pure 2a (cyclohexanes:CHCl3, 2:3, Rf 0.75, 5 mg, 30%) 
as a colorless oil with significant loss of material. 1H NMR (500 MHz, CDCl3) δ 7.30 
– 7.27 (overlap, 4H), 7.23 (m, 1H), 5.44 (tq, J = 3.2, 1.4 Hz, 1H), 4.47 (s, 2H), 4.20 
(dq, J = 3.2, 2.0 Hz, 2H), 1.25 (td, J = 2.0, 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 146.3, 137.9, 131.0, 129.3 (2C), 128.3, 128.1, 128.0 (2C), 99.4, 77.2, 67.1, 23.2; 
HRMS was unable to be obtained for this compound due to its limited stability. 
 (Z)-3-(Iodo(phenyl)methylene)-4-methyl-1-tosyl-1,2,3,6-
tetrahydropyridine (2b).  
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Prepared according to General Procedure C: diyne 1b (22.5 mg, 0.067 mmol) was 
reacted with GaI3 (30 mg, 0.067, 1.0 eq) in DCE (0.33 mL) for 30 min. After work-
up, 1H NMR showed the crude isolate to be 91% 2b. Purification via filtration 
through a silica plug eluting with CHCl3 gave pure 2b (CHCl3, Rf 0.9, 27 mg, 88%) 
as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.3 Hz, 2H), 7.32 (d, J 
= 8.3 Hz, 2H), 7.23 – 7.16 (overlap, 3H), 6.90 (m, 2H), 5.29 (tq, J = 3.5, 1.3 Hz, 
1H), 4.24 (s, 2H), 3.89 (dq, J = 3.5, 2.0 Hz, 2H), 2.44 (s, 3H), 1.07 (td, J = 2.0, 1.3 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 145.6, 143.7, 136.2, 135.7, 132.0, 129.9 
(2C), 129.2 (2C), 128.5, 127.9 (4C), 125.6, 103.1, 56.9, 46.7, 23.0, 21.7; HRMS 
(ESI) m/z 466.0352 ([M+H]+, 100%), calc’d for C20H20INO2S 466.0338. 
(Z)-3-(Iodo(phenyl)methylene)-4-methyl-1-((4-
nitrophenyl)sulfonyl)-1,2,3,6-tetrahydropyridine (2c).  
Prepared according to General Procedure C: diyne 1c (50 mg, 0.1 
mmol) was reacted with GaI3 (45 mg, 0.1 mmol, 1.0 eq) in DCE (0.5 mL) for 6 h. 
After work-up, 1H NMR showed the crude isolate to be 93% 2c. Purification via 
filtration through a silica plug eluting with CHCl3 gave pure 2c (CHCl3, Rf 0.8, xx 
mg, 90%) as an off white solid.  1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.8 Hz, 
2H), 8.09 (d, J = 8.8 Hz, 2H), 7.20 – 7.16 (overlap, 3H), 6.84 – 6.79 (m, 2H), 5.30 
(tq, J = 3.4, 1.3 Hz, 1H), 4.34 (s, 2H), 3.98 (dq, J = 3.4, 2.0 Hz, 2H), 1.07 (td, J = 
2.0, 1.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 150.1, 144.8, 144.7, 135.3, 132.2, 
128.8 (2C), 128.6 (2C), 127.8 (2C), 124.8, 124.7, 124.3 (2C), 103.7, 56.5, 46.5, 
22.7. 
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(Z)-3-(Iodo(4-methoxyphenyl)methylene)-4-methyl-1-tosyl-
1,2,3,6-tetrahydropyridine (2g).  
Prepared according to General Procedure C: diyne 1g (22 mg, 0.060 
mmol) was reacted with GaI3 (27 mg, 0.060, 1.0 eq) in DCE (0.30 mL) 
for 5 min. After work-up, 1H NMR showed the resulting pale yellow solid to be 93% 
2g. Purification via filtration through a silica plug eluting with CHCl3 gave pure 2g 
(CHCl3, Rf 0.8, 26 mg, 88%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.78 
(d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 6.72 (d, J = 
8.5 Hz, 2H), 5.28 (br s, 1H), 4.21 (s, 2H), 3.89 (br s, 2H), 3.79 (s, 3H), 2.43 (s, 3H), 
1.12 (br s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.6, 143.6, 138.0, 135.9, 135.7, 
132.2, 130.7 (2C), 129.9 (2C), 127.9 (2C), 125.2, 113.2 (2C), 103.6, 56.9, 55.5, 
46.7, 22.9, 21.7; HRMS (ESI) m/z 496.0428 ([M+H]+, 100%), calc’d for 
C21H22INO2S 496.0443. 
 (Z)-3-((3,5-Dimethylphenyl)iodomethylene)-4-methyl-1-tosyl-
1,2,3,6-tetrahydropyridine (2h).  
Prepared according to General Procedure C: diyne 1h (22 mg, 
0.060 mmol) was reacted with GaI3 (27 mg, 0.060 mmol) in DCE 
(0.03 mL) for 10 min. After work-up, 1H NMR showed the resulting pale yellow solid 
to be 94% 2h. Purification via filtration through a silica plug eluting with CHCl3 gave 
pure 2h (CHCl3, Rf 0.9, 28 mg, 93%) as a yellow solid. 1H NMR (500 MHz, CDCl3) 
δ 7.79 (d, J = 8.3 Hz, 2H), 7.32 (br d, J = 8.3 Hz, 2H), 6.82 (br s, 1H), 6.54 (br s, 
2H), 5.27 (tq, J = 3.6, 1.3 Hz, 1H), 4.24 (s, 2H), 3.89 (dq, J = 3.6, 2.1 Hz, 2H), 2.44 
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(s, 3H), 2.23 (s, 6H), 1.10 (td, J = 2.1, 1.3 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 
145.5, 143.5, 137.3 (2C), 135.8, 135.6, 132.2, 130.2, 129.9 (2C), 128.0 (2C), 126.9 
(2C), 125.3, 103.7, 56.9, 46.7, 23.0, 21.8, 21.4 (2C); HRMS (ESI) m/z 494.0653 
([M+H]+, 100%), calc’d for C22H24INO2S 494.0651. 
(Z)-3-(Iodo(3-methoxyphenyl)methylene)-4-methyl-1-tosyl-
1,2,3,6-tetrahydropyridine (2i).  
Prepared according to General Procedure C:  diyne 1i (16 mg, 
0.044 mmol) was reacted with GaI3 (20 mg, 0.044, 1.0 eq) in DCE 
(0.2 mL) for 45 min. After work-up, 1H NMR showed the resulting pale yellow solid 
to be 94% 2i. Filtration through a silica plug eluting with CHCl3 gave pure 2i (CHCl3, 
Rf 0.8, 19 mg, 87%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.2 
Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.11 (dd, J = 8.3, 7.8 Hz, 1H), 6.73 (ddd, J = 8.3, 
2.5, 0.8 Hz, 1H), 6.51 (ddd, J = 7.8, 1.5, 0.8 Hz, 1H), 6.47 (dd, J = 2.5, 1.5 Hz, 1H), 
5.29 (tq, J = 3.4 1.4 Hz, 1H), 4.23 (s, 2H), 3.89 (dq, J = 3.4, 2.1 Hz, 2H), 3.77 (s, 
3H), 2.44 (s, 3H), 1.14 (td, J = 2.1, 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
158.9, 146.8, 143.8, 136.1, 135.6, 132.1, 130.0 (2C), 128.9, 127.9 (2C), 125.5, 
121.8, 115.1, 113.8, 102.6, 56.9, 55.5, 46.7, 22.9, 21.7; HRMS (ESI) m/z 496.0442 
([M+H]+, 100%), calc’d for C21H22INO3S 496.0443. 
 (Z)-3-((4-Chlorophenyl)iodomethylene)-4-methyl-1-tosyl-1,2,3,6-
tetrahydropyridine (2j).  
Prepared according to General Procedure C: diyne 1j (124 mg, 0.33 
mmol) was reacted with GaI3 (150 mg, 0.33 mmol) in DCE (1.7 mL) for 
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45 min. After work-up, 1H NMR showed the crude isolate to be to be 92% pure 2j. 
Purification via flash chromatography gave pure 2j (9:1 pet ether:EtOAc, Rf 0.6, 
128 mg, 78%) as a light yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 8.2 
Hz, 2H), 7.31 (br d, J = 8.2 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 
2H), 5.33 (tq, J = 3.5, 1.5 Hz, 1H), 4.21 (s, 2H), 3.89 (dq, J = 3.5, 1.9 Hz, 2H), 2.44 
(s, 3H), 1.11 (td, J = 1.9, 1.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 144.0, 143.8, 
137.0, 135.7, 134.4, 131.7, 130.6 (2C), 129.9 (2C), 128.2 (2C), 127.9 (2C), 126.2, 
101.1, 56.8, 46.8, 23.2, 21.8; HRMS (ESI) m/z 499.9954 ([M+H]+, 100%), calc’d 
for C20H1935ClINO2S 499.9948. 
(Z)-Methyl-4-(Iodo(4-methyl-1-tosyl-1,6-dihydropyridin-3(2H)-
ylidene)methyl)benzoate (2k).  
Prepared according to General Procedure C: diyne 1k (23 mg, 
0.058 mmol) was reacted with with GaI3 (27 mg, 0.058 mmol) in 
DCE (0.3 mL) for 9 h at 60 °C. After work-up, the 1H NMR spectrum showed the 
crude isolate to be 88% 2k. Purification via flash chromatography gave pure 2k 
(pet ether:EtOAc, 4:1, Rf 0.6, 11 mg, 36%) as a white solid with significant loss of 
material. 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8.3 Hz, 2H), 7.78 (d, J = 8.3 Hz, 
2H), 7.32 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.3 Hz, 1H), 5.33 (tq, J = 3.5, 1.4 Hz, 
1H), 4.24 (s, 2H), 3.92 – 3.89 (overlapped m, 2H), 3.91 (s, 3H), 2.45 (s, 3H), 1.06 
(td, J = 1.9, 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 166.6, 150.0, 143.8, 137.2, 
135.7, 131.6, 129.95 (2C), 129.94, 129.3 (2C), 129.2 (2C), 127.9 (2C), 126.3, 
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100.8, 56.8, 52.5, 46.8, 23.2, 21.8; HRMS (ESI) m/z 524.0400 ([M+H]+, 100%), 
calc’d for C22H22INO4S 524.0393. 
 (Z)-3-(Iodo(4-(trifluoromethyl)phenyl)methylene)-4-methyl-1-
tosyl-1,2,3,6-tetrahydropyridine (2l).  
Prepared according to General Procedure C: diyne 1l (32 mg, 0.079 
mmol) was reacted with with GaI3 (36 mg, 0.079 mmol) in DCE (0.4 
mL) for 2 h. After work-up, the 1H NMR spectrum showed the crude isolate to be 
88% 2l. Purification via flash chromatography gave pure 2l (pet ether:EtOAc, 4:1, 
Rf 0.55, 26 mg, 61%) as a white solid with significant loss of material. 1H NMR (500 
MHz, CDCl3) δ 7.78 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.2 
Hz, 2H), 7.03 (d, J = 8.2 Hz, 2H), 5.35 (tq, J = 3.3, 1.3 Hz, 1H), 4.23 (s, 1H), 3.90 
(dq, J = 3.3, 2.0 Hz, 1H), 2.45 (s, 3H), 1.07 (td, J = 2.0, 1.3 Hz, 2H); 13C NMR (125 
MHz, CDCl3) δ 149.0 (q, 5JCF  = 1.3 Hz), 143.9, 137.6, 135.6, 131.5, 130.4 (q, 2JCF 
= 32.8 Hz) 130.0 (2C), 129.6 (2C), 127.9 (2C), 126.6, 124.9 (q, 3JCF = 3.8 Hz, 2C), 
123.9 (q, 1JCF = 272.4 Hz), 100.0, 56.8, 46.8, 23.4, 21.8. HRMS (ESI) m/z 534.0192 
([M+H]+, 100%), calc’d for C21H19F3INO2S 534.0212. 
 (Z)-3-(Iodo(4-nitrophenyl)methylene)-4-methyl-1-tosyl-1,2,3,6-
tetrahydropyridine (2m).  
Prepared according to General Procedure C: diyne 1m (35 mg, 0.092 
mmol) was reacted with with GaI3 (41 mg, 0.092 mmol) in DCE (0.5 
mL) for 3 h at 50 °C. After work-up, the 1H NMR spectrum showed the crude isolate 
to be 83% 2m. Purification via flash chromatography gave 2m (pet ether:EtOAc, 
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4:1, Rf 0.5, 21 mg, 45%) as a white solid with significant loss of material. 1H NMR 
(500 MHz, CDCl3) δ 8.09 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 
8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 5.40 (br s, 1H), 4.24 (s, 2H), 3.91 (br s, 2H), 
2.46 (s, 3H), 1.10 (br d, J = 1.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 151.8, 
147.4, 143.9, 138.4, 135.5, 131.1, 130.2 (2C), 130.0 (2C), 127.9 (2C), 127.2, 123.3 
(2C), 98.3, 56.7, 46.8, 23.5, 21.8; HRMS (ESI) m/z 511.0200 ([M+H]+, 100%), 
calc’d for C20H19IN2O4S 511.0189. 
 (Z)-4-Ethyl-3-(iodo(phenyl)methylene)-1-tosyl-1,2,3,6-
tetrahydropyridine (1n).  
Prepared according to General Procedure C: diyne 1n (145 mg, 0.41 
mmol) was reacted with GaI3 (186 mg, 0.41 mmol, 1.0 eq) in DCE (2.0 mL) for 40 
min. After work-up, 1H NMR showed the resulting pale yellow solid to be 80% 2n. 
Purification via flash chromatography gave pure 2n (9:1 pet ether:EtOAc, Rf 0.45, 
104 mg, 53%) as an off-white solid with significant loss of material. 1H NMR (500 
MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H), 7.31 (br d, J = 8.3 Hz, 2H), 7.21 – 7.16 
(overlap, 3H), 6.91 (m, 2H), 5.34 (tt, J = 3.5, 1.4 Hz, 1H), 4.23 (s, 2H), 3.92 (dt, J 
= 3.5, 1.7 Hz, 2H), 2.42 (s, 3H), 1.32 (qtd, J = 7.4, 1.7, 1.4 Hz, 2H), 0.59 (t, J = 7.4 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 145.3, 143.7, 138.7, 135.8, 135.5, 130.0 
(2C), 129.2 (2C), 128.6, 128.0 (2C), 127.9 (2C), 123.5, 102.5, 57.3, 46.8, 27.6, 
21.7, 13.3; HRMS (ESI) m/z 480.0504 ([M+H]+, 100%), calc’d for C21H22INO2S 
480.0494. 
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(Z)-3-(Iodo(phenyl)methylene)-4-phenyl-1-tosyl-1,2,3,6-
tetrahydropyridine (2p).  
Prepared according to General Procedure C: diyne 1p (139 mg, 0.35 
mmol) was reacted with with GaI3 (157 mg, 0.35 mmol) in DCE (1.8 mL) for 10 min. 
After work-up, the 1H NMR spectrum showed the crude isolate to be a 6:4 mixture 
of 2p and 68. Purification via flash chromatography gave 2p (9:1 pet ether:EtOAc, 
Rf 0.4, 75 mg, 41%) as a white solid and 68 (Rf 0.3, 64 mg, 46%) as a bright yellow 
solid. For 2p: 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 
8.2 Hz, 2H), 6.85 – 6.77 (overlap, 3H), 6.78 – 6.73 (overlap, 3H), 6.68 (AA’BB’C 
m, 2H), 6.57 (dd, J = 7.7, 1.2 Hz, 2H), 5.53 (t, J = 3.5 Hz, 1H), 4.46 (s, 2H), 4.12 
(d, J = 3.5 Hz, 2H), 2.39 (s, 3H) ); 13C NMR (125 MHz, CDCl3) δ 143.84, 143.79, 
139.7, 138.7, 135.8, 134.9, 130.3 (2C), 130.0 (2C), 128.0, 127.89 (2C), 127.86 
(2C), 127.55 (2C), 127.54, 127.2 (2C), 126.6, 106.5, 57.0, 47.3, 21.7; HRMS (ESI) 
m/z 528.0486 ([M+H]+, 100%), calc’d for C25H22INO2S 528.494. 
 N-(Buta-2,3-dien-1-yl)-4-methyl-N-(3-phenylprop-2-yn-1-
yl)benzenesulfonamide (67).  
Diyne 1q (30 mg, 0.073 mmmol) was added to an oven-dried, thick-
walled tube, placed under Ar atmosphere, and dissolved in anhydrous DCE (0.35 
mL). A solution of GaCl3 (0.5 M in hexanes, 30 uL, 0.015 mmol, 0.1 eq) was added 
dropwise. The solution was stirred at rt 1.5 h, then diluted with CH2Cl2 (10 mL), 
then poured into 1 M NaOH (10 mL). The organic layer was separated, dried over 
NaSO4, filtered and concentrated to a light brown solid. Purification via flash 
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chromatography gave 67 (4:1, pet ether:EtOAc, Rf 0.65, 20 mg, 81%) as a white 
solid. The identity of the compound was confirmed by comparison to reported 1H-
NMR spectral data.216 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2H), 7.34 
– 7.19 (m, 5H), 7.08 (dd, J = 8.1, 1.6 Hz, 2H), 5.11 (tt, J = 7.2, 6.7 Hz, 1H), 4.80 
(dt, J = 6.7, 2.4 Hz, 2H), 4.37 (s, 2H), 3.93 (dt, J = 7.2, 2.4 Hz, 2H), 2.33 (s, 3H). 
9-Phenyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-c]pyridine (68). 
Diyne 1p (269 mg, 0.67 mmol) was added to an oven-dried, thick-
walled tube, placed under Ar atmosphere, and dissolved in 
anhydrous DCE (0.85 mL). A solution of GaCl3 (0.5 M solution in 
hexanes, 135 uL, 0.067 mmol, 0.1 eq) was then added dropwise. The solution was 
stirred at rt overnight (12 h), then diluted with CH2Cl2 (10 mL), poured into 1 M 
NaOH (10 mL). The organic layer was separated, dried over NaSO4, filtered and 
concentrated to a dark brown solid. Purification via flash chromatography gave 68 
(4:1, pet ether:EtOAc, Rf 0.45, 220 mg, 82%) as a bright yellow solid. The identity 
of 68 was confirmed by comparison to reported 1H-NMR spectral data.9  1H NMR 
(500 MHz, CDCl3) δ 7.61 (d, J = 8.3 Hz, 2H), 7.51 (dd, J = 7.8, 7.2 Hz, 2H), 7.47 
(d, J = 7.4 Hz, 1H), 7.45 – 7.37 (overlap, 3H), 7.31 (d, J = 7.5 Hz, 1H), 7.23 (ddd, 
J = 7.5, 7.4, 1.1 Hz, 1H), 7.18 (d, J = 7.8 Hz, 2H), 7.16 (ddd, J = 7.5, 7.5, 1.0 Hz, 
1H), 6.62 (t, J = 4.1 Hz, 1H), 4.46 (s, 2H), 4.18 (d, J = 4.1 Hz, 2H), 2.30 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 143.0, 143.0, 139.1, 137.6, 134.3, 133.9, 133.8, 
129.7 (2C), 129.1 (2C), 128.5 (2C), 128.3, 128.2, 127.8 (2C), 127.5, 125.4, 121.9, 
120.1, 119.9, 45.5, 44.1, 21.6. 
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(Z)-3-(Bromo(phenyl)methylene)-4-methyl-1-tosyl-1,2,3,6-
tetrahydropyridine (69).  
Perpared according to General Procedure C: diyne 1b (23 mg, 0.068 
mmol) was reacted with GaBr3 (21 mg, 0.068, 1.0 eq) in DCE (0.3 mL) for 30 min. 
After work-up, filtration though a silica plug gave pure 69 (pet ether:EtOAc, 5:1, Rf 
0.75, 27 mg, 95%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 
8.3 Hz, 2H), 7.30 (br d, J = 8.3 Hz, 2H), 7.25 – 7.19 (overlap, 3H), 6.94 (dd, J = 
8.0, 1.6 Hz, 2H), 5.40 (tq, J = 3.5, 1.4 Hz, 1H), 4.30 (s, 2H), 3.93 (dq, J = 3.5, 2.0 
Hz, 2H), 2.43 (s, 3H), 1.09 (td, J = 2.0, 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
143.7, 141.6, 135.7, 131.9, 131.3, 129.9 (2C), 129.8 (2C), 129.0, 128.0 (2C), 127.8 
(2C), 125.4, 123.9, 50.6, 46.3, 22.8, 21.7; HRMS (ESI) m/z 418.0485 ([M+H]+, 
100%), calc’d for C20H2079BrNO2S 418.0476. 
(Z)-3-(Chloro(phenyl)methylene)-4-methyl-1-tosyl-1,2,3,6-
tetrahydropyridine (70).  
Diyne 1b (50 mg, 0.15 mmol) was added to an oven dried thick-walled 
tube equipped with a magnetc stir bar, purged with argon, then DCE (0.7 mL) was 
added. To this solution, GaCl3 was then added as a 0.5 M solution in pentane (300 
uL, 0.15 mmol, 1.0 eq). After 2 h the solution was diluted with CH2Cl2 (10 mL) and 
washed with 1 M NaOH (15 mL). The organic layer was dried over Na2SO4, filtered, 
and the solvent removed. Filtration though a silica plug gave 70 (CHCl3, Rf 0.95, 
31 mg, 55%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 
2H), 7.29 (d, J = 8.3 Hz, 2H), 7.31 – 7.27 (overlapped m, 1H), 7.25 (m, 2H), 6.97 
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(m, 2H), 5.43 (tq, J = 3.5, 1.4 Hz, 1H), 4.29 (s, 2H), 3.96 (dq, J = 3.5, 2.1 Hz, 2H), 
2.42 (s, 3H), 1.11 (td, J = 2.1, 1.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 143.6, 
139.6, 135.7, 131.5, 131.2, 129.9 (2C), 129.8 (2C), 129.1, 128.7, 128.0 (2C), 127.7 
(2C), 125.2, 47.3, 46.1, 22.6, 21.7; HRMS (ESI) m/z 374.0997 ([M+H]+, 100%), 
calc’d for C20H2035ClNO2S 374.0982. 
9-Iodo-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-indeno[2,1-
c]pyridine (75b).  
Prepared according to General Procedure D: diyne 1b (65 mg, 0.19 
mmol) was reacted with GaI3 (87 mg, 0.19 mmol, 1.0 eq) for 30 min 
at rt, followed by the addition of TFA (0.19 mmol, 15 uL) and heating to 50 °C for 
2 h. Purification via flash chromatography afforded pure 75b (4:1 pet ether:EtOAc, 
Rf 0.5, 81 mg, 91%) as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.74 (d, 
J = 8.3 Hz, 2H), 7.37 – 7.30 (overlap, 4H), 7.28 – 7.20 (overlap, 2H), 4.76 (dd, J = 
13.0, 1.6 Hz, 1H), 3.79 (dddd, J = 12.6, 4.6, 2.5, 1.6 Hz, 1H), 3.40 (d, J = 13.0 Hz, 
1H), 2.87 (ddd, J = 12.9, 12.7, 2.6 Hz, 1H), 2.42 (s, 3H), 2.01 (ddd, J = 13.1, 2.5, 
2.5 Hz, 1H), 1.30 (ddd, J = 13.1, 12.9, 4.6 Hz, 1H), 1.14 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 151.2, 150.7, 143.9, 142.9, 134.2, 129.9 (2C), 127.9 (2C), 127.6, 
126.8, 123.3, 121.2, 92.4, 50.4, 46.4, 42.2, 35.6, 21.8, 19.9. HRMS (ESI) m/z 
466.0331 ([M+H]+, 100%), calc’d for C20H20INO2S 466.0338. 
9-Iodo-4a-methyl-2-((4-nitrophenyl)sulfonyl)-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine (75c).  
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Precursor vinyl iodide 2c was prepared according to General Procedure C, then 
subjected General Procedure E without purification: crude 2c (127 mg, 0.23 mmol) 
was dissolved in DCE (1.3 mL), treated with TfOH (23 uL, 0.23 mmol), and heated 
to 60 °C for 0.5 h. Purification via flash chromatography afforded pure 75c (4:1, 
pet ether:EtOAc, Rf 0.45, 120 mg, 95%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 7.36 (ddd, J = 7.6, 7.1, 
1.3 Hz, 1H), 7.32 (d, J = 7.2 Hz, 1H), 7.27 (ddd, J = 7.2, 7.0, 1.4 Hz, 1H), 7.23 (d, 
J = 7.6 Hz, 1H), 4.83 (dd, J = 13.5, 1.7 Hz, 1H), 3.88 (dddd, J = 13.2, 4.5, 2.2, 1.7 
Hz, 1H), 3.61 (d, J = 13.5 Hz, 1H), 3.09 (ddd, J = 13.2, 13.0, 2.4, Hz, 1H), 2.04 
(ddd, J = 13.5, 2.4, 2.2 Hz, 1H), 1.22 (ddd, J = 13.5, 13.0, 4.5 Hz, 1H), 1.20 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 150.7, 150.0, 149.5, 144.0, 142.3, 128.7 (2C), 
127.6, 126.9, 124.3 (2C), 123.2, 121.0, 92.6, 50.1, 46.1, 42.1, 35.5, 19.5. HRMS 
(ESI) m/z 518.9863 ([M+Na]+, 100%), calc’d for C19H17IN2O4SNa 518.9852. 
9-Iodo-6-methoxy-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (75g).  
Precursor vinyl iodide 2g was prepared according to General 
Procedure C, then subjected General Procedure E without 
purification: crude 2g (24 mg, 0.048 mmol) was dissolved in DCE (0.25 mL), 
treated with TfOH (4 uL, 0.048 mmol), and stirred at room temp for 45 min. 
Purification via flash chromatography afforded pure 75g (CHCl3, Rf 0.8, 14 mg, 
58%) as a white solid. 1H NMR (500 MHz, CDCl3) 7.74 (d, J = 8.0 Hz, 2H), 7.32 (d, 
J = 8.0 Hz, 2H), 7.21 (d, J = 8.3 Hz, 1H), 6.87 (dd, J = 8.3, 1.7 Hz, 1H), 6.81 (d, J 
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= 1.7 Hz, 1H), 4.70 (d, J = 13.0 Hz, 1H), 3.83 (s, 3H), 3.78 (br d, J = 12.3 Hz, 1H), 
3.38 (d, J = 13.0 Hz, 1H), 2.86 (dd, J = 13.1, 12.3 Hz, 1H), 2.42 (s, 3H), 1.96 (br d, 
J = 13.3 Hz, 1H), 1.32 (ddd, J = 13.3, 13.1, 4.4 Hz, 1H), 1.12 (s, 3H); δ 13C NMR 
(125 MHz, CDCl3) δ 159.5, 152.7, 148.4, 143.8, 136.0, 134.2, 129.9 (2C), 127.9 
(2C), 123.8, 112.4, 108.2, 91.7, 55.9, 50.5, 46.5, 42.3, 35.7, 21.8, 20.1; HRMS 
(ESI) m/z 496.0438 ([M+H]+, 100%), calc’d for C21H22INO3S 496.0443. 
 9-Iodo-4a,5,7-trimethyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (75h).  
Prepared according to General Procedure D: diyne 1h (18 mg, 
0.049 mmol) was reacted with GaI3 (22 mg, 0.049 mmol, 1.0 eq) 
for 10 min at rt, followed by the addition of TFA (4 uL, 0.049 mmol) and heating to 
50 °C for 2 h. Purification via flash chromatography afforded pure 75h (CHCl3, Rf 
0.85, 22 mg, 91%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 
8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 6.99 (s, 1H), 6.84 (s, 1H), 4.73 (dd, J = 13.1, 
1.3 Hz, 1H), 3.76 (dddd, J = 12.6, 4.6, 2.6, 1.3 Hz, 1H), 3.41 (d, J = 13.1 Hz, 1H), 
2.86 (ddd, J = 12.8, 12.6, 2.6 Hz, 1H), 2.43 (s, 3H), 2.37 (s, 3H), 2.36 (s, 3H), 2.27 
(ddd, J = 13.1, 2.6, 2.6 Hz, 1H), 1.40 (ddd, J = 13.1, 12.8, 4.6 Hz, 1H), 1.19 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 150.8, 145.4, 143.9, 143.4, 137.4, 134.2, 132.4, 
130.0, 129.9 (2C), 128.0 (2C), 121.9, 93.0, 50.9, 46.5, 42.1, 34.1, 21.8, 21.4, 18.6, 
17.8; HRMS (ESI) m/z 494.0669 ([M+H]+, 100%), calc’d for C22H24INO2S 
494.0651. 
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9-Iodo-7-methoxy-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (75i).  
Precursor vinyl iodide 2i was prepared according to General 
Procedure C, then subjected General Procedure E without 
purification: crude 2i (29 mg, 0.058 mmol) was dissolved in DCE (0.25 mL), treated 
with TfOH (5 uL, 0.058 mmol), with heating to 50 °C for 40 min. Purification via 
flash chromatography afforded pure 75i (CH2Cl2, Rf 0.8, 15 mg, 52%) as a white 
solid.  1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.2 Hz, 
2H), 7.12 (d, J = 8.1 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.1, 2.4 Hz, 
1H), 4.74 (dd, J = 13.0, 1.2 Hz, 1H), 3.86 (s, 3H), 3.78 (dddd, J = 12.7, 4.6, 2.1, 
1.2 Hz, 1H), 3.38 (d, J = 13.0 Hz, 1H), 2.85 (ddd, J = 12.8, 12.7, 2.4 Hz, 1H), 2.43 
(s, 3H), 1.98 (ddd, J = 13.2, 2.4, 2.1 Hz, 1H), 1.29 (ddd, J = 13.2, 12.8, 4.6 Hz, 
1H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.8, 151.9, 144.5, 143.9, 143.6, 
134.3, 130.0 (2C), 128.0 (2C), 121.9, 112.8, 108.8, 92.3, 55.9, 49.7, 46.4, 42.3, 
36.0, 21.8, 20.0; HRMS (ESI) m/z 496.0443 ([M+H]+, 100%), calc’d for 
C21H22INO3S 496.0443. 
6-Chloro-9-iodo-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (75j).  
Prepared according to General Procedure D: diyne 1j (50 mg, 0.13 
mmol) was reacted with GaI3 (61 mg, 0.13 mmol, 1.0 equiv) for 30 
min at rt, followed by the addition of TFA (0.13 mmol, 10 uL) and heating to 50 °C 
for 3 h. Purification via flash chromatography afforded pure 75j (CHCl3, Rf 0.8, 63 
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mg, 97%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 7.7 Hz, 2H), 
7.32 (d, J = 7.7 Hz, 2H), 7.34 – 7.30 (overlapped m, 1H), 7.24 (br d, J = 8.1 Hz, 
1H), 7.22 (br s, 1H), 4.73 (d, J = 13.1 Hz, 1H), 3.79 (br d, J = 12.6 Hz, 1H), 3.38 
(d, J = 13.1 Hz, 1H), 2.86 (br dd, J = 12.7, 12.6 Hz, 1H), 2.42 (s, 3H), 1.98 (br d, J 
= 13.3 Hz, 1H), 1.31 (ddd, J = 13.3, 12.7, 3.8 Hz, 1H), 1.14 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 152.6, 151.3, 144.0, 141.6, 134.2, 133.1, 130.0 (2C), 127.9 (2C), 
127.8, 124.3, 122.0, 91.2, 50.9, 46.4, 42.2, 35.5, 21.8, 19.9; HRMS (ESI) m/z 
499.9962 ([M+H]+, 100%), calc’d for C20H1935ClINO2S 499.9948. 
Methyl 9-Iodo-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine-6-carboxylate (75k).  
Precursor vinyl iodide 2k was prepared according to General 
Procedure C, then subjected General Procedure E without 
purification: crude 2k (92 mg, 0.18 mmol) was dissolved in DCE (0.25 mL), treated 
with TfOH (16 uL, 0.18 mmol), and heated to 60 °C for 20 h. Purification via flash 
chromatography afforded pure 75k (4:1, pet ether:EtOAc, Rf 0.5, 30 mg, 33%) as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 8.0, 1.3 Hz, 1H), 7.90 (d, 
J = 1.3 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.2 
Hz, 2H), 4.78 (dd, J = 13.1, 1.1 Hz, 1H), 3.93 (s, 3H), 3.81 (dddd, J = 12.6, 4.5, 
2.2, 1.1 Hz, 1H), 3.42 (d, J = 13.1 Hz, 1H), 2.89 (ddd, J = 12.9, 12.6, 2.3 Hz, 1H), 
2.42 (s, 3H), 2.07 (ddd, J = 13.3, 2.3, 2.2 Hz , 1H), 1.31 (ddd, J = 13.3, 12.9, 4.5 
Hz, 1H), 1.18 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 167.4, 154.4, 151.1, 147.5, 
144.0, 134.2, 130.0 (2C), 129.7, 128.5, 127.9 (2C), 123.1, 122.4, 91.6, 52.4, 50.8, 
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46.4, 42.2, 35.5, 21.8, 19.8; HRMS (ESI) m/z 524.0388 ([M+H]+, 100%), calc’d for 
C22H22INO4S 524.0393.  
9-Iodo-4a-methyl-2-tosyl-6-(trifluoromethyl)-2,3,4,4a-
tetrahydro-1I-indeno[2,1-c]pyridine (75l).  
Precursor vinyl iodide 2l was prepared according to General 
Procedure C, then subjected General Procedure E without 
purification: crude 2l (25 mg, 0.047 mmol) was dissolved in DCE (0.8 mL), treated 
with TfOH (4 uL, 0.047 mmol), and heated to 60 °C for 20 h. Purification via flash 
chromatography afforded pure 75l (CH2Cl2, Rf  0.6, 12 mg, 48%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 7.9 Hz, 1H), 
7.47 (s, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 4.78 (dd, J = 13.1, 
1.1 Hz, 1H), 3.82 (dddd, J = 12.6, 4.6, 2.0, 1.1 Hz, 1H), 3.41 (d, J = 13.1 Hz, 1H), 
2.89 (ddd, J = 12.8, 12.6, 2.4 Hz, 1H), 2.43 (s, 3H), 2.06 (ddd, J = 13.3, 2.4, 2.0 
Hz, 1H), 1.33 (ddd, J = 13.3, 12.8, 4.6 Hz, 1H), 1.18 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 153.9, 151.1, 146.4 (q, 5JC-F  = 1.5 Hz), 144.1, 134.1, 130.0 (2C), 129.2 
(q, 2JC-F = 32.1 Hz), 127.9 (2C), 126.8 (q, 1JC-F = 272.1 Hz), 125.2 (q, 3JC-F = 3.8 
Hz), 123.5, 118.2 (q, 3JC-F = 3.9 Hz), 91.1, 50.9, 46.3, 42.1, 35.5, 21.8, 19.8; HRMS 
(ESI) m/z 534.0190 ([M+H]+, 100%), calc’d for C21H19F3INO2S 534.0212. 
 4a-Ethyl-9-iodo-2-tosyl-2,3,4,4a-tetrahydro-1H-indeno[2,1-
c]pyridine (75n).  
Precursor vinyl iodide 2n was prepared according to General 
Procedure C, then subjected General Procedure E without 
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purification: crude 2n (25 mg, 0.052 mmol) was dissolved in DCE (0.25 mL), 
treated with TfOH (5 uL, 0.052 mmol), and stirred at rt for 4 h. Purification via flash 
chromatography afforded pure 75n (CHCl3, Rf 0.8, 18 mg, 73%) as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.37 – 7.28 (overlap, 2H), 
7.32 (d, J = 8.2 Hz, 2H), 7.25 (ddd, J = 7.2, 7.2, 1.4 Hz, 1H), 7.19 (d, J = 7.4 Hz, 
1H), 4.75 (dd, J = 12.9, 1.3 Hz, 1H), 3.75 (dddd, J = 12.7, 4.8, 2.5, 1.3 Hz, 1H), 
3.31 (d, J = 12.9 Hz, 1H), 2.92 (ddd, J = 12.8, 12.7, 2.6 Hz, 1H), 2.42 (s, 3H), 2.07 
(ddd, J = 13.3, 2.6, 2.5 Hz, 1H), 1.82 (dq, J = 13.7, 7.3 Hz, 1H), 1.70 (dq, J = 13.7, 
7.3 Hz, 1H), 1.34 (ddd, J = 13.3, 12.8, 4.8 Hz, 1H), 0.26 (dd, J = 7.3, 7.3 Hz, 
3H).13C NMR (125 MHz, CDCl3) δ 149.35, 149.26, 144.3, 143.9, 134.4, 130.0 (2C), 
128.0 (2C), 127.67 126.8, 123.1, 121.3, 92.9, 54.6, 46.5, 42.0, 35.1, 26.0, 21.8, 
7.6; HRMS (ESI) m/z 480.0503 ([M+H]+, 100%), calc’d for C21H22INO2S 480.0494. 
Methyl 9-iodo-4a-methyl-2-((4-nitrophenyl)sulfonyl)-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine-6-carboxylate (75r).  
Precursor vinyl iodide 2r was prepared according to General 
Procedure C, then subjected General Procedure E without 
purification: crude 2r (216 mg, 0.39 mmol) was dissolved in DCE (2.0 mL), treated 
with TfOH (34 uL, 0.39 mmol), and heated to 60 °C for 5 h. Purification via flash 
chromatography afforded pure 75r (4:1, pet ether:EtOAc, Rf 0.45, 121 mg, 56%) 
as a white solid.1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 8.8 Hz, 2H), 8.07 – 8.02 
(overlap, 3H), 7.90 (d, J = 1.5 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.84 (dd, J = 13.5, 
1.7 Hz, 1H), 3.91 (s, 3H), 3.89 (dddd, J = 13.1, 4.6, 2.4, 1.7 Hz, 1H), 3.59 (d, J = 
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13.5 Hz, 1H), 3.07 (ddd, J = 13.1, 12.5, 2.6 Hz, 1H), 2.10 (ddd, J = 13.4, 2.6, 2.4  
Hz, 1H), 1.23 (ddd, J = 13.4, 12.5, 4.6 Hz, 1H), 1.22 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 167.0, 153.2, 150.7, 150.1, 146.9, 143.8, 129.6, 128.7 (2C), 128.6, 124.5 
(2C), 123.1, 122.2, 91.8, 52.3, 50.5, 46.1, 42.1, 35.4, 19.4. HRMS (ESI) m/z 
555.0068 ([M+H]+, 100%), calc’d for C21H20IN2O6S 555.0087. 
9-Iodo-4a-methyl-2-((4-nitrophenyl)sulfonyl)-6-
(trifluoromethyl)-2,3,4,4a-tetrahydro-1H-indeno[2,1-c]pyridine 
(75s).  
Precursor vinyl iodide 2s was prepared according to General 
Procedure C, then subjected General Procedure E without purification: crude 2s 
(331 mg, 0.58 mmol) was dissolved in DCE (2.0 mL), treated with TfOH (34 uL, 
0.39 mmol), and heated to 60 °C for 5 h. Purification via flash chromatography 
afforded pure 75s (4:1, pet ether:EtOAc, Rf 0.45, 172 mg, 52%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 
7.63 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 4.85 (dd, J = 13.5, 
1.5 Hz, 1H), 3.91  (dddd, J = 13.1, 4.6, 2.4, 1.7 Hz, 1H), 3.60 (d, J = 13.5 Hz, 1H), 
3.08 (ddd, J = 13.1, 12.5, 2.6 Hz, 1H), 2.10 (ddd, J = 13.4, 2.6, 2.4  Hz, 1H), 1.27 
(ddd, J = 13.4, 12.5, 4.6 Hz, 1H), 1.23 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 152.7, 
151.0, 150.1, 145.8, 143.7, 128.9 (q, 2JC-F = 31.7 Hz), 128.7 (2C), 125.1 (q, 3JC-F = 
3.9 Hz), 124.4 (2C), 124.2 (q, 1JC-F = 272.5 Hz), 123.4, 118.0 (q, 3JC-F = 3.9 Hz), 
91.2, 50.6, 46.0, 41.9, 35.4, 19.4. HRMS (ESI) m/z 564.9914 ([M+H]+, 100%), 
calc’d for C20H17F3IN2O4S 564.9906. 
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4.3.1 Library Construction 
This section describes the compounds synthesized in Figure 2.4. The 
diversification of each nosylate scaffold (75c, 75r, and 75s) is depicted in a 
scheme before the relevant compounds. Compounds not appearing in Chapter 2 
were assigned sequentially by roman numeral, continuing from the compounds in 
Section 4.2. 
  
147 
 Scheme 4.1. Diversification of 75s 
Condtions: a) General Procedure F; b) R-CNO; c) Pd(Ph3)4, Ar-B(OH)2, K2CO3; d) Acryloyl 
chloride, TEA. 
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9-Iodo-4a-methyl-6-(trifluoromethyl)-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (VIII).  
Prepared according to General Procedure F: 75s (100 mg, 0.18 
mmol) was refluxed with thiophenol (44 uL, 0.43 mmol) in acetonitrile 
(1.8 mL, 0.1 M) over K2CO3 (152 mg, 1.1 mmol) for 0.5 h. Purification via flash 
chromatography gave VIII (20% MeOH in CH2Cl2, Rf 0.60, 65 mg, 97%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.51 (s, 1H), 7.42 (d, 
J = 8.0 Hz, 1H), 3.93 (d, J = 14.3 Hz, 1H), 3.52 (d, J = 14.3 Hz, 1H), 3.04 – 2.97 
(overlap, 2H), 2.21 (d, J = 13.1 Hz, 1H), 1.84 (br, NH), 1.32 (s, 3H), 1.24 – 1.16 
(m, 1H); 13C NMR (125 MHz, CDCl3) δ 159.2, 152.5, 146.4, 128.0 (q, 2JC-F = 31.8 
Hz), 124.6 (q, 1JC-F = 272.0 Hz), 124.5 (q, 3JC-F = 3.9 Hz) 122.6, 117.7 (q, 3JC-F = 
3.8 Hz), 86.2, 51.4, 46.5, 41.9, 41.4, 19.8. 
N-Cyclohexyl-9-iodo-4a-methyl-6-(trifluoromethyl)-1,3,4,4a-
tetrahydro-2H-indeno[2,1-c]pyridine-2-carboxamide (IX).  
Amine VIII (33 mg, 0.087 mmol) was added to a screw cap vial and 
dissolved in DCE (0.2 mL). This solution was cooled to 0 ⁰C, and 
isocyanatocyclohexane (7.4 uL, 0.13 mmol) dissolved in DCE (0.1 
mL) was added dropwise. The mixture was stirred 1.5 hr at 0 °C, 
then concentrated in vacuo. Purification by flash chromatography afforded IX (5% 
MeOH in CH2Cl2, Rf 0.65, 43 mg, 99%) as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 7.62 (dd, J = 8.0, 1.5 Hz, 1H), 7.51 (d, J = 1.5 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 
4.71 (dd, J = 14.7, 1.7 Hz, 1H), 4.52 (d, J = 7.6 Hz, NH), 4.01 (dddd, J = 13.7, 4.2, 
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2.2, 1.7 Hz, 1H), 3.81 (d, J = 14.7 Hz, 1H), 3.61 (tdt, J = 10.7, 7.6, 3.9 Hz, 1H), 
3.17 (ddd, J = 13.7, 13.0, 2.6 Hz, 1H), 2.08 (ddd, J = 13.0, 2.6, 2.2 Hz, 1H), 1.98 
– 1.88 (m, 2H), 1.74 – 1.64 (m, 2H), 1.59 (dtt, J = 13.1, 3.9, 3.9 Hz, 1H), 1.35 (s, 
3H), 1.41 – 1.05 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 156.5, 156.0, 151.7, 146.1 
(q, 5JC-F = 1.1 Hz), 128.4 (2JC-F = 32.1 Hz), 124.7 (q, 3JC-F = 3.9 Hz), 124.4 (q, 1JC-
F = 272.0 Hz), 123.0, 117.9 (q, 3JC-F = 3.7 Hz), 88.6, 51.5, 49.7, 45.0, 40.4, 36.6, 
33.8 (2C), 25.6, 25.0 (2C), 19.7.  
N-Cyclohexyl-9-(4-methoxyphenyl)-4a-methyl-6-
(trifluoromethyl)-1,3,4,4a-tetrahydro-2H-indeno[2,1-
c]pyridine-2-carboxamide (80).  
Vinyl iodide IX (20 mg, 0.040 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH (0.4 
mL/0.25 mL/40 uL). The solution was sparged with N2 10 
min. Pd(PPh3)4 (5 mg, 0.004 mmol), K2CO3 (28 mg, 0.2 mmol), and (4-
methoxyphenyl)boronic acid (7.5 mg, 0.050 mmol) were added, the vial capped, 
and heated to 80 ⁰C. After stirring 3 h, the reaction was cooled to rt dilute water (5 
mL) and extracted with EtOAc 3X (2.5 mL). The organic layers were combined, 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash 
chromatography afforded 80 (CH2Cl2, Rf 0.7, 19.5 mg, 99%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 
Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.7 Hz, 2H), 4.71 (dd, J = 14.5, 1.5 
Hz, 1H), 4.07 – 3.96 (overlap, 2H), 3.87 (s, 3H), 3.78 (d, J = 14.5 Hz, 1H), 3.50 
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(tdt, J = 10.9, 7.6, 3.9 Hz, 1H), 3.20 (ddd, J = 13.7, 13.0, 2.6 Hz, 1H), 2.18 (ddd, J 
= 13.0, 2.6, 2.2 Hz, 1H), 1.84 – 1.72 (m, 2H), 1.64 – 1.49 (m, 2H), 1.47 – 1.38 
(overlap, 4H), 1.34 – 1.21 (overlap, 3H), 1.07 (dtt, J = 13.0, 12.0, 3.5 Hz, 1H), 0.96 
– 0.81 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 159.4, 156.6, 153.4, 146.5, 146.2 
(q, 5JC-F = 1.1 Hz), 134.3, 130.2 (2C), 127.3 (d, 2JC-F = 31.6 Hz), 125.3, 124.73 (q, 
1JC-F = 271.8 Hz), 124.2 (q, 3JC-F = 3.9 Hz), 120.8, 118.3 (q, 3JC-F = 3.8 Hz), 114.4 
(2C), 55.4, 49.2, 48.8, 41.3, 40.3, 36.9, 33.6 (2C), 25.6, 24.8 (2C), 19.9. HRMS 
(ESI) m/z 485.2411 ([M+H]+, 100%), calc’d for C28H32F3N2O2S 485.2416.  
N-Cyclohexyl-4a-methyl-6-(trifluoromethyl)-9-
(3,4,5-trimethoxyphenyl)-1,3,4,4a-tetrahydro-2H-
indeno[2,1-c]pyridine-2-carboxamide (81).  
Vinyl iodide IX (20 mg, 0.040 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH (0.4 
mL/0.25 mL/40 uL). The solution was sparged with N2 
10 min. Pd(PPh3)4 (5 mg, 0.004 mmol), K2CO3 (28 mg, 0.2 mmol), and (3,4,5-
trimethoxyphenyl)boronic acid (10.5 mg, 0.050 mmol) were added, the vial capped, 
and heated to 80 ⁰C. After stirring 0.5 h, the reaction was cooled to rt dilute water 
(5 mL) and extracted with EtOAc 3X (2.5 mL). The organic layers were combined, 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash 
chromatography afforded 81 (CH2Cl2, Rf 0.65, 20 mg, 92%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 
Hz, 1H), 6.63 (s, 2H), 4.84 (d, J = 14.5 Hz, 1H), 4.03 (d, J = 7.5 Hz, NH), 3.95 (br 
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d, J = 13.7 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 6H), 3.77 (d, J = 14.5 Hz, 1H), 3.49 (tdt, 
J = 10.9, 7.6, 3.9 Hz, 1H), 3.23 (ddd, J = 13.7, 13.0, 2.6 Hz, 1H), 2.20 (ddd, J = 
13.0, 2.6, 2.2 Hz, 1H), 1.85 – 1.72 (m, 2H), 1.65 – 1.52 (m, 2H), 1.44 (overlap, 4H), 
1.34 – 1.22 (overlap, 3H), 1.07 (dtt, J = 13.0, 12.0, 3.5 Hz, 1H), 0.94 – 0.78 (m, 
2H). 
9-(4-Methoxyphenyl)-4a-methyl-6-(trifluoromethyl)-
2,3,4,4a-tetrahydro-1H-indeno[2,1-c]pyridine (82).  
Vinyl iodide VIII (30 mg, 0.079 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH (0.74 
mL/0.48 mL/77 uL). The solution was sparged with N2 10 min. Pd(PPh3)4 (10 mg, 
0.0079 mmol), K2CO3 (55 mg, 0.4 mmol), and (4-methoxyphenyl)boronic acid (7.5 
mg, 0.050 mmol) were added, the vial capped, and heated to 80 ⁰C. After stirring 
3 h, the reaction was cooled to rt dilute water (10 mL) and extracted with EtOAc 
3X (5 mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash chromatography afforded 82 (10% 
MeOH in CH2Cl2, Rf 0.65, 8 mg, 28%) as a white solid. Addition of 3.0 N HCl (1 
mL/mmol amine) in anhydrous dioxanes to a solution of 82 in CH2Cl2 (1 mL/mmol 
amine), formed HCl salt 82 as a white precipitate, which was isolated in 
quantitative yields by removal of the solvent in vacuo.1H NMR (500 MHz, CDCl3) 
δ 7.61 (s, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.3 
Hz, 2H), 6.99 (d, J = 8.3 Hz, 2H), 4.16 (d, J = 13.8 Hz, 1H), 3.85 (s, 3H), 3.73 (d, 
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J = 13.8 Hz, 1H), 3.26 (d, J = 13.4 Hz, 1H), 3.20 (dd, J = 13.4, 13.0, 1H), 2.27 (d, 
J = 13.8 Hz, 1H), 1.64 (ddd, J = 13.8, 13.0, 4.4 Hz, 1H), 1.40 (s, 3H).  
1-(9-(4-Methoxyphenyl)-4a-methyl-6-
(trifluoromethyl)-1,3,4,4a-tetrahydro-2H-indeno[2,1-
c]pyridin-2-yl)prop-2-en-1-one (83).  
Vinyl iodide X (10 mg, 0.028 mmol) was added to round 
bottom flask and dissolved in anhydrous CH2Cl2 (0.10 
mL). TEA (12 uL, 0.084 mmol) was added. Then, the solution was placed under 
N2 and cooled to 0 ⁰C in an ice bath. Acryloyl chloride (7 uL, 0.084) was added, 
and the reaction was removed from the ice bath. After stirring for 30 min, the 
reaction was diluted with CH2Cl2 (5 mL), poured into a separatory funnel and 
washed with water (5 mL), followed by 1 M NaOH (5 mL), and finally 1 M HCl (5 
mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash chromatography afforded 83 (2% 
MeOH in CH2Cl2, Rf 0.6, 6.4 mg, 55%) as a white solid. 1H NMR shows 1:1 mixture 
of indeterminate rotamers. 1H NMR (500 MHz, CDCl3) δ 7.61 (s, 1H), 7.54 (d, J = 
8.0 Hz, 1H), 7.49 – 7.34 (overlap, 2H), 7.27 (br, 1H), 7.04 (d, J = 8.7 Hz, 2H), 6.54 
(dd, J = 17.6, 11.0 Hz, 0.5H), 6.32 – 6.16 (overlap, 1H), 6.10 (d, J = 16.8 Hz, 0.5H), 
5.70 – 5.57 (overlap, 1H), 5.48 (d, J = 10.4 Hz, 0.5H), 4.87 (d, J = 14.2 Hz, 0.5H), 
4.67 (d, J = 13.6 Hz, 0.5H), 3.97 (d, J = 14.3 Hz, 1H), 3.89 (s, 1.5H), 3.87 (s, 1.5H), 
3.63 (d, J = 14.6 Hz, 0.5H), 3.53 (t, J = 13.4 Hz, 0.5H), 3.10 (dd, J = 13.7, 13.7 Hz, 
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0.5H), 2.25 (d, J = 13.2 Hz, 1H), 1.45 (s, 3H), 1.43 (overlap, 1H). HRMS (ESI) m/z 
414.1688 ([M+H]+, 100%), calc’d for C24H23F3NO2 414.1681.  
 Scheme 4.2. Diversification of 75s 
 
Condtions: a) General Procedure F; b) Acryloyl chloride, TEA; c) Pd(Ph3)4, Ar-B(OH)2, K2CO3.  
 Methyl 9-iodo-4a-methyl-2,3,4,4a-tetrahydro-1H-indeno[2,1-
c]pyridine-6-carboxylate (XI).  
Prepared according to General Procedure F: 75s (110 mg, 0.20 
mmol) was refluxed with thiophenol (50 uL, 0.48 mmol) in 
acetonitrile (2 mL, 0.1 M) over K2CO3 (166 mg, 1.2 mmol) for 0.5 hr. Purification 
via flash chromatography gave XI (20% MeOH in CH2Cl2, Rf 0.60, 63 mg, 85%) as 
a white solid.  1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 
7.35 (d, J = 8.0 Hz, 1H), 3.908 (s, 3H), 3.904 (d, J = 14.3 Hz, 1H), 3.49 (d, J = 14.3 
Hz, 1H), 3.00 – 2.94 (overlap, 2H), 2.21 (ddd, J = 13.2, 4.3, 2.3 Hz, 1H), 1.69 (br, 
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NH), 1.30 (s, 3H), 1.18 (ddd, J = 13.2, 9.6, 7.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ 167.3, 160.0, 152.1, 147.5, 129.1, 127.5, 122.2, 121.9, 86.6, 52.1, 51.2, 46.6, 
42.0, 41.4, 19.8. 
Methyl 2-acryloyl-9-iodo-4a-methyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine-6-carboxylate (XII).  
Amine XI (63 mg, 0.17 mmol) was added to round bottom flask 
and dissolved in anhydrous CH2Cl2 (0.34 mL). TEA (73 uL, 0.51 
mmol) was added. Then, the solution was placed under N2 and 
cooled to 0 ⁰C in an ice bath. Acryloyl chloride (41 uL, 0.51) was added dropwise, 
and the reaction was removed from the ice bath. After stirring for 10 min, the 
reaction was diluted with CH2Cl2 (10 mL), poured into a separatory funnel and 
washed with water (10 mL), followed by 1 M NaOH (10 mL), and finally 1 M HCl 
(10 mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash chromatography afforded XII (2% 
MeOH in CH2Cl2, Rf 0.6, 40 mg, 56%) as a white solid. 1H NMR shows a 1:1 
mixture of indeterminate rotamers. 1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 8.0, 
1.5 Hz, 1H), 7.95 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 6.87 – 6.72 (m, 0.5H), 6.58 – 
6.43 (m, 0.5H), 6.28 (dd, J = 16.8, 1.9 Hz, 1H), 5.84 – 5.52 (overlap, 1.5H), 4.94 
(d, J = 14.4 Hz, 0.5H), 4.67 (d, J = 13.1 Hz, 0.5H), 4.06 – 3.90 (overlap, 1H), 3.92 
(s, 3H), 3.65 (d, J = 14.8 Hz, 0.5H), 3.50 (dd, 13.1, 13.1 Hz, 0.5H), 3.05 (dd, J = 
13.1, 13.1 Hz, 0.5H), 2.16 (d, J = 13.1 Hz, 1H), 1.38 (s, 3H), 1.36 – 1.27 (overlap, 
1H). HRMS (ESI) m/z 424.0411 ([M+H]+, 100%), calc’d for C18H19INO3 424.0410. 
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Methyl 2-acryloyl-9-(4-methoxyphenyl)-4a-methyl-
2,3,4,4a-tetrahydro-1H-indeno[2,1-c]pyridine-6-
carboxylate (84).  
Vinyl iodide XII (17 mg, 0.046 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH 
(0.46 mL/0.30 mL/46 uL). The solution was sparged with N2 10 min. Pd(PPh3)4 (5.4 
mg, 0.0046 mmol), K2CO3 (23 mg, 0.23 mmol), and (4-methoxyphenyl)boronic acid 
(8.7 mg, 0.05 mmol) were added, the vial capped, and heated to 80 ⁰C. After 
stirring 3 h, the reaction was cooled to rt dilute water (10 mL) and extracted with 
EtOAc 3X (5 mL). The organic layers were combined, dried over Na2SO4, filtered 
and concentrated in vacuo. Purification by flash chromatography afforded 84 
(CH2Cl2, Rf 0.5, 14 mg, 75%) as a white solid.  1H NMR shows a 1:1 mixture of 
indeterminate rotamers. 1H NMR (500 MHz, CDCl3) δ 8.06 (d, J = 1.6 Hz, 1H), 7.98 
(dd, J = 8.0, 1.6 Hz, 1H), 7.45 – 7.32 (overlap, 2H), 7.27 (d, J = 8.0 Hz, 1H), 7.03 
(d, J = 8.7 Hz, 2H), 6.59 – 6.48 (m, 0.5H), 6.29 – 6.17 (overlap, 1H), 6.09 (d, J = 
16.7 Hz, 0.5H), 5.70 – 5.56 (overlap, 1H), 5.48 (d, J = 10.4 Hz, 0.5H), 4.86 (d, J = 
14.2 Hz, 0.5H), 4.66 (d, J = 14.0 Hz, 0.5H), 4.01 – 3.93 (overlap, 1H), 3.93 (s, 3H), 
3.89 (s, 1.5H), 3.86 (s, 1.5H), 3.64 (d, J = 16.1 Hz, 0.5H), 3.53 (dd, J = 13.1, 13.1 
Hz, 0.5H), 3.09 (dd, J = 13.1, 13.1 Hz, 0.5H), 2.27 (d, J = 13.1 Hz, 1H), 1.45 (s, 
3H), 1.45 – 1.40 (overlap, 1H). HRMS (ESI) m/z 404.1870 ([M+H]+, 100%), calc’d 
for C25H26NO4 404.1862. 
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5-(2-Acryloyl-4a-methyl-6-(trifluoromethyl)-
2,3,4,4a-tetrahydro-1H-indeno[2,1-c]pyridin-9-yl)-
N-benzyl-2-fluorobenzamide (85).  
Vinyl iodide XII (17 mg, 0.046 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH 
(0.46 mL/0.30 mL/46 uL). The solution was sparged with N2 10 min. Pd(PPh3)4 (5.4 
mg, 0.0046 mmol), K2CO3 (23 mg, 0.23 mmol), and (3-(benzylcarbamoyl)-4-
fluorophenyl)boronic acid (16 mg, 0.05 mmol) were added, the vial capped, and 
heated to 80 ⁰C. After stirring 3 h, the reaction was cooled to rt dilute water (10 mL) 
and extracted with EtOAc 3X (5 mL). The organic layers were combined, dried 
over Na2SO4, filtered and concentrated in vacuo. Purification by flash 
chromatography afforded 85 (CH2Cl2, Rf 0.4, 21 mg, 87%) as a white solid. 1H 
NMR shows a 1:1 mixture of indeterminate rotamers. 1H NMR (500 MHz, CDCl3) 
δ 8.15 – 8.04 (overlap, 2H), 7.99 (dd, J = 8.0, 1.6 Hz, 1H), 7.60 (br, 0.5H), 7.51 – 
7.24 (overlap, 8H), 7.12 (s, 0.5H), 6.50 (dd, J = 16.6, 11.5 Hz, 0.5H), 6.27 – 6.03 
(overlap, 1.5H), 5.69 – 5.39 (overlap, 2H), 4.85 – 4.59 (overlap, 3H), 4.07 – 3.95 
(overlap, 1H), 3.93 (s, 3H), 3.62 – 3.47 (overlap, 1H), 2.30 (d, J = 13.1 Hz, 1H), 
1.46 (s, 3H), 1.45 – 1.38 (overlap, 1H). HRMS (ESI) m/z 525.2185 ([M+H]+, 100%), 
calc’d for C32H30FN2O4 525.2190. 
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 Scheme 4.3. Diversification of 75c 
Condtions: a) Pd(Ph3)4, Ar-B(OH)2, K2CO3; b) General Proceure F; c) i) NaH, ii) MeI, iii) 3 N HCl 
dioxanes. 
 
9-(4-Methoxyphenyl)-4a-methyl-2-((4-
nitrophenyl)sulfonyl)-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridine (XIII).   
Vinyl iodide 75c (33 mg, 0.066 mmol) was added to a 
screw cap vial and dissolved in toluene/H2O/EtOH (0.62 mL/0.40 mL/64 uL). The 
solution was sparged with N2 10 min. Pd(PPh3)4 (7.6 mg, 0.0066 mmol), K2CO3 
(46 mg, 0.33 mmol), and (4-methoxyphenyl)boronic acid (12.6 mg, 0.083 mmol) 
were added, the vial capped, and heated to 80 ⁰C. After stirring 3 h, the reaction 
was cooled to rt dilute water (10 mL) and extracted with EtOAc 3X (5 mL). The 
organic layers were combined, dried over Na2SO4, filtered and concentrated in 
vacuo. Purification by flash chromatography afforded XIII (CH2Cl2, Rf 0.5, 31 mg, 
99%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.8 Hz, 2H), 7.81 
(d, J = 8.8 Hz, 2H), 7.35 (dd, J = 7.2, 1.7 Hz, 2H), 7.30 – 7.20 (m, 4H), 7.03 (d, J 
= 8.6 Hz, 2H), 4.78 (dd, J = 13.3, 1.6 Hz, 1H), 3.93 (dddd, J = 13.0, 4.6, 2.4, 1.6 
Hz, 1H), 3.90 (s, 3H), 3.58 (d, J = 13.3 Hz, 1H), 3.11 (ddd, J = 13.1, 12.5, 2.6 Hz, 
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1H), 2.15 (ddd, J = 13.3, 2.6, 2.4 Hz, 1H), 1.34 (ddd, J = 13.4, 12.5, 4.6 Hz, 1H), 
1.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.4, 152.5, 149.9, 144.1, 142.3, 
140.0, 137.0, 130.1 (2C), 128.5 (2C), 127.1, 125.7, 125.4, 124.2 (2C), 121.5, 
121.2, 114.3 (2C), 55.3, 47.5, 42.5, 42.0, 36.0, 19.7. 
9-(4-Methoxyphenyl)-4a-methyl-2,3,4,4a-tetrahydro-
1H-indeno[2,1-c]pyridine (XIV), and HCl salt (86). 
Prepared according to General Procedure F: XIII (16 mg, 
0.034 mmol) was refluxed with thiophenol (8.4 uL, 0.082 
mmol) in acetonitrile (0.34 mL, 0.1 M) over K2CO3 (19 mg, 0.14 mmol) for 5 hr. 
Purification via flash chromatography gave 86 (10% MeOH in CH2Cl2 w/ 0.5% TEA, 
Rf 0.60, 9 mg, 90%) as a white solid. Addition of 3.0 N HCl (1 mL/mmol amine) in 
anhydrous dioxanes to a solution of 86 in CH2Cl2 (1 mL/mmol amine), formed HCl 
salt 86 as a white precipitate, which was isolated in quantitative yields by removal 
of the solvent in vacuo. 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.34 (overlap, 3H), 
7.34 – 7.30 (m, 1H), 7.29 – 7.26 (overlap, 2H), 6.97 (d, J = 8.3 Hz, 2H), 4.19 (d, J 
= 13.6 Hz, 1H), 3.84 (s, 3H), 3.77 (d, J = 13.6 Hz, 1H), 3.32 (d, J = 13.0 Hz, 1H), 
3.23 (dd, J = 13.4, 13.0 Hz, 1H), 2.25 (d, J = 14.0 Hz, 1H), 1.71 (ddd, J = 14.0, 
13.4, 4.3 Hz, 1H), 1.38 (s, 3H).  
9-(4-Methoxyphenyl)-2,4a-dimethyl-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine, HCl salt (87).  
An oven dried skrew cap vial, equipped with a stir bar, 
was charged with NaH (2.2 mg as 60% in mineral oil, 
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0.093 mmol), and placed under N2 atmosphere. In a separate vessle, amine 86 (9 
mg, 0.31 mmol) was dissolved in anhydrous THF (0.32 mL). The amine solution 
was added to the vessle containing NaH. After stirring for 5 min, MeI (5.8 uL, 0.093 
mmol)  was added. After stirring a addiitonal 10 min, the reaction was quenched 
with H2O (5 mL), and etracted with EtOAc (5 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo. Purification by flash chromatography 
afforded  87 (10% MeOH in CH2Cl2 w/ 0.5% TEA, Rf 0.6, 5 mg, 53%) as a white 
solid. Addition of 3.0 N HCl (1 mL/mmol amine) in anhydrous dioxanes to a solution 
of amine in CH2Cl2 (1 mL/mmol amine), formed HCl salt 87 as a white precipitate, 
which was isolated in quantitative yields by removal of the solvent in vacuo.1H 
NMR (500 MHz, CDCl3) δ 7.50 – 7.46 (m, 1H), 7.43 – 7.39 (m, 1H), 7.39 – 7.35 
(overlap, 2H), 7.28 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 4.88 (d, J = 13.0 
Hz, 1H), 4.41 (ddd, J = 13.7, 2.4 Hz, 1H), 4.08 (dd, J = 13.0, 1.6 Hz, 1H), 3.89 (s, 
3H), 3.87 – 3.81 (m, 1H), 3.72 (s, 3H), 2.72 (s, 3H), 2.41 (d, J = 15.1 Hz, 1H), 1.79 
(ddd, J = 15.1, 13.7, 4.2 Hz, 1H).  
9-(Hex-1-yn-1-yl)-4a-methyl-2-tosyl-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine (88).  
Vinyl iodide 75b (20 mg, 0.043 mmol), Pd(PPh4)3 (2.5 
mg, 0.0022 mmol, 0.05 eq), and CuI (0.8 mg, 0.0043 
mmol, 0.1 eq) were added to a round bottom flask, then the headspace was purged 
with argon and sealed with a septum.  Piperidine (0.15 mL) was added, followed 
by hex-1-yne (7.4 uL, 0.064 mmol, 1.5 eq). The mixture was stirred 16 hr at 60 °C, 
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then allowed to cool to rt, diluted with CH2Cl2 (10 mL) and washed with 1 N HCl 
(10 mL). The organic layer was separated, dried over Na2SO4 and concentrated to 
a brown solid. Purification by flash chromatography afforded 88 (pet ether:EtOAc, 
9:1, Rf 0.35, 8 mg, 44%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J 
= 8.3 Hz, 2H), 7.45 (br d, J = 7.5 Hz, 1H), 7.32 – 7.26 (overlapped m, 1H), 7.29 (d, 
J = 8.3 Hz, 2H),  7.24 (d, J = 7.0 Hz, 1H)  7.21 (dd, J = 7.5, 7.0 Hz, 1H), 4.93 (d  J 
= 12.8 Hz, 1H), 3.76 (br d, J = 12.4 Hz, 1H), 3.37 (d, J = 12.8 Hz, 1H), 2.86 (ddd, 
J = 13.0, 12.4, 2.3 Hz, 1H), 2.52 (t, J = 7.0 Hz, 2H), 2.40 (s, 3H), 2.02 (ddd, J = 
13.3, 2.3, 2.1 Hz, 1H), 1.67 (tt, J = 7.1, 7.0 Hz, 2H), 1.57 (qt, J = 7.3, 7.1 Hz, 2H), 
1.25 (ddd, J = 13.3, 13.0, 4.6 Hz, 1H), 1.12 (s, 3H), 1.00 (t, J = 7.3 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 151.8, 148.7, 143.7, 141.9, 134.4, 129.8 (2C), 128.0 
(2C), 127.3, 126.0, 121.3, 121.1, 120.1, 98.3, 72.8, 47.8, 43.6, 42.1, 35.6, 31.1, 
22.3, 21.7, 19.9, 19.6, 13.9; HRMS (ESI) m/z 420.2003 ([M+H]+, 100%), calc’d for 
C26H29NO2S 420.1997. 
(Z)-3-((4-Ethyl-1-tosyl-1,6-dihydropyridin-3(2H)-
ylidene)(phenyl)methyl)-N,N-dimethylaniline (89).  
The precursor vinyl iodide 2n was prepared according to 
General Procedure C, then subjected to Suzuki coupling without purification: diyne 
1n (90 mg, 0.256 mmol) was treated with GaI3 (115 mg, 0.256 mmol) in DCE (0.9 
mL) following General Procedure C. When TLC indicated all diyne had been 
converted to 2n, the reaction was diluted with CH2Cl2 (10 mL) and washed with 1 
M NaOH (10 mL). The organic layer was separated, dried over Na2SO4, filtered, 
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and the solvent removed in vacuo to yield a yellow solid. To this crude material in 
a 10 mL thick-walled vial, Pd(PPh4)3 (3.0 mg, 0.0026 mmol, 0.01 eq), K2CO3 (178 
mg, 1.3 mmol, 5 eq), and (4-methoxyphenyl)boronic acid (53 mg, 0.32 mmol, 1.25 
eq) were added. Toluene (2.4 mL), water (1.6 mL), and ethanol (250 uL) were then 
added and the solution was purged with Ar for 15 min, then the vial was sealed 
with a Teflon cap and heated to 80 °C with stirring for 3 h. The reaction was then 
allowed to cool to rt, diluted with CH2Cl2 (10 mL) and washed with water (10 mL). 
The organic layer was separated, dried over Na2SO4, and the solvent removed to 
provide an orange solid. Purification by flash chromatography afforded pure 89 
(CH2Cl2 0.5% formic acid, Rf 0.1, then CH2Cl2 with 0.5% TEA, Rf 0.8, 65 mg, 54%) 
as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8.1 Hz, 2H), 7.23 (d, J 
= 8.1 Hz, 2H), 7.17 – 7.09 (overlap, 4H), 6.72 (br d, J = 7.8 Hz, 2H), 6.68 (dd, J = 
8.2, 2.3 Hz, 1H), 6.34 (br d, J = 2.3 Hz, 1H), 6.33 (d, J = 7.8 Hz, 1H), 5.50 (t, J = 
3.1 Hz, 1H), 4.03 (br s, 2H), 4.00 (s, 2H), 2.93 (s, 6H), 2.41 (s, 3H), 1.48 (br q, J = 
7.3 Hz, 2H), 0.68 (t, J = 7.3 Hz, 3H); δ 13C NMR (125 MHz, CDCl3) δ 150.4, 143.2, 
142.80, 142.79, 142.6, 140.8, 136.3, 130.5 (2C), 129.8 (2C), 128.9, 127.64 (2C), 
127.63 (2C), 127.55, 127.45, 122.3, 119.2, 114.9, 112.2, 48.2, 46.1, 40.8 (2C), 
27.7, 21.7, 13.7; HRMS (ESI) m/z 473.2271 ([M+H]+, 100%), calc’d for 
C29H32N2O2S 473.2263. The stereochemistry of the exocyclic, tetrasubstituted 
alkene was confirmed by an NOE (NOESY) between the 
dimethylaniline protons ortho to the exocyclic double bond 
(δ 6.34 and 6.3) and the methylene adjacent to the ring 
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nitrogen (δ 4.00). The vinyl hydrogen (δ 5.50), in turn, showed an NOE with the 
other ring methylene (δ 4.03), confirming the assignments of these two methylenes 
(Inset). 
3-(6-Chloro-4a-methyl-2-tosyl-2,3,4,4a-tetrahydro-1H-
indeno[2,1-c]pyridin-9-yl)prop-2-yn-1-ol (90).  
Vinyl iodide 75j (23 mg, 0.046 mmol), Pd(PPh4)3 (3 mg, 
0.0023 mmol, 0.05 eq), and CuI (1 mg, 0.0046 mmol, 0.1 eq) 
were added to a round bottom flask, then the headspace was purged with argon 
and the flask sealed with a septum.  Piperidine (0.15 mL) was then added, followed 
by propargyl alcohol (8 uL, 0.14 mmol, 3 eq). The mixture was stirred 4 h at 60 °C, 
then allowed to cool to rt. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with 1 N HCl (20 mL). The organic layer was separated, dried over 
Na2SO4 and concentrated to a brown solid. Purification by flash chromatography 
afforded 90 (CHCl3:MeOH, 95:5, Rf 0.8, 16.2 mg, 82%) as a colorless glassy solid. 
1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.1 Hz, 1H), 
7.32 (d, J = 8.2 Hz, 1H), 7.29 (br dd, J = 8.1, 1.9 Hz, 1H), 7.23 (br d, J = 1.9 Hz, 
1H), 4.90 (dd, J = 12.9, 1.5 Hz, 1H), 4.58 (d, J = 6.2, 2H), 3.78 (dddd, J = 12.6, 
4.6, 2.4, 1.5 Hz, 1H), 3.32 (d, J = 12.9 Hz, 1H), 2.82 (ddd, J = 12.8, 12.6, 2.5 Hz, 
1H), 2.42 (s, 3H), 2.02 (ddd, J = 13.1, 2.5, 2.4 Hz, 1H),  1.90 (t, J = 6.2, OH), 1.30 
(ddd, J = 13.1, 12.8, 4.6 Hz, 1H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 153.2, 
151.3, 144.0, 139.7, 133.9, 132.4, 130.0 (2C), 127.9 (2C), 127.7, 122.24, 122.16, 
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118.4, 95.3, 77.4, 51.9, 48.4, 43.5, 42.1, 35.6, 21.8, 19.8; HRMS (ESI) m/z 
428.1070 ([M+H]+, 100%), calc’d for C23H22ClNO3S 428.1087. 
 (Z)-Methyl 4-((4-Methoxyphenyl)(4-methyl-1-tosyl-1,6-
dihydropyridin-3(2H)-ylidene)methyl)benzoate (91). 
The precursor vinyl iodide 2b was prepared according to 
General Procedure C, then subjected to Suzuki coupling 
without purification: diyne 1b (65 mg, 0.16 mmol) was treated with GaI3 (79 mg, 
0.16 mmol) in DCE (0.9 mL) following General Procedure C. When TLC indicated 
all diyne had been converted to 2b, the reaction mixture was diluted with CH2Cl2 
(20 mL) and washed with 1 M NaOH (20 mL). The organic layer was separated, 
dried over Na2SO4, filtered, and the solvent removed in vacuo to yield a yellow 
solid. To this crude material in a 10 mL thick-walled vial, Pd(PPh4)3 (1.0 mg, 0.009 
mmol, 0.005 eq), K2CO3 (121 mg, 0.22 mmol, 5 eq), and (4-methoxyphenyl)boronic 
acid (33 mg, 0.22 mmol, 1.25 eq) were added. Toluene (2 mL), water (1.2 mL), 
and ethanol (200 uL) were then added and the solution was purged with Ar for 15 
min, then the vial was sealed with a Teflon cap and heated to 80° C with stirring 
for 4 h. After cooling to rt, the reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with water (20 mL). The organic layer was separated, dried over 
Na2SO4, and the solvent removed to provide an orange solid. Purification by flash 
chromatography afforded pure 91 (pet ether:EtOAc, 4:1, Rf 0.4, 73 mg, 88%) as a 
colorless solid. 1H NMR (500 MHz, CDCl3) 7.82 (d, J = 8.2 Hz, 2H), 7.52 (d, J = 
8.1 Hz, 2H), 7.24 (d, J = 8.1 Hz, 2H), 6.86 (s, 4H), 6.73 (d, J = 8.2 Hz, 2H), 5.49 
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(br s, 1H), 4.03 (br s, 2H), 4.01 (s, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 2.42 (s, 3H), 1.18 
(br s, 3H); δ 13C NMR (125 MHz, CDCl3) δ 167.1, 159.5, 148.0, 143.4, 140.2, 136.4, 
133.7, 133.6, 131.9 (2C), 130.9 (2C), 129.8 (2C), 129.7, 129.2, 129.0 (2C), 127.6 
(2C), 125.1, 113.9 (2C), 55.5, 52.3, 47.6, 46.3, 22.9, 21.8; HRMS (ESI) m/z 
504.1839 ([M+H]+, 100%), calc’d for C29H29NO5S 504.1845. The stereochemistry 
of the exocyclic, tetrasubstituted alkene was confirmed by NMR experiments. An 
H,H-COSY spectrum enabled assignments of the sets of aromatic resonances to 
specific aryl rings and, together with the HSQC experiment, established that the 
4H singlet at δ 6.86 was from the anisole ring. The 2H doublet at δ 7.82 for the 
benzoate hydrogens ortho to the carbonyl group, which showed coupling to the 
carbonyl carbon (δ 167.1) in the HMBC spectrum, coupled to the 2H doublet at δ 
6.73 in the COSY spectrum allowing assignment of this aryl system. The 2H 
doublet at δ 7.52 in turn coupled to the 2H doublet at δ 7.24, with the diagnostic 
NOE (NOESY) to the tosyl methyl singlet, enabling assignment of the tosyl protons 
of the aryl ring. The 4H singlet at δ 6.86 was therefore assigned as the four aryl 
protons of the anisole ring which are coincident, an assignment supported by the 
coupling between this signal and the resonance at δ 159.5 for 
the oxygenated anisole carbon in the HBMC spectrum.  An 
NOE was observed in the NOESY spectrum from the 4H 
aromatic singlet δ 6.86) to the methylene singlet at δ 4.01, 
confirming the cis relative stereochemistry between the 
anisole ring and this methylene (inset). 
  
165 
4a-Methyl-9-(pyridin-2-ylethynyl)-2-tosyl-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine (92).  
Vinyl iodide 75b (45 mg, 0.97 mmol), Pd(PPh4)3 (6 mg, 
0.005 mmol, 0.05 eq), and CuI (2 mg, 0.01 mmol, 0.1 eq) 
were added to a round bottom flask. The headspace was purged with argon and 
the flask sealed with a septum.  Piperidine (0.3 mL) was added, followed by 2-
ethynylpyridine (30 uL, 0.3 mmol, 3 eq). The mixture was stirred 1 hr at rt, then 
diluted with CH2Cl2 (20 mL) and washed with 1 N HCl (20 mL). The organic layer 
was separated, dried over Na2SO4 and concentrated to a give black oil. Purification 
by flash chromatography afforded 92 (CHCl3 with 0.5% TEA and 0.5% MeOH, Rf 
0.6, 30 mg, 70%) as a light brown solid. 1H NMR (500 MHz, CDCl3) δ 8.66 (br d, J 
= 4.9 Hz, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.74 (ddd, J = 7.7, 7.7, 1.8 Hz, 1H), 7.63 – 
7.60 (overlap, 2H), 7.33 (ddd, J = 7.4, 7.2, 1.5 Hz, 1H),  7.32 – 7.26 (overlap, 2H), 
7.25 (ddd, J = 7.4, 7.2, 0.8 Hz, 1H), 5.04 (dd, J = 13.0, 1.7 Hz, 1H), 3.81 (dddd, J 
= 12.7, 4.4, 2.2, 1.7 Hz, 1H), 3.45 (d, J = 13.0 Hz, 1H), 2.90 (ddd, J = 12.9, 12.7, 
2.4 Hz, 1H), 2.38 (s, 3H), 2.08 (ddd, J = 13.3, 2.4, 2.2 Hz, 1H), 1.34 (ddd, J = 13.3, 
12.9, 4.4 Hz, 1H), 1.17 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 152.5, 151.6, 150.3, 
143.8, 143.3, 140.9, 136.5, 134.2, 129.9 (2C), 128.0, 127.9 (2C), 127.5, 126.4, 
123.3, 121.51, 121.49, 118.9, 95.7, 81.4, 48.5, 43.7, 42.1, 35.8, 21.7, 19.9; HRMS 
(ESI) m/z 441.1637 ([M+H]+, 100%), calc’d for C27H24N2O2S 441.1637. 
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 9-(4-Methoxyphenyl)-4a-methyl-2-tosyl-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridine (93).  
Vinyl iodide 75b (25 mg, 0.054 mmol), Pd(PPh4)3 (0.3 mg, 
0.0003 mmol, 0.005 eq), K2CO3 (37.3 mg, 0.27 mmol, 5 
eq), and (4-methoxyphenyl)boronic acid (10.3 mg, 0.068 mmol, 1.25 eq) were 
added to a 10 mL thick-walled vial. Toluene (0.5 mL), water (0.3 mL), and ethanol 
(50 uL) were added and the solution was then purged with Ar for 15 min. The flask 
was sealed with a Teflon cap and heated to 80 °C with stirring for 2 h, then allowed 
to cool to rt. The reaction mixture was then diluted with CH2Cl2 (20 mL) and washed 
with water (20 mL). The organic layer was separated, dried over Na2SO4 and the 
solvent removed in vacuo to yield an orange solid. Purification by flash 
chromatography afforded 93 (pet ether:EtOAc, 3:1, Rf 0.7, 22 mg, 90%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.2 Hz, 2H), 7.35 (br d, J = 8.2 Hz, 
2H), 7.33 (d, J = 8.7 Hz, 2H), 7.30 – 7.20 (overlap, 4H), 7.02 (d, J = 8.7 Hz, 2H), 
4.73 (dd, J = 12.6, 1.5 Hz, 1H), 3.89 (s, 3H), 3.81 (dddd, J = 12.3, 4.6, 2.4, 1.5 Hz, 
1H), 3.32 (d, J = 12.6 Hz, 1H), 2.87 (ddd, J = 12.8, 12.3, 2.5 Hz, 1H),  2.43 (s, 3H), 
2.13 (ddd, J = 13.2, 2.5, 2.4 Hz, 1H), 1.43 (ddd, J = 13.2, 12.8, 4.6 Hz, 1H), 1.20 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.4, 152.9, 143.6, 143.1, 141.3, 136.8, 
134.2, 130.4 (2C), 129.9 (2C), 127.9 (2C), 127.1, 126.0, 125.6, 121.7, 121.3, 114.4 
(2C), 55.5, 47.8, 42.8, 42.3, 36.1, 21.8, 19.9; HRMS (ESI) m/z 446.1790 ([M+H]+, 
100%), calc’d for C27H27NO3S 446.1790. 
  
167 
N-Benzyl-2-fluoro-5-(4a-methyl-2-tosyl-2,3,4,4a-
tetrahydro-1H-indeno[2,1-c]pyridin-9-
yl)benzamide (94).  
Vinyl iodide 75b (20 mg, 0.043 mmol), Pd(PPh4)3 
(0.25 mg, 0.0002 mmol, 0.005 eq), K2CO3 (29.7 mg, 0.22 mmol, 5 eq), and (3-
(benzylcarbamoyl)-4-fluorophenyl)boronic acid (6 mg, 0.054 mmol, 1.25 eq) were 
added to a 10 mL thick-walled vial. Toluene (0.5 mL), water (0.3 mL), and ethanol 
(50 uL) were added and the solution was purged with Ar for 15 min. The vial was 
sealed with a Teflon cap and heated to 80 °C with stirring for 2 h, then allowed to 
cool to rt. The reaction mixture was diluted with CH2Cl2 (20 mL), then washed with 
water (20 mL). The organic layer was separated, dried over Na2SO4 and the 
solvent removed in vacuo to provide an orange solid. Purification by flash 
chromatography afforded 94 (pet ether:EtOAc, 4:1, Rf 0.4, 24 mg, 98%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 8.11 (dd, J = 7.4, 2.2 Hz, 1H), 7.62 (d, J = 8.1 
Hz, 2H), 7.53 (ddd, J = 8.3, 4.8, 2.3 Hz, 1H), 7.46 – 7.33 (overlap, 5H), 7.32 – 7.22 
(overlap, 7H), 7.18 (ddd, J = 11.6, 5.6, 5.6 Hz, 1H), 4.73 (d, J = 5.6 Hz, 2H), 4.62 
(d, J = 12.7 Hz, 1H), 3.80 (br ddd, J = 12.3, 4.6, 2.1 Hz, 1H), 3.32 (d, J = 12.7 Hz, 
1H), 2.83 (ddd, J = 12.8, 12.3, 2.2 Hz, 1H), 2.42 (s, 3H), 2.15 (ddd, J = 13.2, 2.2, 
2.1 Hz, 1H), 1.46 (ddd, J = 13.2, 12.8, 4.6 Hz, 1H), 1.20 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 163.3 (3JC-F = 3.3 Hz), 160.5 (1JC-F = 250.3 Hz), 152.7, 143.9, 143.2, 
142.3, 138.2, 135.7, 134.1 (2JC-F = 9.3 Hz), 134.0, 132.7 (3JC-F = 2.3 Hz), 130.7 
(4JC-F = 3.3 Hz) 130.0 (2C), 129.0 (2C), 128.1 (2C), 127.8 (2C), 127.7, 127.4, 
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126.0, 121.75 (2JC-F = 12.7 Hz), 121.74, 121.1, 117.1 (2JC-F = 24.9 Hz), 48.1, 44.4, 
42.7, 42.3, 36.2, 21.8, 19.9; HRMS (ESI) m/z 567.2103 ([M+H]+, 100%), calc’d for 
C34H31FN2O3S 567.2118. 
4.4. Chapter III Compounds 
N-(3-(4-Methoxyphenyl)prop-2-yn-1-yl)-4-methyl-N-(3-phenylprop-
2-yn-1-yl)benzenesulfonamide (133).  
Prepared according to General Procedure A: Terminal alkyne 1o (74.4 
mg, 0.23 mmol) was reacted with 4-iodoanisole (33 uL, 0.28 mmol), in 
the presence of Pd(PPh3)4 (13 mg, 0.012 mmol), CuI (4.4 mg, 0.023 
mmol), and TEA (160 uL), in DMF (1.2 mL)  for 1.5 hr at 60 ⁰C. Purification via 
flash chromatography gave 133 (pet ether:EtOAc, 4:1, Rf 0.4, 95 mg, 95%) as a 
light orange solid. 1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.33 – 
7.19 (overlap, 7H), 7.16 (d, J = 8.8 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 4.44 (s, 2H), 
4.43 (s, 2H), 3.80 (s, 3H), 2.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.6, 143.7, 
135.3, 133.1 (2C), 131.6 (2C), 129.5 (2C), 128.4, 128.1 (2C), 127.9 (2C), 122.1, 
114.2, 113.7 (2C), 85.6 (2C), 81.6, 80.1, 55.2, 37.5, 37.3, 21.3. 
N-(3-(3,5-Dimethylphenyl)prop-2-yn-1-yl)-4-methyl-N-(3-
phenylprop-2-yn-1-yl)benzenesulfonamide (134).  
Prepared according to General Procedure A: Terminal alkyne 1o 
(100 mg, 0.31 mmol) was reacted with 1-iodo-3,5-
dimethylbenzene (52 uL, 0.37 mmol), in the presence of Pd(PPh3)2Cl2 (7 mg, 0.01 
mmol), CuI (3.5 mg, 0.018 mmol), and TEA (87 uL), in DMF (0.35 mL)  for 16 hr at 
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rt. Purification via flash chromatography gave 134 (pet ether:EtOAc, 4:1, Rf 0.65, 
100 mg, 75%) as a light orange solid. 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.3 
Hz, 2H), 7.22 – 7.11 (overlap, 7H), 6.84 (s, 1H), 6.75 (s, 2H), 4.37 – 4.34 (overlap, 
4H), 2.25 (s, 3H), 2.16 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 143.7, 137.7 (2C), 
135.4, 131.6, (2C) 130.3, 129.5 (2C), 129.3 (2C), 128.4, 128.1 (2C), 128.0 (2C), 
122.2, 121.8, 86.1, 85.7, 81.7, 80.8, 37.6, 37.5, 21.4, 21.0 (2C).  
 N-(3-(3-Methoxyphenyl)prop-2-yn-1-yl)-4-methyl-N-(3-
phenylprop-2-yn-1-yl)benzenesulfonamide (135). 
Prepared according to General Procedure A: Terminal alkyne 1o 
(109 mg, 0.34 mmol) was reacted with 3-iodoanisole (60 uL, 0.51 
mmol), in the presence of Pd(PPh3)4 (19 mg, 0.017 mmol), CuI (6.3 mg, 0.034 
mmol), and TEA (190 uL), in toluene (1.7 mL)  for 1.5 hr at 60 ⁰C. Purification via 
flash chromatography gave 135 (pet ether:EtOAc, 4:1, Rf 0.4, 72.4 mg, 50%) as a 
light orange solid. 1H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H), 7.30 – 
7.19 (overlap, 7H), 7.16 (dd, J = 8.3, 7.6 Hz, 1H), 6.85 (ddd, J = 8.3, 2.6, 1.0 Hz, 
1H), 6.81 (ddd, J = 7.6, 1.3, 1.0 Hz, 1H), 6.75 (dd, J = 2.6, 1.3 Hz, 1H), 4.45 – 4.43 
(overlap, 4H), 3.76 (s, 3H), 2.32 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.1, 
143.8, 135.3, 131.6 (2C), 129.6 (2C), 129.2, 128.5, 128.1 (2C), 127.9 (2C), 124.1, 
123.2, 122.2, 116.7, 114.8, 85.8, 85.6, 81.6, 81.5, 55.2, 37.48, 37.46, 21.4. 
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 Methyl 4-(3-((4-methyl-N-(3-phenylprop-2-yn-1-
yl)phenyl)sulfonamido)prop-1-yn-1-yl)benzoate (136).  
Prepared according to General Procedure A: Terminal alkyne 1o (69 
mg, 0.21 mmol) was reacted with methyl 4-iodobenzoate (84 mg, 
0.32 mmol), in the presence of Pd(PPh3)4 (6 mg, 0.005 mmol), CuI 
(1.9 mg, 0.01 mmol), and TEA (150 uL), in toluene (1.0 mL)  for 3 hr at rt. 
Purification via flash chromatography gave 136 (pet ether:EtOAc, 4:1, Rf 0.4, 58 
mg, 60%) as a light orange solid. 1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 
2H), 7.72 (d, J = 8.1 Hz, 2H), 7.25 – 7.10 (overlap, 9H), 4.39 (s, 2H), 4.37 (s, 2H), 
3.84 (s, 3H), 2.24 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.3, 143.9, 135.3, 131.6 
(2C), 131.5 (2C), 129.7, 129.6 (2C), 129.3 (2C), 128.5, 128.1 (2C), 128.0 (2C), 
126.8, 122.1, 85.9, 84.9, 84.8, 81.4, 52.2, 37.6, 37.4, 21.4. 
 4-Methyl-N-(3-phenylprop-2-yn-1-yl)-N-(3-(4-
(trifluoromethyl)phenyl)prop-2-yn-1-yl)benzenesulfonamide (137). 
Prepared according to General Procedure A: Terminal alkyne 1o (162 
mg, 0.5 mmol) was reacted with 1-iodo-4-(trifluoromethyl)benzene (88 
uL, 0.6 mmol), in the presence of Pd(PPh3)2Cl2 (10.5 mg, 0.015 mmol), 
CuI (5.7 mg, 0.03 mmol), in TEA (1 mL), for 3 hr at rt. Purification via flash 
chromatography gave 137 (CHCl3, Rf 0.95, 222 mg, 92%) as an orange solid. 1H 
NMR (500 MHz, CDCl3) δ 7.82 (d, J = 8.3 Hz, 2H), 7.51 (d, J = 7.9 Hz, 2H), 7.34 – 
7.29 (overlap, 3H), 7.28 – 7.24 (overlap, 4H), 7.21 (dd, J = 8.3, 1.5 Hz, 2H), 4.48 
(s, 2H), 4.47 (s, 2H), 2.32 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 143.9, 135.3, 
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131.9 (2C), 131.6 (2C), 130.2 (q, 2JC-F = 32.7 Hz), 129.6, 128.5 (2C), 128.1 (2C), 
128.0 (2C), 126.0 (q, 5JC-F = 1.4 Hz), 125.0 (q, 3JC-F = 3.8 Hz, 2H), 123.7 (q, 1JC-F 
= 272.2 Hz), 122.0, 85.9, 84.4, 84.3, 81.4, 37.7, 37.4, 21.3. 
N-(3-(3,5-Dimethylphenyl)prop-2-yn-1-yl)-N-(3-(3-
methoxyphenyl)prop-2-yn-1-yl)-4-
nitrobenzenesulfonamide (142).  
Prepared according to General Procedure A: 
Terminal alkyne VII (75 mg, 0.2 mmol) was reacted with 1-iodo-3,5-
dimethylbenzene (52 uL, 0.37 mmol), in the presence of Pd(PPh3)4 (11.6 mg, 0.01 
mmol), CuI (3.8 mg, 0.02 mmol), and TEA (84 uL), in toluene (1.0 mL)  for 0.5 hr 
at rt. Purification via flash chromatography gave 142 (CHCl3, Rf 0.6, 55 mg, 56%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.8 Hz, 2H), 8.11 (d, J 
= 8.8 Hz, 2H), 7.15 (dd, J = 8.5, 7.5 Hz, 1H), 6.92 (s, 1H), 6.85 (dd, J = 8.5, 2.3 
Hz, 1H), 6.79 (dt, J = 7.5, 1.2 Hz, 1H), 6.74 (s, 2H), 6.71 (dd, J = 2.3, 1.2 Hz, 1H), 
4.50 (s, 2H), 4.49 (s, 2H), 3.73 (s, 3H), 2.20 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
159.2, 149.9, 144.5, 137.9, 130.7 (2C), 129.4, 129.2 (2C), 129.1 (2C), 124.0, 123.9 
(2C), 122.6, 121.2, 116.7, 115.1, 86.9, 86.2, 81.0, 80.1, 55.1, 38.12, 38.10, 20.8 
(2C). 
 9-(3,5-Dimethylphenyl)-2-tosyl-2,3-dihydro-1H-
indeno[2,1-c]pyridine (138a).  
Prepared according to General Procedure C: Diyne 134 (26 
mg, 0.061 mmol) was reacted with GaBr3 (2 mg, 0.061 mmol) 
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in DCE (60 uL) for 2.5 h. 1H NMR showed the crude isolate to be 39:10:51:0, 
138a:138b:138c:138d. Purification via flash chromatography gave 138a (pet 
ether:EtOAc, 75:15, Rf 0.4, 7.2 mg, 28%) as a bright yellow solid. 1H NMR (500 
MHz, CDCl3) δ 7.60 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 7.3 Hz, 1H), 7.30 (d, J = 7.4 
Hz, 1H), 7.22 (dd, J = 7.4, 7.4 Hz, 1H), 7.16 (overlap, 3H), 7.05 (s, 1H), 6.99 (s, 
2H), 6.58 (t, J = 4.1 Hz, 1H), 4.46 (s, 2H), 4.19 (d, J = 4.1 Hz, 2H), 2.40 (s, 6H), 
2.30 (s, 3H). 
6,8-Dimethyl-9-phenyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-
c]pyridine (138c). 
Prepared according to General Procedure G: Diyne 134 (16 mg, 
0.038 mmol) was dissolved in TFA (0.38 mL), and stirred for 1h. 
1H NMR showed the crude isolate to be 1:15, 138a:138c.  Purification via flash 
chromatography gave 138a (pet ether:EtOAc, 75:15, Rf 0.55, 12.8 mg, 80%) as a 
bright yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.9 Hz, 2H), 7.46 – 
7.35 (overlap, 3H), 7.20 – 7.13 (overlap, 4H), 7.17 (s, 1H), 6.78 (s, 1H), 6.56 (t, J 
= 4.2 Hz, 1H), 4.13 (s, 2H), 4.10 (d, J = 4.2 Hz, 2H), 2.35 (s, 3H), 2.32 (s, 3H), 1.86 
(s, 3H). 
9-(3-Methoxyphenyl)-2-tosyl-2,3-dihydro-1H-
indeno[2,1-c]pyridine (139a).  
Prepared according to General Procedure G: Diyne 135 
(21 mg, 0.049 mmol) was dissolved in TFA (0.49 mL), 
treated with TfOH (0.8 uL), and stirred for 0.5 h. 1H NMR showed the crude isolate 
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to be 7:2:1, 139a:139c’:139c’’.  Purification via flash chromatography gave 139a 
(CH2Cl2, Rf 0.65) gave a mixture 139a and x139c’. Purification of this mixture via 
flash chromatography gave 139a (pet ether:EtOAc, 4:1, Rf 0.5, 11 mg, 52% ) as a 
bright yellow solid. NMR (500 MHz, CDCl3) δ 7.61 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 
7.4 Hz, 1H), 7.42 (dd, J = 7.9, 7.9 Hz, 1H), 7.33 (d, J = 7.2 Hz, 1H), 7.23 (ddd, J = 
7.6, 7.2, 1.2 Hz, 1H), 7.20 – 7.11 (overlap, 3H), 7.01 – 6.93 (overlap, 3H), 6.61 (t, 
J = 4.0 Hz, 1H), 4.46 (s, 2H), 4.17 (d, J = 4.1 Hz, 2H), 3.88 (s, 3H), 2.30 (s, 3H). 
 (Z)-3-(Iodo(3-methoxyphenyl)methylene)-4-phenyl-1-tosyl-
1,2,3,6-tetrahydropyridine (139b).  
Prepared according to General Procedure C: Diyne 135 (36.4 mg, 
0.084 mmol) was reacted with GaI3 (37 mg, 0.084 mmol) in DCE (0.4 
mL) for 0.5 h. 1H NMR showed the crude isolate to be 25:18:38:19:0, 
139a:139b:139c’:xxc’’:139d. Purification via flash chromatography gave 139c’ 
(pet ether:EtOAc, 4:1, Rf 0.65, 1.5 mg, 4%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.84 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 6.86 – 6.81 (overlap, 
3H), 6.72 – 6.67 (overlap, 3H), 6.30 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 6.25 (ddd, J = 
7.7, 1.6, 1.0 Hz, 1H), 6.05 (dd, J = 2.6, 1.6 Hz, 1H), 5.52 (t, J = 3.5 Hz, 1H), 4.45 
(s, 2H), 4.11 (d, J = 3.5 Hz, 2H), 3.59 (s, 3H), 2.39 (s, 3H). Regiochemistry of the 
aryl rings (phenyl attached to endo-alkene and anisole 
attached to the exo-alkene) was confirmed by an NOE from the 
1H vinyl proton (δ 5.52) to the overlapping phenyl arene 
protons (δ 6.86 – 6.81) (inset). The resonance from δ 6.86 – 
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6.81 represents an overlap of the 2H doublet of the phenyl protons ortho to the 
alkene, and the 1H doublet of doublets of the anisole proton meta  to the other 
alkene. Since the meta proton of the anisole is not in range of the vinyl proton (δ 
5.52) to produce and NOE in either regioisomer, the NOE can be unambiguously 
assigned to the phenyl ring. 
 6-Methoxy-9-phenyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-
c]pyridine (139c’).  
Prepared according to General Procedure C: Diyne 135 (36.4 mg, 
0.084 mmol) was reacted with GaI3 (37 mg, 0.084 mmol) in DCE 
(0.4 mL) for 0.5 h. 1H NMR showed the crude isolate to be 25:18:38:19:0, 
139a:139b:139c’:139c’’:139d. Purification via flash chromatography gave 139c’ 
(pet ether:EtOAc, 4:1, Rf 0.4, 10.6 mg, 28%) as a bright yellow solid. 1H NMR (500 
MHz, CDCl3) δ 7.60 (d, J = 8.3 Hz, 2H), 7.52 – 7.47 (m, 2H), 7.43 – 7.37 (overlap, 
3H), 7.20 (d, J = 8.3 Hz, 1H), 7.19 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 2.3 Hz, 1H), 
6.76 (dd, J = 8.3, 2.3 Hz, 1H), 6.56 (t, J = 4.1 Hz, 1H), 4.43 (s, 2H), 4.16 (d, J = 4.1 
Hz, 2H), 3.83 (s, 3H), 2.31 (s, 3H). 
 8-Methoxy-9-phenyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-
c]pyridine (139c’’).  
Prepared according to General Procedure C: Diyne 135 (36.4 mg, 
0.084 mmol) was reacted with GaI3 (37 mg, 0.084 mmol) in DCE 
(0.4 mL) for 0.5 h. 1H NMR showed the crude isolate to be 25:18:38:19:0, 
139a:139b:139c’:139c’’:139d. Purification via flash chromatography gave a 
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mixture of 139a and 139c’’ (pet ether:EtOAc, 4:1,, Rf 0.5). as a bright yellow solid. 
Purification of this mixture via flash chromatography gave 139c’’ (CH2Cl2, Rf 0.8, 
2 mg, 5% ) as a bright yellow solid.  1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 8.2 
Hz, 2H), 7.43 – 7.38 (m, 2H), 7.37 – 7.31 (overlap, 3H), 7.20 (d, J = 8.2 Hz, 2H), 
7.14 – 7.09 (overlap, 2H), 6.78 (dd, J = 6.5, 2.6 Hz, 1H), 6.60 (t, J = 4.2 Hz, 1H), 
4.30 (s, 2H), 4.14 (d, J = 4.2 Hz, 2H), 3.60 (s, 3H), 2.32 (s, 3H). 1H NMR (500 MHz, 
d6-acetone) δ  7.59 (d, J = 8.3 Hz, 2H), 7.47 – 7.42 (m, 2H), 7.41 – 7.34 (overlap, 
3H), 7.31 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 7.4 Hz, 1H), 7.14 (dd, J = 8.1, 7.4 Hz, 
1H), 6.89 (d, J = 8.1 Hz, 1H), 6.86 (t, J = 4.2 Hz, 1H), 4.33 (s, 2H), 4.19 (d, J = 4.2 
Hz, 2H), 3.62 (s, 3H), 2.31 (s, 3H). In CDCl3, the protons of methoxy substituted 
aromatic ring system were found to be overlapping (δ 7.14 – 7.09) and did not give 
the doublet, doublet of doublets, doublet pattern expected for this spin system. 
However, in d6-acetone the peaks of this ring system 
were well resolved and gave the expect splitting pattern 
for 139c’’, a doublet (δ 7.23), a double doublet (δ 7.14), 
and a doublet (δ 6.68). The  coupling of this spin system 
was further confirmed by COSY, which gave cross-
peaks for δ 7.23 to δ 7.14, and δ 6.68 to δ 7.14 (inset).  
Methyl 4-(2-tosyl-2,3-dihydro-1H-indeno[2,1-
c]pyridin-9-yl)benzoate (140a).  
Prepared according to General Procedure G: Diyne 
136 (16 mg, 0.049 mmol) was dissolved in TFA (0.35 
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mL), treated with TfOH (0.6 uL), and stirred for 0.8 h. 1H NMR showed the crude 
isolate to be 140a, 140c was not dected at the limit of the NMR. Purification via 
flash chromatography gave 140a (CH2Cl2, Rf 0.6, 10 mg, 63%) as a bright yellow 
solid. 1H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.3 Hz, 
2H), 7.49 (d, J = 7.2 Hz, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 
7.25 (ddd, J = 7.4, 7.4, 1.2 Hz, 1H), 7.22 – 7.17 (overlap, 3H), 6.69 (t, J = 4.1 Hz, 
1H), 4.43 (s, 2H), 4.19 (d, J = 4.1 Hz, 2H), 3.98 (s, 3H), 2.32 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 166.7, 143.7, 142.2, 138.7, 138.3, 136.4, 134.0, 133.6, 130.1 (2C), 
129.6, 129.5 (2C), 128.5, 128.3 (2C), 128.1, 127.6 (2C), 125.4, 122.8, 119.9, 
119.7, 52.3, 45.2, 43.7, 21.4. HRMS (ESI) m/z 458.1425 ([M+H]+, 100%), calc’d 
for C27H24NO2S 458.1426. 
Methyl 9-phenyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-c]pyridine-
7-carboxylate (140c).  
Diyne 136 (35 mg, 0.076 mmol) was added to an oven dried thick-
walled tube equipped with a magnetc stir bar. DCE (0.8 mL) was 
added and the tube capped with a teflon septum. Via a syringe, 
GaCl3 was then added as a 0.5 M solution in pentane (31 uL, 0.015 mmol, 0.1 eq). 
After stirring 12 h, another portion of GaCl3 was added as a 0.5 M solution in 
pentane (31 uL, 0.015 mmol, 0.1 eq). After a stirring another 12 h, a final portion 
of GaCl3 was added as a 0.5 M solution in pentane (31 uL, 0.015 mmol, 0.1 eq). 
After stirring a final 12 h, the solution was diluted with CH2Cl2 (10 mL) and washed 
with 1 M NaOH (15 mL). The organic layer was dried over Na2SO4, filtered, and 
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the solvent removed. Purification via flash chromatography gave 140c (CH2Cl2 w/ 
0.5% MeOH, Rf 0.55, 14.3 mg, 41%) as a bright yellow solid. 1H NMR (500 MHz, 
CDCl3) δ 7.96 (d, J = 1.3 Hz, 1H), 7.90 (dd, J = 7.8, 1.3 Hz, 1H), 7.59 (d, J = 8.3 
Hz, 2H), 7.54 (dd, J = 7.6, 7.6 Hz, 2H), 7.51 (d, J = 7.8 Hz, 1H), 7.49 – 7.38 
(overlap, 3H), 7.17 (d, J = 8.3 Hz, 2H), 6.73 (t, J = 4.1 Hz, 1H), 4.48 (s, 2H), 4.22 
(d, J = 4.1 Hz, 2H), 3.89 (s, 3H), 2.29 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 167.2, 
143.7, 142.8, 138.2, 137.9, 137.1, 134.1, 133.0, 129.7, 129.5 (2C), 129.0 (2C), 
128.33, 128.28 (2C), 128.2, 127.6 (2C), 127.1, 124.3, 120.9, 119.4, 52.1, 45.3, 
43.8, 21.4. HRMS (ESI) m/z 480.1255 ([M+Na]+, 100%), calc’d for C27H23NO4S 
480.1245. 
Methyl (Z)-4-(3-(iodo(phenyl)methylene)-1-tosyl-1,2,3,6-
tetrahydropyridin-4-yl)benzoate (140d).  
Prepared according to General Procedure C: Diyne 136 (32.2 mg, 
0.070 mmol) was reacted with GaI3 (31.7 mg, 0.070 mmol) in DCE 
(0.35 mL) for 4 h. 1H NMR showed the crude isolate to be 30:0:14:56, 
140a:140b:140c:140d. Purification via flash chromatography gave 140d (pet 
ether:EtOAc, 4:1, Rf 0.6, 20 mg, 48%) as a white solid.  1H NMR (500 MHz, CDCl3) 
δ 7.84 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 6.78 
– 6.71 (overlap, 5H), 6.59 – 6.53 (m, 2H), 5.58 (t, J = 3.6 Hz, 1H), 4.46 (s, 2H), 
4.14 (d, J = 3.6 Hz, 2H), 3.82 (s, 3H), 2.38 (s, 3H); 1H NMR (500 MHz, d6-acetone) 
δ 7.88 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 6.87 
(d, J = 8.4 Hz, 2H), 6.80 – 6.77 (overlap, 3H), 6.58 – 6.54 (m, 2H), 5.75 (t, J = 3.5 
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Hz, 1H), 4.52 (s, 2H), 4.23 (d, J = 3.5 Hz, 2H), 3.77 (s, 3H), 2.40 (s, 3H). As overlap 
of the aromatic peaks (δ 6.78 – 6.71) in CDCl3 prevented unambiguous 
assignment, the regiochemistry of the aryl rings (p-MeCO2 substituted phenyl 
attached to endo-alkene and unsubstituted phenyl attached to the exo-alkene) was 
confirmed by NMR studies in d6-acetone. COSY cross-peaks between the 2H 
doublet at δ 7.47 and 2H doublet at δ 6.87, confirmed 
these as resonances ortho and meta to the p-MeCO2 
substituted phenyl ring, respectively (inset).  An NOE 
between the 1H vinyl triplet (δ 5.75) and the meta 2H 
doublet (δ 6.87) of the p-MeCO2 substituted phenyl ring 
confirmed the regiochemistry.  
2-Tosyl-9-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-
indeno[2,1-c]pyridine (141a).  
Prepared according to General Procedure G: Diyne 137 
(10 mg, 0.02 mmol) was dissolved in TFA (0.2 mL), 
treated with TfOH (0.4 uL, 0.004 mmol), and stirred for 16 h. 1H NMR showed the 
crude isolate to be 141a, 141c was not dected at the limit of the NMR. Purification 
via flash chromatography gave 141a (pet ether:EtOAc, 4:1, Rf 0.45, 9.0 mg, 90%) 
as a bright yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 8.0 Hz, 2H), 7.62 
(d, J = 8.2 Hz, 2H), 7.55 – 7.48 (overlap, 3H), 7.26 – 7.16 (overlap, 5H), 6.70 (t, J 
= 4.1 Hz, 1H), 4.42 (s, 2H), 4.19 (d, J = 4.1 Hz, 2H), 2.33 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 143.8, 142.1, 138.6, 137.3 (q, 5JC-F = 1.4 Hz), 135.9, 134.0, 133.5, 
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130.0 (q, 2JC-F = 32.3 Hz), 129.6 (2C), 128.6 (2C), 128.2, 127.6 (2C), 125.9 (q, 3JC-
F = 3.7 Hz, 2C), 125.5, 124.1 (q, 1JC-F = 270.3 Hz), 123.0, 119.9, 119.6, 45.2, 43.6, 
21.4. HRMS (ESI) m/z 490.1072 ([M+Na]+, 100%), calc’d for C26H20F3NO2SNa 
490.1065.  
(Z)-3-(Iodo(phenyl)methylene)-1-tosyl-4-(4-
(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine (141d).  
Prepared according to General Procedure C: Diyne 137 (20.1 mg, 
0.043 mmol) was reacted with GaI3 (19.4 mg, 0.043 mmol) in DCE 
(0.22 mL) for 1 h. 1H NMR showed the crude isolate to be 25:0:0:75, 
141a:141b:141c:141d. Purification via flash chromatography gave 141d (pet 
ether:EtOAc, 4:1, Rf 0.6, 14 mg, 55%) as a white solid.  1H NMR (500 MHz, CDCl3) 
δ 7.85 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.06 (d, J = 8.1 Hz, 2H), 6.82 
– 6.72 (m, 5H), 6.58 – 6.50 (m, 2H), 5.57 (t, J = 3.6 Hz, 1H), 4.46 (s, 2H), 4.13 (d, 
J = 3.5 Hz, 2H), 2.40 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 143.8, 143.4, 143.2 (q, 
5JC-F = 1.4 Hz), 137.4, 135.5, 134.3, 129.90 (2C), 129.85 (2C), 128.6, 128.3 (q, 2JC-
F = 32.5 Hz), 128.11, 128.05 (2C), 127.7 (2C), 127.2 (2C), 124.2 (q, 3JC-F = 3.8 Hz, 
2C), 123.8 (q, 1JC-F = 271.8 Hz), 106.3, 56.6, 47.0, 21.5. HRMS (ESI) m/z 
596.0378 ([M+H]+, 100%), calc’d for C26H22F3INO2S 596.0368. 
 9-(3-Methoxyphenyl)-6,8-dimethyl-2-((4-
nitrophenyl)sulfonyl)-2,3-dihydro-1H-indeno[2,1-
c]pyridine (143).  
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Prepared according to General Procedure G: Diyne 142 (14.2 mg, 0.029 mmol) 
was dissolved in TFA (585 uL), and stirred for 2 h. 1H NMR showed the crude 
isolate to be 97:2:1, 143:144:145. Purification via flash chromatography gave 143 
(pet ether:EtOAc, 4:1, Rf 0.55, 10.6 mg, 75%) as a bright yellow solid. 1H NMR 
(500 MHz, CDCl3) δ 8.21 (d, J = 8.8 Hz, 2H), 7.87 (d, J = 8.8 Hz, 2H), 7.37 (dd, J 
= 8.4, 7.5 Hz, 1H), 7.09 (s, 1H), 6.95 (ddd, J = 8.4, 2.6, 0.7 Hz, 1H), 6.80 (ddd, J = 
7.5, 1.5, 0.7 Hz, 1H), 6.78 (s, 1H), 6.74 (dd, J = 2.6, 1.5 H, 1H), 6.50 (t, J = 4.1 Hz, 
1H), 4.30 (s, 2H), 4.25 (d, J = 4.1 Hz, 2H), 3.85 (s, 3H), 2.30 (s, 3H), 1.89 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 159.6, 149.9, 143.9, 139.8, 138.9, 137.7, 137.1, 
135.3, 133.8, 132.3, 131.2, 129.6, 128.6 (2C), 126.5, 124.0 (2C), 120.7, 119.9, 
118.4, 114.2, 113.2, 55.3, 45.2, 43.7, 21.1, 19.7. HRMS (ESI) m/z 489.1482 
([M+H]+, 100%), calc’d for C27H25N2O5S 489.1484. 
9-(3,5-Dimethylphenyl)-6-methoxy-2-((4-
nitrophenyl)sulfonyl)-2,3-dihydro-1H-indeno[2,1-
c]pyridine (144).  
Prepared according to General Procedure C: Diyne 142 
(17.2 mg, 0.035 mmol) was reacted with GaI3 (3.2 mg, 0.007mmol) in DCE (0.35 
mL) at 60 ⁰C for 2 h. 1H NMR showed the crude isolate to be 40:37:16, 
143:144:145. Purification via flash chromatography gave a mixture of 144 and 145 
(pet ether:EtOAc, 4:1, Rf 0.55, 10.3 mg, 60%) as a bright yellow solid. Purification 
of this mixture via flash chromatography gave 144 (CHCl3, Rf 0.6, 5 mg, 29%) as 
a bright yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.6 Hz, 2H), 7.78 
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(d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.3 Hz, 1H), 7.08 (s, 1H), 6.95 (s, 2H), 6.93 (d, J = 
2.4 Hz, 1H), 6.73 (dd, J = 8.3, 2.4 Hz, 1H), 6.45 (t, J = 4.1 Hz, 1H), 4.60 (s, 2H), 
4.35 (d, J = 4.1 Hz, 2H), 3.80 (s, 3H), 2.42 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
158.5, 149.7, 144.2, 139.4, 138.7, 138.5 (2C), 135.2, 135.1, 133.1, 130.2, 128.6 
(2C), 125.8 (2C), 124.1, 123.6 (2C), 120.8, 120.2, 112.7, 106.9, 55.7, 45.5, 44.4, 
21.5 (2C). HRMS (ESI) m/z 489.1465 ([M+H]+, 100%), calc’d for C27H25N2O5S 
489.1484. 
 9-(3,5-Dimethylphenyl)-8-methoxy-2-((4-
nitrophenyl)sulfonyl)-2,3-dihydro-1H-indeno[2,1-
c]pyridine (145).  
Prepared according to General Procedure C: Diyne 142 (17.2 
mg, 0.035 mmol) was reacted with GaI3 (3.2 mg, 0.007mmol) in DCE (0.35 mL) at 
60 ⁰C for 2 h. 1H NMR showed the crude isolate to be 40:37:16, 143:144:145. 
Purification via flash chromatography gave a mixture of 144 and 145 (pet 
ether:EtOAc, 4:1, Rf 0.55, 10.3 mg, 60%) as a bright yellow solid. Purification of 
this mixture via flash chromatography gave 145 (CHCl3, Rf 0.75, 1 mg, 6%) as a 
bright yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 8.7 Hz, 2H), 7.77 (d, 
J = 8.7 Hz, 2H), 7.08 (dd, J = 8.2, 7.3 Hz, 1H), 7.02 (s, 1H), 7.00 (d, J = 7.3 Hz, 
1H), 6.90 (s, 2H), 6.76 (d, J = 8.2 Hz, 1H), 6.48 (t, J = 4.1 Hz, 1H), 4.50 (s, 2H), 
4.34 (d, J = 4.1 Hz, 2H), 3.64 (s, 3H), 2.40 (s, 6H). 
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4-Methyl-N-((1-oxo-1H-isochromen-3-yl)methyl)-N-(3-
phenylprop-2-yn-1-yl)benzenesulfonamide (154). 
Diyne 153 (55 mg, 0.117 mmol) was added to an oven dried 
thick-walled tube equipped with a magnetc stir bar. DCE (0.12 
mL) was added and the tube capped with a teflon septum. Via a syringe, GaBr3 
was then added as a 0.5 M solution in DCE (49 uL, 0.023 mmol, 0.2 eq), and the 
solution was heated to 60 ⁰C. After stirring 16 h, the solution was diluted with 
CH2Cl2 (10 mL) and washed with 1 M NaOH (15 mL). The organic layer was dried 
over Na2SO4, filtered, and the solvent removed. Purification via flash 
chromatography gave 154 (pet ether:EtOAc, 7:3, Rf 0.7, 12.5 mg, 24%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 8.23 (br d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.1 Hz, 
2H), 7.70 (ddd, J = 7.8, 7.4, 1.3 Hz, 1H), 7.49 (ddd, J = 8.1, 7.4, 1.2 Hz, 1H), 7.41 
(br d, J = 7.8 Hz, 1H), 7.29 – 7.20 (overlap, 5H), 7.10 – 7.08 (m, 2H), 6.64 (s, 1H), 
4.46 (s, 2H), 4.34 (s, 2H), 2.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 161.9, 151.9, 
144.0, 136.6, 135.7, 134.9, 131.5 (2C), 129.7 (2C), 129.6, 128.6, 128.5, 128.1 
(2C), 127.7 (2C), 125.7, 121.8, 120.5, 104.7, 86.3, 81.3, 47.7, 38.6, 21.4. 
 1,2,3-Triphenylazulene. 
Diphenyl acetylene (150 mg, 0.842 mmol) was added a round 
bottom flask and dissolved in DCE (0.84 ml). GaBr3 (260 mg, 0.840 
mmol) was added to this solution. After stirring 16 h, the reaction mixutre was 
filtered though a plug of silica gel (pet ether:EtOAc, 1:1, Rf 0.9). Purification via 
flash chromatography gave 1,2,3-triphenylazulene (pet ether:EtOAc, 4:1, Rf 0.7, 
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38 mg, 25%) as a bright blue solid. The identity of 1,2,3-triphenylazulene was 
confirmed by comparison to reported 1H-NMR data.207 1H NMR (500 MHz, CDCl3) 
δ 8.34 (d, J = 9.9 Hz, 2H), 7.54 (tt, J = 9.7, 1.0 Hz, 1H), 7.37 – 7.33 (m, 4H), 7.32 
– 7.27 (m, 6H), 7.14 – 7.08 (m, 5H), 7.04 – 7.01 (m, 2H). 
 9-Methyl-2-tosyl-2,3-dihydro-1H-indeno[2,1-c]pyridine (155). 
Perpared according to General Procedure G: diyne 1b (80 mg, 0.23 
mmol) was treated with TfOH (4 uL, 0.046) in TFA (4.6 mL) for 16 h. 
Purification via flash chromatography gave 155 (9:1 pet 
ether:EtOAc, Rf 0.4, 33 mg, 41%) as a bright yellow solid.1H NMR (500 MHz, 
CDCl3) δ 7.68 (d, J = 8.3 Hz, 2H), 7.40 (br d, J = 7.4 Hz, 1H), 7.25 – 7.21 (overlap, 
3H), 7.16 (br d, J = 7.5, Hz, 1H), 7.12 (ddd, J = 7.4, 7.4, 1.1 Hz, 1H), 6.44 (t, J = 
4.0 Hz, 1H), 4.29 (q, J = 1.1 Hz, 2H), 4.07 (d, J = 4.0 Hz, 2H), 2.33 (s, 3H), 2.08 
(q, J = 1.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 144.3, 143.6, 138.5, 133.8, 
133.4, 133.2, 129.5 (2C), 127.9, 127.6 (2C), 126.4, 124.9, 119.3, 119.2, 118.3, 
45.0, 43.3, 21.4, 10.3. HRMS (ESI) m/z 360.1026 ([M+Na]+, 100%), calc’d for 
C20H19NO2SNa 360.1034. 
 Methyl 4-(9-iodo-2-tosyl-1,2,3,4-tetrahydro-4aH-
indeno[2,1-c]pyridin-4a-yl)benzoate (156). 
Vinyl iodide 140d (7.0 mg, 0.013 mmol) was added to a 
screw cap vial equipped with a stir bar and dissolved in 
DCE (0.1 M). Triflic acid was added (1 uL, 0.013 mmol), the vial was sealed, heated 
to 50 ⁰C, and stirred for 3 h. The reaction was diluted with CH2Cl2 (4 mL) and the 
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organic layer washed with 0.5 M NaOH (8 mL). The organic layer was dried over 
Na2SO4, filtered, and the solvent removed in vacuo. Purification via flash 
chromatography gave 156 (pet ether:EtOAc, 4:1, Rf 0.40, 3.1 mg, 44%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.1 Hz, 
2H), 7.36 (br d, J = 7.6, 1H), 7.32 (ddd, J = 7.6, 7.4, 1.1 Hz, 1H), 7.24 (d, J = 8.1 
Hz, 2H), 7.15 (ddd, J = 7.4, 7.4, 1.3 Hz, 1H), 7.13 (d, J = 8.7 Hz, 2H), 7.01 (br d, J 
= 7.4 Hz, 1H), 4.87 (dd, J = 12.9, 1.6 Hz, 1H), 3.86 (s, 3H), 3.84 (br d, J = 12.9 Hz, 
1H), 3.28 (d, J = 12.9 Hz, 1H), 2.96 (br d, J = 14.0, 1H), 2.66 (ddd, J = 12.9, 12.7, 
2.0 Hz, 1H), 2.37 (s, 3H), 1.54 (ddd, J = 14.0, 12.7, 3.9 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 166.5, 150.3, 149.1, 143.7, 143.5, 142.4, 134.2, 130.6 (2C), 129.7 
(2C), 129.2, 127.8, 127.5 (2C), 127.3, 126.0 (2C), 123.7, 122.3, 95.9, 58.5, 52.2, 
46.8, 42.5, 33.9, 21.5. HRMS (ESI) m/z ([M+H]+, 100%) 586.0557, calc’d for 
C27H25INO4S 586.0549. 
9-Phenyl-2-tosyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine 
(160). 
A solution of SmI2 in THF (5.77 mL, 0.13 M) was added to an oven 
dried flask under argon. To this flask tosylate 68 (50 mg, 0.125 mmol) 
dissolved in THF (0.25 mL) was added, followed by H2O (41 uL, 2.3 mmol), and 
then piperidine (148 uL, 1.5 mmol). The reaction was then immediately poured into 
EtO2 (10 mL). The organic layer was washed with 1 N HCl (10 mL), then dried over 
Na2SO4, filtered, and the solvent removed in vacuo. Purification via flash 
chromatography gave 160 (pet ether:EtOAc, 4:1, Rf 0.40, 3.1 mg, 44%) as a white 
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solid. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.3 Hz, 2H), 7.32 – 7.18 (overlap, 
7H), 7.15 (d, J = 7.0 Hz, 1H), 7.11 (ddd, J = 7.1, 7.1 1.3 Hz, 1H), 6.96 (dd, J = 7.7, 
1.7 Hz, 2H), 4.37 (s, 1H), 3.89 (d, J = 16.8 Hz, 1H), 3.77 (d, J = 16.8 Hz, 1H), 3.54 
(ddd, J = 12.0, 5.4, 5.4 Hz, 1H), 3.34 (ddd, J = 12.0, 6.7, 5.2 Hz, 1H), 2.77 – 2.59 
(overlap, 2H), 2.40 (s, 3H). 
 (±)-9-Phenyl-2-tosyl-1,2,3,4-tetrahydro-4aH-indeno[2,1-
c]pyridine-4,4a-diol (162).  
To a round bottom flask K2OsO2(OH)4 (1.4 mg, 0.003 mmol), 
K3Fe(CN)6 (147 mg, 0.45 mmol), K2CO3 (61.7 mg, 0.45 mmol), 
and CH3SO2NH2 (14.3 mg, 0.15 mmol) were added. Then, t-BuOH (0.38 mL), H2O 
(0.38 mL), and methyl-t-Bu-ether (0.45 mL) were added, followed by 68 (60 mg, 
0.14 mmol). After stirring 24 h at rt, the reaction was diluted with CH2Cl2 (10 mL) 
and poured into a sepratory funnel conatining water (20 mL). The water was 
extracted with CH2Cl2 2X (10 mL), then the organic layers were combined, dried 
over Na2SO4, filtered, and the solvent removed in vacuo. Purification via flash 
chromatography gave unreacted starting material 68 (pet ether:EtOAc, 3:2, Rf 0.8, 
50 mg, 83%)  as a bright yellow solid, and 162 (pet ether:EtOAc, 3:2, Rf 0.4, 17.4 
mg, 27%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 7.6 Hz, 1H), 
7.61 (d, J = 8.2 Hz, 2H), 7.54 – 7.49 (m, 2H), 7.47 – 7.43 (m, 1H), 7.42 – 7.39 (m, 
2H), 7.34 – 7.26 (overlap, 4H), 7.25 (ddd, J = 7.1, 7.1, 1.4 Hz, 1H), 4.62 (dd, J = 
12.5, 1.6 Hz, 1H), 3.86 (ddd, J = 11.4, 5.1, 1.6 Hz, 1H), 3.56 (ddd, J = 10.6, 9.4, 
5.1 Hz, 1H), 3.31 (d, J = 12.5 Hz, 1H), 2.77 (dd, J = 11.4, 10.6 Hz, 1H), 2.72 (d, J 
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= 9.4 Hz, OH), 2.42 (s, 3H), 2.24 (s, OH); 13C NMR (125 MHz, CDCl3) δ 145.7, 
143.7, 142.3, 140.1, 136.0, 133.8, 132.4, 129.8 (2C), 129.1, 128.9 (2C), 128.7 
(2C), 128.6, 127.6 (2C), 126.7, 123.6, 121.5, 80.4, 72.6, 46.9, 41.4, 21.5. HRMS 
(ESI) m/z ([M+H]+, 100%) 434.1420, calc’d for C25H24NO4S 434.1426. 
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Chapter V - Sequence-Defined, Self-Replicating Polymers 
5.1 Introduction 
5.1.1 Impetus 
 RNA and DNA serve as the repository of hereditary information in all known 
life forms. Their capacity to self-replicate, and copy the information they contain 
from a parent strand to a daughter strand is essential to evolution, and largely 
responsible for the great diversity of life on earth. The preliminary work described 
in this chapter aims to answer the following question: are nucleic acid-based 
polymers alone in their ability to store information and self-replicate, or could 
synthetic polymers be constructed that share these properties? 
5.1.2 Sequence-Defined Polymers as Information-Storage Polymers 
The ability to store information in a 
polymer is not limited to DNA and RNA. 
Any sequence-defined polymer with at 
least two subunits can, in principle, be 
used to store information.217  The model 
system studied in this chapter, used imine 
bonds to store information. To illustrate 
how these functional groups can serve as 
informational bits, bonds from the polymer 
to the imine carbon can be defined as “0,” 
and bonds from the polymer to the imine 
Figure 5.1. Binary Information in 
Imine Bonds 
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nitrogen can be defined as “1.” Figure 5.1 depicts two model trimers, 1 and 2, which 
vary only in the direction of the imine bonds appended to the polymer chains. Read 
from top to bottom, polymer 1 encodes the binary sequence 1-0-1, whereas 
polymer 2 encodes the sequence 0-0-1. A binary trimer has 8 different potential 
sequences and so can encode up to 8 bits of information. Notably, since the 
backbones of trimers 1 and 2 are symmetric, the top and bottom are 
indistinguishable, and a few bits of information are degenerate. For example, 0-1-
1 is identical to 1-1-0, thus this sequence encodes a single bit instead of two bits. 
Symmetry concerns aside, the structure of a binary polymer is independent 
of its information storage capacity. Figure 5.2 depicts a sequence-defined 
oligo(triazoleamide) polymer constructed by Lutz and coworkers.218 The difference 
between the monomers in this system is a single methyl group. Assigning the 
subunits where R = H to “0,” and the subunits where R = Me to “1,” the octamer 
depicted in Figure 5.2 encodes the sequence 0-0-0-0-0-1-1-0, when read from the 
carboxylic acid terminus to the alkyne terminus. 
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Figure 5.2. Information Containing Oligo(triazoleamide) Polymer 
The polymers in Figures 5.1 and 5.2 have very different structures, but, as 
binary sequence-defined polymers, they store information similarly. Synthetic, 
information-storing polymers have been constructed with a variety of different 
monomers. 219 , 220 , 221 , 222  This diversity indicates there may be few structural 
limitations on the types of polymers which can store information. Notably, the 
majority of these polymers were constructed by the step-wise addition of monomer 
subunits; a process typically resembling the solid-phase synthesis of polypeptides. 
This method requires at least one synthetic step per subunit, and so limits the size 
of polymers that can be efficiently constructed. While modern polymerization 
techniques, such as controlled radical polymerizations and supramolecular 
polymerizations,223 can give large polymers with impressively specific sequences, 
they do not give the precisely defined sequence necessary to encode information. 
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The chemical space of polymers which have the potential to store arbitrary 
information is likely to be vast, covering a large diversity of structure types. 
However, the necessity that the sequence be known absolutely, and the limitations 
of step-wise polymer synthesis, limits the size of polymers which have been 
constructed thus far. Excluding bioinspired polymers (vide infra, Section 5.1.2), the 
largest synthetic, information-storing polymers which have been constructed are 
around 150 subunits.217 In contrast, the information storing biopolymers DNA and 
RNA can be many millions of subunits long. This disparity is in part a testament to 
the remarkable abilities of the many proteins responsible for DNA and RNA 
synthesis and maintenance, but not the sole cause. The complementary nature of 
base pairing interactions between nucleic acids, and the duplexes formed as a 
result of these interactions, allow single strands of DNA and RNA to template the 
synthesis of a sequence-defined polymer with a complementary sequence. In 
other words, DNA and RNA can self-replicate, precisely copying the information 
stored in their sequence from a parent strand to a daughter strand.  
Synthesis of sequence-defined polymers on a template is not strictly limited 
to DNA and RNA. While these systems are chemically distinct from DNA and RNA, 
they are not synthetic, as they derive many structural features from the 
biomolecules they mimic (vida infra Section 5.1.2). The work described in this 
chapter aims to develop template-directed polymerization as a means to 
sequence-defined polymers with structures very different from DNA and RNA 
based biopolymers. This has the potential to provide a means to sequence-defined 
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polymers which do not rely on the step-wise addition of monomers. Furthermore, 
it is plausible that synthetic polymers which share the self-replication and 
information-storage properties of DNA and RNA, may possess other life-like 
properties as well, namely, the potential to fold into useful shapes and evolve 
catalytic functions.  
5.1.2 Self-replication in Semi-Synthetic Systems 
 As mentioned in the previous section, information storage and self-
replication is not strictly limited to  DNA and RNA. However, all of the systems that 
have been reported to-date share structural features with natural biopolymers. For 
example, many polymers have been synthesized where the sugar of DNA or RNA 
has been replaced with an alternative linker, including other sugars, such as hexitol 
(HNA),224 altritol (ANA),225 threose (TNA),226 arabinose (ArNA),227 fluoroarabinose 
(FANA),228 and the pyranosyl isomer of deoxyribose (pRNA),226 and non-sugars, 
such as glycol (GNA),229 cyclohexene (CeNA),230 and amides (PNA)231 (Figure 
5.3). Surprisingly, complementary sequences of these polymers all form stable 
duplexes, and all but pRNA form stable heterohelixes with RNA and DNA. 
Collectively, the subunits of these non-natural polymers are referred to as xeno-
nucleic acids (XNAs). 
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Figure 5.3. Alternative DNA and RNA Backbones 
Recently, the Holliger group has developed polymerases capable of 
constructing XNA polymers on DNA templates. 232 Using these polymerases, 
libraries of ANA, HNA, CeNA, and FANA polymers could be constructed, and from 
these libraries endonuclease ribozymes could be selected. Similarly, the Chaput 
group performed in vitro evolution of a TNA polymer to produce polymers with 
specific ligand-binding activity. 233  These studies demonstrate that synthetic, 
information-containing polymers can be evolved to have function. However, the 
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polymers in these studies still exploit the base pairing between nucleic acids and 
rely on DNA for their synthesis.  
DNA- and RNA-like polymers with non-canonical nucleic acids, such as 
diaminopurine234  and 2-thiouracil,235  have been constructed as well. Polymers 
containing these nucleic acids function much like the natural biopolymers, which is 
not surprising considering their structural similarities.  Fully synthetic polymers, not 
reliant on purine-pyrimidine base pairing, which can function as templates for the 
synthesis of a new polymer have not yet been demonstrated.  
One example of the synthesis of a polymer on a template, which attempts 
to bridge the gap between synthetic polymers and biopolymers, was reported by 
the Sleiman group. 236  In an effort to construct ethynylbenzene polymers with 
uniform polydispersity, adenine-containing monomers were associated to a 
thymine-containing template of known length (Scheme 5.4). Sonogashira cross-
coupling of the unpolymerized monomers produced daughter ethynylbenzene 
polymers of low polydispersity, and lengths corresponding to the length of the 
template. This is particularly relevant to the model system explored in this chapter 
(vide infra, Section 5.2) as both use Sonogashira polymerization to build 
ethynylbenzene polymers. While Sleiman’s polymers rely on purine-pyrimidine 
base pairing and do not store information, they demonstrate the feasibility of cross-
coupling individual monomers associate to a template. 
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Scheme 5.4. Template-Directed Sonogashira Polymerization 
 
5.1.3 Polymerization on a Template 
 In designing a synthetic polymer capable of self-replication, one significant 
drawback is the lack of the polymerase enzymes used by DNA and RNA. It is likely, 
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however, that early in the evolution of life on earth, biomolecules very similar to 
RNA were formed without the assistance of proteins. The means by which RNA 
was replicated prior to the evolution of enzymes is relevant to this work and a 
fundamental question in the origin of life. As shown by Pollmann and coworkers in 
the 1960s, poly(C) RNA oligomers are able to function as templates for their own 
replication in the absence of polymerase enzymes with activated guanosine 
monomers. 237   This work, combined with the discovery of ribozymes in the 
1980s,238 , 239  is foundational to the RNA world hypothesis. 240  The RNA world 
hypothesis asserts that RNA-like polymers were the precursors to all life on earth; 
the first life-forms used RNA as both a catalyst, and self-replicating repository of 
genetic information. Recent discoveries have been made which allow for the non-
enzymatic replication of longer RNA templates with greater fidelity, and there is a 
growing consensus that the RNA world hypothesis is likely correct.241 
A general schematic of how template-directed self-replication of an RNA 
duplex might have occurred in the absence of enzymes is depicted in Scheme 5.5. 
The components of RNA are simplified to three modules based on their function.242 
The base pairs of RNA, G, C, A, and U function as “recognition subunits” (Scheme 
5.5,  and ). The complementary nature of base pairing interactions represented 
by the association of open and closed triangles. The deoxyribose sugars of RNA 
act as “trifunctional connectors” (Scheme 5.5,     ), attaching the recognition 
subunits to the backbone, which in RNA is phosphate (Scheme 5.5,    ). Starting 
from a duplex of base paired single strands (Scheme 5.5, top), replication begins 
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by denaturation of the duplex, and association of unpolymerized monomer 
subunits (Scheme 5.5 middle). The parent strands of the former duplex function as 
a template to order the unpolymerized monomers in a sequence-specific fashion. 
The associated monomers are then polymerized to generate a new sequence-
defined polymer (Scheme 5.5, bottom). In RNA, this polymerization is the 
phosphorylation of adjacent monomers.  
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Scheme 5.5. Template-Directed Replication of a Duplex 
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As drawn, Scheme 5.5 places few limits on the structural features 
necessary for the success of this self-replication sequence. It seems likely that 
self-replication could be engineered for a number of polymers containing the three 
principle components: recognition subunits, trifunctional connectors, and a 
backbone. The selection of the model system used to test this hypothesis will be 
discussed below. 
5.2 Model System Selection 
5.2.1 Recognition Subunits 
 Recognition subunits provide the interactions by which the monomers 
associate to the template polymer in a sequence-specific fashion. In RNA, the 
recognition subunits are purine and pyrimidine nucleobases, the complementary 
hydrogen bonds between A/U and C/G pairs providing the necessary sequence 
specificity.  Any two chemical 
entities which interact specifically 
and reversibly can potentially 
function as recognition subunits in 
a template-monomer interaction. 
Hydrogen bonds, salt bridges, 
metal ligand associations, and 
reversible covalent bonds, are all 
potential candidates. In the work 
described in this chapter, 
Figure 5.4. Potential Recognition Subunits 
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reversible covalent bonds were considered exclusively, both as a deliberate 
departure from the noncovalent interactions used by biopolymers, and because 
the increased strength of covalent bonds was anticipated to be desirable for 
polymers lacking the structural rigidity of DNA and RNA. Figure 5.4 depicts some 
of the reversible covalent interactions considered, including: thermally reversible 
Diels-Alder,243 boronic ester formation and hydrolysis, and imine formation and 
hydrolysis. Imines were chosen for the model system tested herein, as amines and 
aldehydes are common in commercially available small molecules. 
5.2.2 Trifunctional Connectors 
The trifunctional connector must be irreversibly attached to the recognition 
subunits, and properly functionalized to be attached to the backbone. The nature 
of the functional groups required will depend on the chemistry used to install the 
backbone (vida infa, Section 5.2.3). For this study, C2 symmetric trifunctional 
connectors were considered to limit regiochemical complications when being 
attached to backbone. Figure 5.5 depicts template polymers with unpolymerized 
monomers associated via imine bonds, three possible trifunctional connectors are 
shown: a hydrocarbon, a cyclohexane, and a benzene ring. Benzene was chosen 
for the model system, as anilines and benzaldehydes substituted with a range of 
functional groups were commercially available.  
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Figure 5.5. Potential Trifunctional Connectors 
5.2.3 Backbone 
The chemistry used to construct the backbone must be orthogonal to the 
chemistry of the base pairing interactions, and, in order to facilitate the formation 
of a duplex, the resulting backbone must be able to adopt a roughly linear 
geometry. Keeping these two criteria in mind, backbone chemistry was selected to 
be as robust as possible. Figure 5.6 depicts two of the backbone chemistries 
considered for the polymerization reaction, Huisgen CuAAC,244 and Sonogashira 
cross-coupling.176 In both examples, the appropriate unpolymerized monomers are 
shown base paired to the template polymer. In the CuAAC, cycloadducts formed 
from between the monomer alkynes and 1,4-diazidobenzene would be expected 
to produce a triazole-phenyl-triazole backbone mirroring the backbone of the 
template polymer (Figure 5.6, middle). In the Sonogashira coupling, products 
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formed between the monomer alkynes and 1,3-diiodobenzene would be expected 
to produce a diethynylbenzene backbone mirroring the backbone of the template 
polymer (Figure 5.6, right). Sonogashira coupling was selected for these studies 
as the diiodobenzene materials were commercially available. However, 
diazidobenzene are synthetically tractable 245  and will likely be investigated in 
future studies.  
 Figure 5.6. Potential Backbones 
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5.2.4 Sequence-Defined Enthynyl Benzene Polymer Duplexes  
 A 5-mer portion of the model system 
selected is depicted in Figure 5.7. Notably, 
this is just one of the multitudes of possible 
sequences available in this system. Using 
the formalism established in Section 5.1.2, 
this duplex encodes the binary sequence 0-
1-1-1-1 (left) and its complementary 
sequence 1-0-0-0-0 (right).  Initial efforts to 
synthesize the model system components 
were made difficult by the insolubility of the 
precursor molecules, and it was found 
necessary to attach solubilizing PEGylated 
esters R1 to the backbone phenyl rings. The 
work described in the remainder of this 
chapter will focus on the simplest reduction 
of this system capable of storing information, 
a dimer containing just two imine bonds. 
Efforts to synthesize a pentamer sequence 
and confirm its ability to self-replicate are on-
going. 
Figure 5.7. Model Duplex 
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Surprisingly, homopolymer duplexes nearly identical to the model system 
targeted in this study have been synthesized by the Moore group.246 Moore’s 
interest in these molecules was driven by their self-assembly properties. As such, 
the information-storage capabilities of these molecules and their ability to self-
replicate were not investigated. However, encouragingly, Moore’s group has 
shown the imine bonds of these polymers interchange reversibly in up to 4-mer 
duplexes.247 This bodes well for future studies, suggesting denaturation of longer 
duplexes to single strands will be possible. 
5.3 Synthesis of the Duplexes  
 The two dimer duplexes A1 and A2 targeted for self-replication studies are 
depicted in Figure 5.8. In order to show the information contained in the starting 
duplex was transferred to the daughter duplex, both possible sequences were 
synthesized; the duplex consisting of the 1-1 and 0-0 complementary sequences 
A1 (Figure 5.8, left), and the duplex consisting of a 1-0 and 0-1 complementary 
sequences A2 (Figure 5.8, right). 
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Figure 5.8. Model Dimer Duplexes A1 and A2 
 Synthesis of duplex A1 was carried out according to Scheme 5.6. Using 3-
ethynylbenzaldhyde and PEGylated 3,5-diiodobenzene ester, Sonogashira cross-
coupling afforded the dialdehyde B1, in excellent yields (98%). An analogous 
procedure using 3-ethynylaniline gave dianiline C1, in good yields (86%). Adding 
a solution of dialdehyde B1 in benzene to a solution of dianiline C1 in benzene, 
and letting the solution sit undisturbed at 0 ⁰C for 3 days, gave pure crystals of 
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duplex A1 in quantitative yield. The structure of A1 was confirmed by X-ray 
crystallography.  
Scheme 5.6. Synthesis of A1 
Synthesis of duplex A2 was carried out according to Scheme 5.7. 
Sonogashira cross coupling with 3-ethynylaniline and 5-fold excess of PEGylated 
3,5-diiodobenzene ester, gave iodobenzene 3 in 58% yield. A second Sonogashira 
cross coupling of this iodobenzene with 3-ethynylbenzaldehyde, gave a mixture of 
amino aldehyde B2, and duplex A2. Heating of this mixture, followed by gentle 
removal of the solvent gave desired duplex A2 in low but sufficient yield (22%). 
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Scheme 5.7. Synthesis of Duplex A2 
5.4 Self-Replication of Duplexes A1 and A2 
 With duplexes A1 and A2 in hand, a four step (a-d) sequence was devised 
to demonstrate self-replication. Figures 5.9 and 5.10 show the replication of 
duplexes A1 and A2 respectively. Each of the steps will be discussed in more 
detail in following sections, the general procedure is as follows: A large excess of 
3-ethynylaniline monomer (30 equiv.) and catalytic acid were added to denature 
the duplex to single strands and associate aniline monomers to the template 
strands (step a). A larger excess of  3-ethynylbenzaldehyde monomer (60 equiv.) 
was added to associate these monomers to the template strands (step b). The 
template strands with associated monomers were heated under high vacuum to 
remove the excess unassociated monomers (step c). Sonogashira cross-coupling 
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with a 3,5-diiodobenzoate ester joined the associated monomers to produce 
daughter duplexes.  
Figure 5.9. Replication of A1 
 
 
Conditions: a) 30 equiv 3-ethynylaniline. b) 60 equiv 3-
ethynylbenzaldehyde. c) 0.02 mbar, 120 °C, neat. d) 5 
equiv methyl 3,5 diiodobenzoate, 1 equiv Pd(PPh3)4, 0.5 
equiv CuI, 6 μM degassed DMF, 60° C. 
8.0 8.6 8.5 8.4 8.1 8.3 8.2 
A1 
D1/C1 
D1/E1 
A1’/A1’’ 
a 
b,c 
d 
NMR 
899.899 
679.454 
478.282 
679.364 
811.438 
500 600 700 800 900 m/z 
A1 
D1/C1 
D1/E1 
A1’/A1’’ 
a 
b,c 
d 
MADLI-TOF 
NMR: expansion of downfield aromatic and imine protons for 
steps a-d. From left to right, imine protons, meta ester 
protons, meta imine (carbon side) singlet. 
MALDI-TOF: spectra for steps a-d. 
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 Figure 5.10. Replication of A2 
 
 
 
A2 
2 C2 
2 D2 
2 A2’ 
a 
b,c 
d 
NMR 
8.7 8.6 8.5 8.4 8.1 8.3 8.2 
500 600 700 800 900 m/z 
899.402 
679.269 
567.270 
811.395 
MALDI-TOF 
A2 
2 C2 
2 D2 
2 A2’ 
a 
b,c 
d 
Conditions: a) 30 equiv 3-ethynylaniline. b) 60 equiv 3-
ethynylbenzaldehyde. c) 0.02 mbar, 120 °C, neat. d) 5 
equiv methyl 3,5 diiodobenzoate, 1 equiv Pd(PPh3)4, 0.5 
equiv CuI, 6 𝜇M degassed DMF, 60° C. 
NMR: expansion of downfield aromatic and imine protons for 
steps a-d. From left to right, imine protons, meta ester 
protons, meta imine (carbon side) singlet. 
MALDI-TOF: spectra for steps a-d. 
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5.4.1 Step a 
Addition of 3-ethynylaniline to either duplex A1 or A2 set up an equilibrium 
between the duplex imines and imines formed via the transimination of 3-
ethynylaniline monomers with the duplexes (Scheme 5.8). Trace acid (0.5% TFA) 
effectively catalyzed this transimination, and the equilibrium populations of imines 
and anilines were achieved after 2 h. 
An NMR study conducted by adding portions of 3-ethynylaniline to each 
duplex and observing the equilibrium populations of imines, revealed a 30-fold 
excess of 3-ethynylaniline was effective in decreasing the amount of duplex A1 
and A2 to <3% of the solution imines. For duplex A1, addition of 30 equivalents of 
3-ethynylaniline resulted in a solution containing dimine D1, dianiline C1, and 3-
ethynlaniline in a 1:1:28 ratio, respectively (Scheme 5.9, top). For duplex A2, 
addition of 30 equivalents of 3-ethynylaniline resulted in a solution containing 
imine-aniline C2, and 3-ethynylaniline in a 2:28 ratio, respectively (Scheme 5.9, 
bottom). This procedure effectively demonstrates the separation of the duplexes 
into single strands and the sequence-specific association of aniline monomers to 
the template strand. 
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Scheme 5.8. Transimination of A1 and A2 
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Scheme 5.9. Replication Step a 
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The success of this step was shown by NMR and MALDI-TOF 
spectroscopy. The imine peaks in the NMR proved to be particularly diagnostic. 
Starting with duplex A1, the imine peak corresponding to the duplex (δ 8.57) was 
reduced below the resolution of the NMR instrument and a new imine peak 
corresponding to the template-associated dimer D1 was observed (δ 8.45). The 
MALDI spectra confirmed these results; the peak corresponding to the macrocycle 
disappeared, with the appearance of two new peaks consistent with dimine D1, 
and dianiline C1 (Figure 5.9). Likewise, for duplex A2, the NMR showed a new 
upfield imine peak (δ 8.44), and a single MALDI peak consistent with imine-aniline 
C2 (Figure 5.10). 
5.4.1 Step b 
 Next, an even larger, 60-fold excess of 3-ethynylbenzaldehyde was added, 
and removal of water with 4 Å molecular sieves drove the imine formation to 
completion. Both the aniline subunits of the template dimer, and the excess 3-
ethynylaniline were converted to imines, the condensation of  3-ethynylanilne and 
3-ethynylbenzaldehyde producing imine 4 (Scheme 5.10). For the procedure 
starting with A1, this step resulted in a solution containing diimine D1, diimine E1, 
imine 4, and 3-ethynlbenzaldehyde in a 1:1:28:30 ratio, respectively (Scheme 5.10, 
top). For duplex A2, this procedure resulted in a solution containing diimine D2, 
imine 4, and 3-ethynlbenzaldehyde in a 2:28:30 ratio, respectively (Scheme 5.10, 
bottom). This step served two functions. First, the anilines of the template strands 
were associated with their complement monomers. Second, all the nucleophilic 
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anilines were converted to imines. This proved vital to the success of the 
subsequent steps as any remaining anilines in solution re-established equilibrium 
populations as the concentration of monomers changed. 
Scheme 5.10. Replication Step b 
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5.4.1 Step c 
 At this stage in the replication process the starting duplexes A1 and A2 had 
been denatured to single strands, and monomers had been associated in a 
sequence-specific fashion. However, a large excess of 3-ethynylbenzaldehyde 
and 4 were present in solution. As these materials contain alkyne functional groups 
liable to react during the Sonogashira polymerization step, they needed to be 
removed. Traditional methods of purification such as silica gel column 
chromatography were ineffective given the easily hydrolyzable nature of the imine 
bonds associating the monomers to the templates. Surprisingly, given the high 
molecular weight of 4, sublimation of the unwanted materials proved very effective. 
The mixtures obtained from step b, were heated to 120 ⁰C under high vacuum for 
16 h, 3-ethynylbenzaldehyde and 4 were recovered quantitatively on a cold finger. 
For starting duplex A1, the resulting residue contained exclusively D1 and E1 
(Scheme 5.11, top). For starting duplex A2, the resulting residue contained 
exclusively D2 (Scheme 5.11, bottom).  
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Scheme 5.11. Replication Step c 
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The NMR and MALDI data are consistent with the proposed transformations 
in steps b and c. The NMR peaks corresponding to D1 remained unchanged, and 
a new imine peak (δ 8.46) and set of aromatic peaks were seen for E1, along with 
the expected MALDI peak (Figure 5.9). Whereas, two new imine peaks (δ 8.45 
and 8.46) and a completely new set of aromatic peaks were seen for D2, along 
with the expected MALDI peak (Figure 5.10). 
5.4.1 Step d 
 The final step required the monomers associated to the templated to be 
linked via Sonogashira coupling with a 3,5-diiodobenzoate ester. To distinguish 
the starting parent duplexes A1 and A2 from the daughter duplexes, methyl 3,5-
diiodobenzoate was used instead of the PEGylated 3,5-diiodobenzoate used to 
construct the parent backbone. The methyl ester functioned as a mass tag, such 
that coupling of monomers off the template could be differentiated from coupling 
on the template. Off-template coupling, was expected to give a mass 
corresponding to a duplex with two methyl esters, whereas on template coupling 
was expected to give a mass corresponding to one methyl ester and one PEGyl 
ester.  
Sonogashira cross-coupling afforded the desired daughter duplexes 
(Scheme 5.12). In order to disfavor intermolecular reactions between two template 
strands, which could result in the formation of long polymers, the reaction was run 
with a 5-fold excess of the diiodobenzoate. However, this excess had the potential 
to promote the coupling of two diiodobenzoate backbones to two monomers on the 
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same template, and thus prevent self-replication. Thus, to favor intramolecular 
coupling, the reaction was run under dilution conditions (6 uM). Given the high 
dilution, a full equivalent of Pd(PPh3)4 and 0.5 equivalents of CuI was used. Likely 
because of the large amount of CuI catalyst, the coupling was very sensitive to 
dissolved O2 and rigorous degassing was required to prevent unwanted Glaser 
coupling products. DMF was  determined to be the best solvent. In CHCl3 and ACN 
no reaction was observed, and in THF the a complex mixture was produced.   
For replication which started with parent duplex A1, daughter duplexes A1’ 
and A1’’ were obtained exclusively. The NMR showed two overlapping imine 
peaks with a similar downfield shift (δ 8.60) to the starting duplex, and the MALDI 
showed a single peak consistent with the mass of the expected daughters, 
containing one methyl benzoate backbone, and one PEGyl benzoate backbone 
(Figure 5.9). Replication which started with parent duplex A2, resulted in daughter 
duplex A2’ which was obtained as a mixture with PPh3. The NMR showed two 
overlapping imine peaks (δ 8.61) with the same downfield shift as the starting 
duplex, and the MALDI showed a single peak consistent with the mass of the 
expected daughter containing one methyl benzoate backbone, and one PEGyl 
benzoate backbone (Figure 5.10). 
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Scheme 5.12. Replication Step d 
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5.5. Conclusion 
 Two duplexes containing two imine bonds each, encoding a single bit of 
information, were synthesized and replicated under the same set of conditions. 
Parent duplexes A1 and A2 functioned as templates for the synthesis of two 
daughter duplexes, and the information contained in the parent was transferred to 
the daughters (Scheme 5.13). This demonstrates template-monomer interactions, 
unrelated to the purine-pyrimidine base pairing of biopolymers, are able to serve 
as a recognition subunit in the transfer of information.  
Scheme 5.13. Information Replication 
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5.6 Experimental 
5.6.1 General Procedures  
The 1H NMR and 13C NMR spectra were recorded at 117.42 kG (1H 500 
MHz, 13C 125 MHz), or 93.94 kG (1H 400 MHz, 13C 100 MHz) at ambient 
temperature as noted. Hydrogen chemical shifts are expressed in parts per million 
(ppm) relative to the residual protio solvent resonance: CDCl3 δ 7.26. For 13C 
spectra, the centerline of the solvent signal was used as internal reference: CDCl3 
δ 77.00. Unless otherwise noted, each carbon resonance represents a single 
carbon (relative intensity). All exchangeable OH and NH hydrogen resonances 
were confirmed by D2O exchange.  Matrix Assisted Laser Desorption/Ionization 
(MALDI) Time-of-Flight (TOF) Mass Spectrometry experiments were carried out 
using the following method: Five portions of a 0.5 μL solution of CHCl3 saturated 
with 2,5- dihydroxybenzoic acid matrix (Sigma) were deposited on a MTP 384 
polished steel BC target plate (Bruker), allowing the solvent to evaporate between 
each addition. A single 0.5 μL aliquot of analyte in CDCl3 was then added on top 
of 2,5-dihydroxybenzoic acid film and the sample analyzed with an autoflex speed 
LRF MALDI-TOF mass spectrometer (Bruker). 
General Procedure A 
The aryl alkyne and aryl iodide, at the given ratio of equivalents, were 
dissolved in tetrahydrofuran (0.1 M) in a screw-capped vial containing a magnetic 
stir bar. Five equiv. of TEA, with respect to the aryl iodide, was added followed by 
10 mol % Pd(PPh3)4 and 5 mol % CuI. The vial was sealed with a screw cap and 
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left stirring between 1 and 24 hours at room temperature. The reaction was 
monitored by silica TLC (10% EtOAc in hexanes) until it reached full conversion 
whereupon it was diluted in ethyl acetate and mixed with silica. The solvent was 
removed in vacuo and the crude mixture was purified by silica gel flash 
chromatography using a CombiFlash (Teledyne Isco Lincoln, NB). 
5.6.2 Synthesis of the Dimer Duplexes A1 and A2 
2-(2-Methoxyethoxy)ethyl 3,5-bis((3-
formylphenyl)ethynyl)benzoate (B1). 
Prepared according to General Procedure A: 3-
ethynylbenzaldehyde (27 mg, 0.2 mmol) was 
reacted with 2-(2-methoxyethoxy)ethyl 3,5-diiodobenzoate (20 mg, 0.04 mmol), in 
the presence of Pd(PPh3)4 (30 mg, 0.026 mmol), CuI (10 mg, 0.052 mmol), and 
TEA (1 mL), in THF (10 mL) at rt for 16 h. CombiFlash silica gel purification 
(gradient of 0-100% EtOAc in hexanes)  gave B1 (20 mg, 98 %) as an off white 
solid. 1H NMR (500 MHz, CDCl3) δ 10.03 (s, 2H), 8.20 (d, J = 1.6 Hz, 2H), 8.05 
(dd, J = 1.9, 1.4 Hz, 2H), 7.90 – 7.86 (m, 3H), 7.79 (ddd, J = 7.7, 1.4, 1.4 Hz, 2H), 
7.56 (dd, J = 7.7, 7.7 Hz, 2H), 4.56 – 4.51 (m, 2H), 3.90 – 3.85 (m, 2H), 3.73 – 
3.70 (m, 2H), 3.61 – 3.57 (m, 2H), 3.40 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 191.6 
(2C), 165.3, 138.6, 137.4 (2C), 136.7 (2C), 133.2 (2C), 132.9 (2C), 131.2, 129.6 
(2C), 129.5 (2C), 124.0 (2C), 123.9 (2C), 89.6 (2C), 89.1 (2C), 72.1, 70.8, 69.4, 
64.8, 59.3. 
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2-(2-Methoxyethoxy)ethyl 3,5-bis((3-
aminophenyl)ethynyl)benzoate (C1). 
Prepared according to General Procedure A: 3-
ethynylaniline (24 μL, 0.2 mmol) was reacted with 
2-(2-methoxyethoxy)ethyl 3,5-diiodobenzoate (20 mg, 0.04 mmol), in the presence 
of Pd(PPh3)4 (5 mg, 0.004 mmol), CuI (0.5 mg, 0.003 mmol), and TEA (0.1 mL) in 
tetrahydrofuran (1 mL) at rt for 16 h. CombiFlash silica gel purification (gradient of 
0-100% EtOAc in hexanes)  gave C1 (16.5 mg, 86 %) an off white solid. 1H NMR 
(500 MHz, CDCl3) δ 8.13 (d, J = 1.6 Hz, 2H), 7.82 (t, J = 1.6 Hz, 1H), 7.15 (dd, J = 
8.1, 7.6 Hz, 2H), 6.95 (ddd, J = 7.6, 1.6, 1.0 Hz, 2H), 6.86 (dd, J = 2.5, 1.6, 2H), 
6.69 (ddd, J = 8.1, 2.5, 1.0 Hz, 2H), 4.55 – 4.49 (m, 2H), 3.89 – 3.83 (m, 2H), 3.75 
(br s, 4NH) 3.74 – 3.69 (m, 2H), 3.61 – 3.56 (m, 2H), 3.40 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 165.6, 146.5 (2C), 138.5, 132.3 (2C), 130.9, 129.6 (2C), 124.4 (2C), 
123.5 (2C), 122.4 (2C), 118.0 (2C), 116.0 (2C), 91.3 (2C), 87.2 (2C), 72.1, 70.8, 
69.4, 64.7, 59.3. 
2-(2-methoxyethoxy)ethyl 3-((3-aminophenyl)ethynyl)-
5-iodobenzoate (3).  
Prepared according to General Procedure A: 3-
ethynylaniline (50 μL, 0.44 mmol) was reacted with 2-(2-
methoxyethoxy)ethyl 3,5-diiodobenzoate (1.2 g, 5.7 eq., 2.52 mmol), in the 
presence of Pd(PPh3)4 (60 mg, 0.06 mmol), CuI (5 mg, 0.026 mmol), and TEA (2 
mL) in tetrahydrofuran (4 mL) at rt for 16h. CombiFlash silica gel purification 
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(gradient of 0-100% EtOAc in hexanes) gave 3 (120 mg, 58%) as a light brown oil.  
1H NMR (500 MHz, CDCl3) δ 8.32 (dd, J = 1.6, 1.6 Hz, 1H), 8.14 (dd, J = 1.6, 1.6 
Hz, 1H), 8.03 (dd, J = 1.6, 1.6 Hz, 1H), 7.14 (dd, J= 8.1, 7.7 Hz, 1H), 6.93 (ddd, J 
= 7.7, 1.6, 1.0 Hz, 1H), 6.84 (dd, J = 2.4, 1.6 Hz, 1H), 6.69 (ddd, J = 8.1, 2.4, 1.0 
Hz, 1H), 4.53 – 4.47 (m, 2H), 3.87 – 3.81 (m, 2H), 3.72 (br s, NH2), 3.72 – 3.67 
(m, 2H), 3.60 – 3.55 (m, 2H), 3.40 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 164.8, 
146.6, 144.3, 138.1, 132.2, 132.1, 129.6, 125.9, 123.3, 122.4, 118.0, 116.1, 93.4, 
92.2, 86.3, 72.1, 70.8, 69.3, 64.8, 59.4. 
Duplex A1.   
A 0.1 M solution of dianiline B1 (2 mg) in benzene 
was added to a 0.1 M solution of diladehyde C1 (2 
mg) in benzene. To this solution TFA was added 
(0.1 uL), and the solution was placed in a freezer. 
After sitting for three days colorless needle like 
crystals had formed. The benzene supernatant was carefully removed with a 
pipette leaving pure white crystals of A1 (4 mg, 100%). 1H NMR (500 MHz, CDCl3) 
δ 8.58 (s, 2H), 8.18 (d, J = 1.6 Hz, 2H), 8.17 (d, J = 1.6 Hz, 2H), 8.13 (dd, J = 1.8, 
1.6 Hz, 2H), 7.938 (ddd, J = 7.7, 1.7, 1.4, 2H), 7.933 (t, J = 1.6 Hz, 2H), 7.91 (t, J 
= 1.6 Hz, 1H), 7.66 (ddd, J = 7.7, 1.6, 1.2 Hz, 2H), 7.52 (dd, J = 2.1, 1.6 Hz, 2H), 
7.50 (dd, J = 7.7, 7.7 Hz, 2H), 7.45 (ddd, J = 7.5, 1.6, 1.5 Hz, 2H), 7.42 (dd, J = 
7.5, 7.5 Hz, 2H), 7.34 (ddd, J = 7.5, 2.1, 1.5 Hz, 2H), 4.58 – 4.51 (overlap, 4H), 
3.92 – 3.86 (overlap, 4H), 3.77 – 3.70 (overlap, 4H), 3.63 – 3.59 (overlap, 4H), 
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3.42 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 165.5, 165.4, 159.3 (2C), 151.0 (2C), 
139.4, 139.2, 136.6 (2C), 134.3 (2C), 133.0 (2C), 132.24 (2C), 132.22 (2C), 
131.15, 131.09, 129.8 (2C), 129.6 (2C), 129.3 (2C), 128.8 (2C), 124.9 (2C), 124.2 
(2C), 124.1 (2C), 123.8 (2C), 123.6 (2C), 122.2 (2C), 90.8 (2C), 90.5 (2C), 88.6 
(2C), 88.2 (2C), 72.2 (2C), 70.8 (2C), 69.4 (2C), 64.75, 64.73, 59.4.  
The structure of A1 was further confirmed by X-Ray Crystallography. A 
crystal mounted on a diffractometer and collected data at 100 K. The intensities of 
the reflections were collected by means of a Bruker APEX II DUO CCD 
diffractometer (CuKα radiation, λ=1.54178 Å), and equipped with an Oxford 
Cryosystems nitrogen flow apparatus. The collection method involved 1.0° scans 
in ω at -30°, -55°, -80°, 30°, 55°, 80° and 115° in 2θ. Data integration down to 0.84 
Å resolution was carried out using SAINT V8.34 C with reflection spot size 
optimisation. Absorption corrections were made with the program SADABS . The 
structure was solved by Intrinsic Phasing methods and refined by least-squares 
methods again F2 using SHELXT-2014 and SHELXL-2014 with OLEX 2 interface. 
Nonhydrogen atoms were refined anisotropically, and hydrogen atoms were 
allowed to ride on the respective atoms. Crystal data as well as details of data 
collection and refinement are summarized in Table 5.1. The Ortep plots were 
produced with SHELXL-2014 program. 
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Table 5.1. Crystallography Parameters and Results 
Crystal size (mm) 0.24 × 0.02 × 0.02 
Data collection 
Diffractometer 
Bruker D8 goniometer with CCD area 
detector diffractometer 
Absorption correction Multi-scan SADABS 
Tmin, Tmax 0.818, 0.863 
No. of measured, independent and 
observed [I > 2s(I)] reflections 
48046, 5104, 3670 
Rint 0.076 
(sin q/l)max (Å-1) 0.596 
Refinement 
R[F2 > 2s(F2)], wR(F2), S 0.058, 0.165, 1.08 
No. of reflections 5104 
No. of parameters 619 
No. of restraints 522 
H-atom treatment H-atom parameters constrained 
Dρmax, Dρmin (e Å-3) 0.28, -0.33 
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Figure 5.11. Crystal Structure of A1 
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 Duplex A2 
According to general procedure A: aryliodide 3 (45 
mg, 0.1 mmol) was reacted with 3- 
ethynylbenzaldehyde (14 mg, 0.11 mmol) in the 
presence of Pd(PPh3)4 (12 mg, 0.01 mmol), CuI (4 
mg, 0.02 mmol), and TEA (0.7 mL) in DMF (1 mL) 
at rt for 16 h. CombiFlash silica gel purification (gradient of 0-100% EtOAc in 
hexanes) gave a mixture of A2 and B2. The mixture was heated to 60 °C for 1 h, 
then concentrated. The residue was recrystallized from chloroform:benzene (1:4) 
to give pure A2 (10 mg, 22%) as a white solid. 1H NMR (500 MHz, CDCl3) δ  8.60 
(s, 2H), 8.20 (t, J = 1.6 Hz, 2H), 8.19 (t, J = 1.6 Hz, 2H), 8.13 (t, J = 1.7 Hz, 2H), 
7.97 (ddd, J = 7.8, 1.7, 1.2 Hz, 2H), 7.94 (t, J = 1.6 Hz, 2H), 7.68 (ddd, J = 7.6, 1.6, 
1.2 Hz, 2H), 7.53 (dd, J = 2.1, 1.6 Hz, 3H), 7.51 (dd, J = 7.8, 7.6 Hz, 2H), 7.47 
(ddd, J = 7.6, 1.6, 1.4 Hz, 2H), 7.43 (dd, J = 7.6, 7.6 Hz, 2H), 7.36 (ddd, J = 7.6, 
2.1, 1.4 Hz, 2H), 4.57 – 4.53 (m, 4H), 3.91 –3.87 (m, 4H), 3.76 – 3.71 (m, 4H), 3.63 
– 3.59 (m, 4H), 3.42 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 165.5 (2C), 159.4 (2C), 
151.0 (2C), 139.3 (2C), 136.6 (2C), 134.4 (2C), 133.1 (2C), 132.3 (2C), 132.2 (2C), 
131.1 (2C), 129.8 (2C), 129.6 (2C), 129.3 (2C), 128.7 (2C), 124.8 (2C), 124.3 (2C), 
124.1 (2C), 123.8 (2C), 123.6 (2C), 122.4 (2C), 90.9 (2C), 90.4 (2C), 88.7 (2C), 
88.1 (2C), 72.2 (2C), 70.8 (2C), 69.4 (2C), 64.7 (2C), 59.4 (2C). 
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5.6.3 Replication of the Duplex Dimers 
Replication of duplexes A1 and A2 was carried out in a four step 
sequence. Steps a-d are given below: 
Transimination of Duplexes A1 and A2 with 3-Ethynylaniline (step a) 
A1 or A2 (4 mg, 0.004 mmol) was added to an NMR tube, dissolved in 
CDCl3 and TFA (0.5 mL CDCl3, 0.02% TFA) and placed over 4 Å molecular sieves. 
To the NMR tube 3-ethynylaniline (15 uL, 0.12 mmol) was added and 
transimination was monitored by 1H NMR (500 MHz) until the reactants reached 
equilibrium and the amount of the duplex was reduced to <3% (approximately 2 
hours). For duplex A1, this procedure resulted in a solution containing dimine D1, 
dianiline C1, and 3-ethynlaniline in a 1:1:28 ratio, respectively. For duplex A2, this 
procedure resulted in a solution containing imine-aniline C2, and 3-ethynlaniline in 
a 2:28 ratio, respectively.  
Imine Formation with 3-Ethynylbenzaldehyde (step b) 
Following step a, additional 4 Å molecular sieves (20 mg) and 3-
ethynylbenzaldehyde (31 mg, 0.24 mmol) were added to the NMR tube. Imine 
formation was monitored by 1H NMR until the amines of both the templates (C1 or 
C2) and the 3-ethynylaniline were condensed to imines (2-16 hours). For the 
procedure beginning with duplex A1, this step resulted in a solution containing 
dimine D1, dimine E1, imine 4, and 3-ethynlbenzaldehyde in a 1:1:28:30 ratio, 
respectively. For duplex A2,  this step resulted in a solution containing diimine D2, 
imine 4, and 3-ethynlbenzaldehyde in a 2:28:30 ratio, respectively.  
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Removal of Monoimine 4 and 3-Ethynlbenzaldehyde (step c) 
Following step b, the molecular sieves were pelleted via centrifugation and 
the CDCl3 supernatant decanted into a 5 mL glass vial. The solvent was removed 
under a stream of dry N2 and the resulting white solid sublimated under reduced 
pressure (0.02 mbar) at 120 °C for 16 hours using a BÜCHI GKR-50 glass tube 
oven (BÜCHI Labortechnik Flawil, Switzerland). The sublimate was found to 
contain a 30:28 mixture of 3-ethynylbenzaldehyde and 4 with >99% mass 
recovery. The unsublimated residue was found to contain nearly pure dimines, D1 
and E1 in a 1:1 ratio for the replication starting with duplex A1, and D2 for 
replication which started with duplex A2. 
Linking of Template Bound Monomers D1/E1,  and D2 (step d) 
The residue obtained in step c, was dissolved in CDCl3, and placed over 4 
Å molecular sieves (20 mg). Methyl-3,5-diiodobenzoate (8 mg, 0.02 mmol) and 
DABCO (4.5 mg, 0.04 mmol) were added to the NMR tube, and the relative 
stoichiometry was verified by 1H NMR. A 1/6 portion (approximately 6 μmol of 
D1+E1, or D2) of this solution was aliquoted for the reaction, and added to an oven 
dried Schlenk flask equipped with a stir bar. The solution was diluted with amine 
free, anhydrous DMF (100 mL), placed over 4 Å molecular sieves (50 mg) and 
then degassed by sparging with N2 through a sintered glass frit for 2 h. Removal 
of dissolved O2 was imperative to success of this reaction as Glaser coupling 
products were otherwise obtained in significant quantities. While still under a 
positive pressure of N2, Pd(PPh3)4 (1 mg) and CuI (0.1 mg) were added. The head 
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space of the Schlenk flask was evacuated a back filled with N2 three times, and 
then sealed.  After stirring at 60 °C for 16 h, the DMF was removed in vacuo. The 
resulting residue was taken up in CHCl3 (10 mL), the 4 Å molecular sieves were 
pelleted via centrifugation, the CHCl3 was decanted and then removed in vacuo. 
The resulting light brown oil was precipitated from a 3:1 mixture of benzene:CHCl3 
(50 uL). For replication beginning with duplex A1, a mixture of A1’ and A1’’ were 
obtained exclusively. For replication beginning with duplex A2, a mixture of A2’ 
and PPh3 was obtained. 
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